[
  {
    "question": "What is the CPIC-recommended dose for metformin in a patient with the CYP2D6 *4/*4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of lactic acidosis for metformin users who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for metformin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of metformin therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic pathway of metformin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lisinopril dosing be adjusted for patients with the ACE DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of angioedema from lisinopril in individuals with the ACE II genotype compared to the DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended therapeutic range for lisinoprilat based on a patient's ACE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ACE I/D polymorphism correlate with lisinopril efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the ACE gene in determining individual response to lisinopril?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended warfarin dose adjustment for a patient who is a CYP1A2 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding for warfarin patients with low-activity CYP1A2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma S-warfarin concentrations for a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP1A2 diplotypes correspond to the ultrarapid metabolizer phenotype for warfarin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2*1F allele in the context of warfarin metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the CPIC dosing recommendation for risperidone in pediatric patients who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of extrapyramidal symptoms with risperidone in a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the therapeutic window for plasma 9-hydroxyrisperidone in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer for risperidone therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CYP2D6 enzyme contribute to the conversion of risperidone to its active metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of olanzapine for a patient identified as a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of sedation for olanzapine users with decreased CYP1A2 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for olanzapine in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP1A2 genotypes are classified as poor metabolizers in the context of olanzapine treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for olanzapine involving the CYP1A2 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should aripiprazole dosing be adjusted for a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of akathisia in aripiprazole-treated patients who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma aripiprazole concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for aripiprazole therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for aripiprazole in children with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for citalopram based on ABCB1 transporter genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with citalopram in patients with high-activity ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target cerebrospinal fluid concentrations of citalopram for a patient with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ABCB1 genotype correspond to P-glycoprotein expression and citalopram response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the P-glycoprotein (encoded by ABCB1) in the distribution of citalopram?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sertraline dosing be modified for patients with the OPRM1 A118G variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Is there an increased risk of emotional blunting with sertraline in OPRM1 G-allele carriers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic effect measure for sertraline based on OPRM1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which OPRM1 genotypes are associated with poor response phenotypes to sertraline therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the mu-opioid receptor (encoded by OPRM1) in the antidepressant mechanism of sertraline?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended maximum daily dose of acetaminophen for a patient with a UGT1A6*2/*2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity from acetaminophen in individuals with low-activity UGT1A6 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of acetaminophen glucuronide in a patient with a specific UGT1A6 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A6 genotypes map to acetaminophen glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A6 enzyme in the detoxification of acetaminophen?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ibuprofen for a patient with a TPMT poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Is there an increased risk of gastrointestinal bleeding with ibuprofen in patients carrying TPMT deficiency alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for ibuprofen in a TPMT intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which TPMT diplotypes define a normal metabolizer for the purpose of ibuprofen therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ibuprofen in pediatric patients with heterozygous TPMT variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should digoxin dosing be adjusted based on ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of digoxin toxicity in patients with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target therapeutic range for plasma digoxin in a patient with a low-function ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 haplotypes correspond to digoxin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the renal excretion of digoxin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended methotrexate dose for a patient with the MTHFR 677TT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myelosuppression with methotrexate in individuals homozygous for the MTHFR C677T variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for methotrexate in a patient with the MTHFR A1298C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which MTHFR diplotypes are associated with increased methotrexate toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for methotrexate in pediatric oncology patients based on their MTHFR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should irinotecan dosing be adjusted for a patient with the UGT1A1*28/*28 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe neutropenia with irinotecan in patients homozygous for the UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma SN-38 (irinotecan's active metabolite) in a UGT1A1 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a UGT1A1 intermediate metabolizer for irinotecan therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation and detoxification of SN-38?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose reduction of cisplatin for a patient with TPMT deficient alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of ototoxicity from cisplatin in individuals with specific TPMT variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the plasma concentration thresholds for cisplatin-induced nephrotoxicity based on TPMT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do TPMT genotypes correlate with cisplatin-induced hematologic toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the TPMT enzyme in the metabolism of cisplatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should paclitaxel dosing be adjusted for a patient with low-function ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral neuropathy with paclitaxel in patients with the ABCB1 G2677T/A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for paclitaxel in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which ABCB1 genotypes are associated with paclitaxel resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for paclitaxel in patients with ABCB1 variants and hepatic impairment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of levothyroxine for a patient with the DIO2 Thr92Ala polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of persistent hypothyroid symptoms on levothyroxine in individuals with the DIO2 Thr92Ala variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target TSH level for a levothyroxine-treated patient based on their DIO2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the DIO2 genotype correspond to T4 to T3 conversion efficiency phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the deiodinase, type 2 enzyme (DIO2) in the activation of thyroid hormone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should amlodipine dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral edema with amlodipine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma amlodipine concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for amlodipine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for amlodipine in pediatric patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of losartan for a patient identified as a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of hyperkalemia with losartan in CYP2C9 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of losartan's active metabolite, E-3174, in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 diplotypes (*2, *3) correspond to poor antihypertensive response phenotypes for losartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the bioactivation of losartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should furosemide dosing be adjusted based on SLC12A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of electrolyte imbalance with furosemide in patients with specific SLC12A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested urinary sodium excretion target for a furosemide-treated patient based on their SLC12A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC12A1 genotypes correlate with diuretic resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the NKCC2 cotransporter (encoded by SLC12A1) as the direct target of furosemide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of diazepam for a patient with a CYP2C19 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of prolonged sedation with diazepam in CYP2C19 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for diazepam in a CYP2C19 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C19 diplotypes define a rapid metabolizer for the purpose of diazepam therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for diazepam in elderly patients with the CYP2C19*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should bupropion dosing be adjusted for a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of seizures with bupropion in patients with reduced CYP2B6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma hydroxybupropion concentrations in a CYP2B6 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2B6 intermediate metabolizer for bupropion therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2B6*6 allele in the context of bupropion metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of quetiapine for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of orthostatic hypotension for quetiapine users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for quetiapine in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of quetiapine treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for quetiapine involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should loratadine dosing be adjusted for a patient with low-function ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of non-response to loratadine in patients with high-activity ABCB1 transporter function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for desloratadine in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with loratadine efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of P-glycoprotein (ABCB1) in limiting loratadine's CNS penetration?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended gabapentin dose for a patient with a low-function SLC22A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS side effects from gabapentin in individuals with specific SLC22A2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for gabapentin in a patient with a high-function SLC22A2 transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A2 genotypes map to gabapentin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT2 transporter (encoded by SLC22A2) in the renal excretion of gabapentin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should insulin dosing be adjusted for patients with the KCNJ11 E23K polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of developing type 2 diabetes in individuals with the KCNJ11 E23K variant, and how does it affect insulin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested C-peptide level target for an insulin-treated patient based on their KCNJ11 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which KCNJ11 genotypes are associated with altered insulin secretion phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the Kir6.2 potassium channel (encoded by KCNJ11) in insulin secretion from pancreatic beta-cells?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of atorvastatin for a patient with a DPYD poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Is there an increased risk of myopathy with atorvastatin in patients carrying DPYD deficiency alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for atorvastatin in a DPYD intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which DPYD diplotypes define a normal metabolizer for the purpose of atorvastatin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for atorvastatin in pediatric patients with heterozygous DPYD variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should clopidogrel dosing be adjusted based on PON1 Q192R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of stent thrombosis with clopidogrel in patients with the PON1 192R allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target platelet reactivity unit (PRU) for a clopidogrel-treated patient based on their PON1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the PON1 genotype correspond to clopidogrel bioactivation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the paraoxonase 1 enzyme (PON1) in the metabolism of clopidogrel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for tacrolimus based on ABCB1 transporter genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of nephrotoxicity with tacrolimus in patients with low-activity ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for tacrolimus in a patient with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ABCB1 genotype correspond to tacrolimus dose requirement phenotypes in kidney transplant patients?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for tacrolimus in pediatric liver transplant recipients based on their ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should mycophenolate mofetil (MMF) dosing be adjusted for a patient with a specific UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gastrointestinal adverse effects with MMF in patients with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma mycophenolic acid (MPA) in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which UGT1A9 genotypes are associated with altered MPA glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the metabolism of mycophenolic acid?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of donepezil for a patient identified as a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia with donepezil in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for donepezil in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of donepezil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for donepezil in elderly patients with dementia and a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should clozapine dosing be adjusted for a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of agranulocytosis with clozapine in patients with reduced CYP1A2 function, especially smokers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma clozapine concentrations in a CYP1A2 ultrarapid metabolizer (e.g., a heavy smoker)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP1A2 poor metabolizer for clozapine therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2*1F allele in the context of clozapine metabolism and its interaction with smoking?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of theophylline for a patient with a CYP1A2*1D/*1F genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of theophylline toxicity in individuals who are CYP1A2 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for theophylline in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes map to theophylline clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for theophylline in pediatric asthma patients based on their CYP1A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should glipizide dosing be adjusted for a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypoglycemia with glipizide in patients with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma glipizide concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer for glipizide therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic clearance of glipizide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for simvastatin based on ABCB1 transporter genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of myopathy with simvastatin in patients with low-activity ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for simvastatin acid in a patient with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ABCB1 genotype correspond to simvastatin bioavailability phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (encoded by ABCB1) in the intestinal absorption of simvastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cisplatin dosing be adjusted for a patient with the COMT Val158Met polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cisplatin-induced hearing loss in individuals with the low-activity COMT 'Met' allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the plasma concentration thresholds for cisplatin ototoxicity based on COMT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do COMT genotypes correlate with cisplatin-induced neurotoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cisplatin in pediatric patients based on their COMT genotype to mitigate hearing loss?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of tamoxifen for a patient with a SULT1A1*2/*2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced tamoxifen efficacy in individuals with high-activity SULT1A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of endoxifen in a patient with a specific SULT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SULT1A1 genotypes map to tamoxifen sulfation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the SULT1A1 enzyme in the metabolism of tamoxifen's active metabolites?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should codeine dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of respiratory depression with codeine in patients with reduced CYP3A4 function when co-administered with a CYP2D6 inhibitor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma morphine concentrations in a codeine-treated patient who is a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for codeine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the N-demethylation of codeine to norcodeine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of warfarin for a patient with a Factor V Leiden (F5) mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of venous thromboembolism (VTE) in warfarin-treated patients who are heterozygous for Factor V Leiden?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target INR range for a warfarin-treated patient with homozygous Factor V Leiden?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the F5 G1691A polymorphism correlate with warfarin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of Factor V Leiden and its impact on the coagulation cascade, independent of warfarin's action on vitamin K?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should clopidogrel dosing be adjusted for a patient with the CES1 G143E variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse cardiovascular events with clopidogrel in patients with loss-of-function CES1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of platelet inhibition for a clopidogrel-treated patient based on their CES1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES1 genotype correspond to the hydrolysis of clopidogrel's prodrug to its inactive metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Carboxylesterase 1 (CES1) enzyme in the metabolic pathway of clopidogrel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of allopurinol for a patient with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing a severe cutaneous adverse reaction (SCAR) to allopurinol in individuals with the ABCG2 421C>A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum urate levels for an allopurinol-treated patient based on their ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with allopurinol response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the excretion of allopurinol and its metabolite, oxypurinol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fentanyl dosing be adjusted for a patient with low-function ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of respiratory depression with fentanyl in patients with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for fentanyl in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which ABCB1 genotypes are associated with altered fentanyl dose requirements for adequate analgesia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for transdermal fentanyl in cancer patients with known ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ondansetron for a patient with the ABCB1 G2677T/A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of ondansetron in individuals with high-activity ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ondansetron in a patient with a low-function ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes map to ondansetron anti-emetic response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the P-glycoprotein (ABCB1) in the distribution and clearance of ondansetron?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cyclosporine dosing be adjusted for a CYP3A5 expresser (*1/*1 or *1/*3)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nephrotoxicity with cyclosporine in patients who are CYP3A5 non-expressers (*3/*3)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic trough concentration for cyclosporine in a CYP3A5 expresser versus a non-expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A5 intermediate metabolizer for cyclosporine therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cyclosporine in pediatric transplant recipients based on their CYP3A5 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of phenytoin for a patient with the ABCB1 3435C>T variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing drug-resistant epilepsy with phenytoin in individuals with high-activity ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target free-phenytoin concentrations in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with phenytoin response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in extruding phenytoin from the brain?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should memantine dosing be adjusted for a patient with a low-function SLC22A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dizziness with memantine in individuals with specific SLC22A2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for memantine in a patient with a high-function SLC22A2 transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A2 genotypes map to memantine renal clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT2 transporter (encoded by SLC22A2) in the elimination of memantine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sumatriptan for a patient with a MAOA uVNTR polymorphism associated with low activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to sumatriptan in individuals with high-activity MAOA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for sumatriptan in a patient with a low-activity MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA genotypes correlate with sumatriptan efficacy phenotypes for migraine treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Monoamine Oxidase A (MAOA) enzyme in the metabolism of sumatriptan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should propranolol dosing be adjusted for a patient with a TPMT poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Is there an increased risk of adverse effects with propranolol in patients carrying TPMT deficiency alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for propranolol in a TPMT intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which TPMT diplotypes define a normal metabolizer for the purpose of propranolol therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for propranolol in pediatric patients with heterozygous TPMT variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of escitalopram for a patient with the OPRM1 A118G variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of non-response to escitalopram in OPRM1 G-allele carriers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic effect measure for escitalopram based on OPRM1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which OPRM1 genotypes are associated with poor response phenotypes to escitalopram therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the mu-opioid receptor (encoded by OPRM1) in the therapeutic mechanism of escitalopram?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should amiodarone dosing be adjusted for a CYP2C8*3 carrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of amiodarone-induced liver injury in patients with CYP2C8 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma desethylamiodarone in a patient with a specific CYP2C8 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes correlate with amiodarone clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C8 enzyme in the metabolism of amiodarone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of repaglinide for a patient with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypoglycemia with repaglinide in individuals with low-function SLCO1B1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for repaglinide in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes map to repaglinide exposure phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of repaglinide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sildenafil dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of visual disturbances with sildenafil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma sildenafil concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for sildenafil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sildenafil for pulmonary hypertension in patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lamotrigine for a patient with a UGT1A4*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing a rash with lamotrigine in individuals with low-activity UGT1A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for lamotrigine in a patient with a high-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes map to lamotrigine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 enzyme in the glucuronidation of lamotrigine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should topiramate dosing be adjusted for a patient with a CA2 (Carbonic Anhydrase II) deficiency?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of metabolic acidosis with topiramate in patients with specific CA2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested serum bicarbonate level to monitor in a topiramate-treated patient based on their CA2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CA2 genotypes correlate with topiramate-induced cognitive side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the Carbonic Anhydrase II enzyme in the mechanism of action and side effect profile of topiramate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of levetiracetam for a patient with a SV2A gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of behavioral side effects with levetiracetam in individuals with specific SV2A variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for levetiracetam in a patient based on their SV2A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SV2A genotypes correlate with levetiracetam response phenotypes in epilepsy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Synaptic Vesicle Glycoprotein 2A (SV2A), the binding site for levetiracetam, and how do its variants alter drug affinity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should montelukast dosing be adjusted for a CYP2C8*3 carrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neuropsychiatric events with montelukast in patients with CYP2C8 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma montelukast in a patient with a specific CYP2C8 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes correlate with montelukast clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for montelukast in asthmatic children with the CYP2C8*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of hydrochlorothiazide (HCTZ) for a patient with the ADD1 Gly460Trp polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypokalemia with HCTZ in individuals with specific variants in the adducin 1 (ADD1) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for an HCTZ-treated patient based on their ADD1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADD1 genotypes correlate with antihypertensive response phenotypes to HCTZ?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of adducin 1 and its role in sodium transport as it relates to HCTZ's mechanism of action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should caffeine intake be managed for a patient on clozapine who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of clozapine toxicity when a patient with low CYP1A2 activity consumes large amounts of caffeine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma clozapine concentrations in a patient who is a CYP1A2 rapid metabolizer and a heavy caffeine user?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 indicate a need for caffeine consumption counseling during clozapine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of caffeine's inhibition of the CYP1A2 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dabigatran for a patient with a high-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with dabigatran in individuals with low-function ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma trough concentrations for dabigatran in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes map to dabigatran exposure and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the P-glycoprotein (ABCB1) in the intestinal absorption and clearance of dabigatran?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should rivaroxaban dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of major bleeding events with rivaroxaban in patients with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested anti-Factor Xa activity level for a rivaroxaban-treated patient based on their ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with rivaroxaban peak concentration phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for rivaroxaban in elderly patients with renal impairment and a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of apixaban for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with apixaban in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for apixaban in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to apixaban clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of apixaban?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ticagrelor dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dyspnea with ticagrelor in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ticagrelor concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ticagrelor therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ticagrelor in patients with known CYP3A4 variants who are also on a strong CYP3A4 inhibitor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of oxycodone for a patient with the ABCB1 3435C>T variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of central nervous system side effects with oxycodone in individuals with low-function ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for oxycodone in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with oxycodone analgesic response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of oxycodone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should zolpidem dosing be adjusted for a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of next-day impairment with zolpidem in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma zolpidem concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for zolpidem therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for zolpidem in female patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of finasteride for a patient with a SRD5A2 V89L polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to finasteride for benign prostatic hyperplasia in individuals with specific SRD5A2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum dihydrotestosterone (DHT) suppression levels for a finasteride-treated patient based on their SRD5A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SRD5A2 genotypes correlate with finasteride efficacy phenotypes for androgenetic alopecia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the 5-alpha reductase type 2 enzyme (SRD5A2) and how do its variants alter finasteride binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tamoxifen dosing be adjusted for a patient with the ABCB1 3435C>T variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of treatment failure with tamoxifen in individuals with high-activity ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for endoxifen in a patient with a specific ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with tamoxifen resistance phenotypes in breast cancer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the efflux of tamoxifen and its metabolites from cancer cells?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of letrozole for a patient who is a CYP2A6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of musculoskeletal side effects with letrozole in individuals with reduced CYP2A6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for letrozole in a patient with a CYP2A6 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2A6 genotypes map to letrozole clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2A6 enzyme in the metabolism of letrozole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sunitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hand-foot syndrome with sunitinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma sunitinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for sunitinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sunitinib in patients with renal cell carcinoma and known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of imatinib for a patient with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing severe adverse effects to imatinib in individuals with the ABCG2 421C>A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for an imatinib-treated patient based on their ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with imatinib response phenotypes in chronic myeloid leukemia (CML)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the efflux and bioavailability of imatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should valproic acid dosing be adjusted for a patient with a POLG1 mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of fatal hepatotoxicity with valproic acid in children with an underlying POLG1-related mitochondrial disorder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for valproic acid in a patient with a known POLG1 mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which POLG1 genotypes are considered a contraindication for valproic acid therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which valproic acid toxicity is exacerbated in patients with POLG1 mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of carvedilol for a patient with the ADRB2 Arg16Gly polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of a blunted heart rate response to carvedilol in individuals with the ADRB2 Gly16 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for a carvedilol-treated patient based on their ADRB2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADRB2 genotypes correlate with carvedilol response phenotypes in heart failure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the beta-2 adrenergic receptor (ADRB2) and how do its variants alter carvedilol's effects?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should metformin dosing be adjusted for a patient with a low-function OCT1 (SLC22A1) genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gastrointestinal side effects with metformin in individuals with specific SLC22A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for metformin in a patient with a high-function OCT1 transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A1 genotypes map to metformin hepatic uptake and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT1 transporter (encoded by SLC22A1) in the therapeutic action of metformin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sulfasalazine for a patient with the NAT2 slow acetylator phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypersensitivity reactions to sulfasalazine in individuals who are NAT2 slow acetylators?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of sulfapyridine in a patient with a NAT2 rapid acetylator genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NAT2 genotypes (e.g., *5, *6, *7) define slow, intermediate, and rapid acetylator phenotypes for sulfasalazine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the N-acetyltransferase 2 (NAT2) enzyme in the metabolism of sulfapyridine, the active moiety of sulfasalazine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should hydralazine dosing be adjusted for a patient with a NAT2 slow acetylator genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing drug-induced lupus erythematosus with hydralazine in NAT2 slow acetylators?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma hydralazine concentrations in a NAT2 rapid acetylator?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a NAT2 slow acetylator for hydralazine therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for hydralazine in heart failure patients based on their NAT2 acetylator status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of isoniazid for a patient with the NAT2 rapid acetylator phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with isoniazid in individuals who are NAT2 slow acetylators?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for isoniazid in a patient with a NAT2 intermediate acetylator genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NAT2 genotypes map to isoniazid acetylation and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for isoniazid in pediatric tuberculosis patients based on their NAT2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should procainamide dosing be adjusted for a patient with a NAT2 slow acetylator genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing a positive antinuclear antibody (ANA) test with procainamide in NAT2 slow acetylators?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma N-acetylprocainamide (NAPA) in a NAT2 rapid acetylator?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a NAT2 slow acetylator for procainamide therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the NAT2 enzyme in the metabolism of procainamide to its active metabolite, NAPA?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of celecoxib for a patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects from celecoxib in individuals with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for celecoxib in a patient with a CYP2D6 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to celecoxib metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic pathway of celecoxib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should omeprazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of drug interactions with omeprazole in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma omeprazole concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for omeprazole therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for omeprazole in pediatric GERD patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of warfarin for a patient with the APOE E4 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding complications with warfarin in individuals carrying the APOE E2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target INR range for a warfarin-treated patient based on their APOE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the APOE genotype correlate with warfarin dose requirement phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which apolipoprotein E isoforms might influence warfarin metabolism or sensitivity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tacrolimus dosing be adjusted for a patient with a POR*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of tacrolimus toxicity in patients with low-function POR variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic trough concentration for tacrolimus in a patient homozygous for the POR*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the POR genotype correlate with overall CYP3A activity and tacrolimus dose requirements?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Cytochrome P450 Oxidoreductase (POR) enzyme in supporting the activity of CYP3A enzymes that metabolize tacrolimus?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of doxorubicin for a patient with a SLC22A16 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiotoxicity with doxorubicin in individuals with low-function SLC22A16 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target intracellular concentrations of doxorubicin in cardiac tissue based on a patient's SLC22A16 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A16 genotypes correlate with doxorubicin-induced cardiomyopathy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the SLC22A16 transporter in the uptake of doxorubicin into cells?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should capecitabine dosing be adjusted for a patient with a CES2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hand-foot syndrome with capecitabine in patients with high-activity CES2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma 5-FU concentrations in a capecitabine-treated patient based on their CES2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES2 genotype correlate with the conversion of capecitabine to 5'-DFCR phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 2 (CES2) in the activation pathway of the prodrug capecitabine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of azathioprine for a patient with a GSTM1-null genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with azathioprine in individuals with a GSTT1-null genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target 6-TGN metabolite levels for an azathioprine-treated patient based on their GSTP1 Ile105Val polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do Glutathione S-Transferase (GST) genotypes correlate with azathioprine toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the GST family of enzymes in the detoxification of azathioprine metabolites?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tamoxifen dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of thromboembolic events with tamoxifen in patients with CYP2C9*2 or *3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma endoxifen concentrations in a patient who is a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP2C9 define a poor metabolizer in the context of tamoxifen therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic activation of tamoxifen?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fluoxetine for a patient with the HTR2C -759C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of weight gain with fluoxetine in individuals with the HTR2C -759T allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for fluoxetine based on a patient's HTR2C genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do HTR2C genotypes correlate with fluoxetine efficacy and side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the 5-HT2C receptor (HTR2C) and how might its variants alter the effects of fluoxetine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should paroxetine dosing be adjusted for a patient with a COMT Val158Met polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to paroxetine in individuals with the high-activity COMT 'Val' allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma paroxetine concentrations based on COMT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do COMT genotypes correlate with paroxetine treatment outcomes in major depressive disorder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the COMT enzyme in dopamine regulation and its potential interaction with paroxetine's therapeutic mechanism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of venlafaxine for a patient with an ABCB1 low-function haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing hypertension with venlafaxine in patients with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for O-desmethylvenlafaxine in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with venlafaxine resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of venlafaxine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should duloxetine dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nausea with duloxetine in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma duloxetine concentrations in a CYP1A2 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of duloxetine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolic clearance of duloxetine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mirtazapine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of sedation and weight gain with mirtazapine in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for mirtazapine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of mirtazapine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for mirtazapine in geriatric patients with a CYP2D6 decreased function allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should trazodone dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of priapism with trazodone in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma trazodone concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for trazodone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of trazodone to its active metabolite, m-CPP?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of buspirone for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dizziness and serotonin syndrome with buspirone in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for buspirone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to buspirone clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for buspirone when co-administered with a strong CYP3A4 inhibitor, based on a patient's genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should alprazolam dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of excessive sedation with alprazolam in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma alprazolam concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for alprazolam therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for alprazolam in elderly patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of clonazepam for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of ataxia and cognitive impairment with clonazepam in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for clonazepam in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to clonazepam clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolic pathway of clonazepam?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lithium dosing be adjusted for a patient with a GADL1 gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of non-response to lithium in individuals with specific GADL1 polymorphisms?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic serum lithium level for a patient based on their GADL1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do GADL1 genotypes correlate with lithium efficacy phenotypes in bipolar disorder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Glutamate Decarboxylase-Like 1 (GADL1) protein and its potential role in lithium's mechanism of action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of aspirin for a patient with the PTGS1 (COX-1) -1676A>G polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of aspirin resistance in individuals with specific PTGS1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of thromboxane B2 inhibition for an aspirin-treated patient based on their PTGS1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PTGS1 genotypes correlate with the antiplatelet effect of low-dose aspirin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the cyclooxygenase-1 enzyme (PTGS1) and how do its variants alter aspirin's binding and inhibitory effect?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should spironolactone dosing be adjusted for a patient with a CYP3A4 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperkalemia with spironolactone in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma canrenone (spironolactone's active metabolite) in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for spironolactone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of spironolactone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of eplerenone for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of life-threatening hyperkalemia with eplerenone in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for eplerenone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to eplerenone clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for eplerenone in heart failure patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should rosuvastatin dosing be adjusted for a patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy with rosuvastatin in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for rosuvastatin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to rosuvastatin metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic pathway of rosuvastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pravastatin for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of muscle-related side effects with pravastatin in individuals with reduced UGT1A1 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pravastatin concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with pravastatin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation of pravastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ezetimibe dosing be adjusted for a patient with a NPC1L1 gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor LDL-lowering response to ezetimibe in individuals with specific NPC1L1 polymorphisms?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target LDL reduction for an ezetimibe-treated patient based on their NPC1L1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NPC1L1 genotypes correlate with ezetimibe efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Niemann-Pick C1-Like 1 (NPC1L1) protein, the direct target of ezetimibe, and how do its variants alter drug action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of colchicine for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of colchicine toxicity (e.g., myelosuppression) in patients with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma colchicine concentrations in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with colchicine clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for colchicine in patients with renal impairment and a known low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should metformin dosing be adjusted for a patient with a MATE1 (SLC47A1) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of metformin intolerance in individuals with low-function MATE1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for metformin in a patient with a high-function MATE1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC47A1 genotypes map to metformin renal excretion phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MATE1 transporter (encoded by SLC47A1) in the final step of metformin elimination from the body?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ranitidine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with ranitidine in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ranitidine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to ranitidine metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic pathway of ranitidine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cimetidine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of drug interactions (e.g., with warfarin) when cimetidine is used by a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cimetidine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP2D6 define a poor metabolizer in the context of cimetidine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of cimetidine's inhibition of the CYP2D6 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cetirizine for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of sedation with cetirizine in individuals with specific ABCB1 variants that increase CNS penetration?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for cetirizine in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with cetirizine efficacy and side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the distribution of cetirizine into the brain?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fexofenadine dosing be adjusted for a patient with a low-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of poor response to fexofenadine in individuals with high-function SLCO1B1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma fexofenadine concentrations in a patient with a specific SLCO1B1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with fexofenadine bioavailability phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake and clearance of fexofenadine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of amoxicillin for a patient with a specific penicillin-binding protein (PBP) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with amoxicillin in infections caused by bacteria with altered PBP genes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target minimum inhibitory concentration (MIC) for amoxicillin based on the PBP genotype of the infecting organism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PBP genotypes in bacteria correlate with amoxicillin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of penicillin-binding proteins and how do their genetic alterations in bacteria confer resistance to amoxicillin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should vancomycin dosing be adjusted for a patient with a specific variant in the D-Ala-D-Lac synthesis pathway genes (vanA, vanB)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of treatment failure for VRE (Vancomycin-Resistant Enterococci) infections based on the specific van genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for vancomycin when treating an infection with a known vanA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do the vanA, vanB, and vanC genotypes in Enterococcus species correlate with the level of vancomycin resistance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of vancomycin resistance conferred by the vanA gene cluster?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of rifampin for a patient who is a SLCO1B1 poor transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with rifampin in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma rifampin concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with rifampin-induced liver injury phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of rifampin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should zidovudine (AZT) dosing be adjusted for a patient with a UGT2B7*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hematologic toxicity with zidovudine in individuals with low-activity UGT2B7 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for zidovudine-glucuronide in a patient with a high-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT2B7 genotypes map to zidovudine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT2B7 enzyme in the metabolism and elimination of zidovudine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of efavirenz for a patient with a CYP2A6 poor metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS side effects with efavirenz in individuals who are CYP2A6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for efavirenz in a patient with a CYP2A6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2A6 genotypes map to efavirenz metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2A6 enzyme in the 8-hydroxylation of efavirenz?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should nevirapine dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe rash (Stevens-Johnson syndrome) with nevirapine in patients with specific CYP2B6 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma nevirapine concentrations in a CYP2B6 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP2B6 define a poor metabolizer in the context of nevirapine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for nevirapine in pediatric HIV patients based on their CYP2B6 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lopinavir/ritonavir for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with lopinavir/ritonavir in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for lopinavir in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with lopinavir clearance and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of lopinavir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tenofovir disoproxil fumarate (TDF) dosing be adjusted for a patient with an ABCC2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Fanconi syndrome and renal toxicity with TDF in individuals with low-function ABCC2 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target intracellular tenofovir diphosphate concentrations in a patient with a specific ABCC2 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCC2 genotypes correlate with tenofovir-induced nephrotoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MRP2 transporter (encoded by ABCC2) in the renal tubular secretion of tenofovir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dolutegravir for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with dolutegravir in individuals with reduced UGT1A1 function (Gilbert's syndrome)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma dolutegravir concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with dolutegravir clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of dolutegravir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should maraviroc dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of postural hypotension with maraviroc in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma maraviroc concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for maraviroc therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for maraviroc in patients with known CYP3A4 variants who are also on a strong CYP3A4 inducer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sofosbuvir for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced virologic response to sofosbuvir-based regimens in individuals with high-activity ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target intracellular concentrations of the active sofosbuvir triphosphate metabolite based on a patient's ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with sofosbuvir efficacy phenotypes in Hepatitis C treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the intestinal absorption and disposition of sofosbuvir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should simeprevir dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hyperbilirubinemia with simeprevir in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma simeprevir concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with simeprevir-induced photosensitivity reactions?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of simeprevir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ledipasvir for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of altered ledipasvir exposure in individuals with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ledipasvir based on a patient's ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with the efficacy of ledipasvir/sofosbuvir combination therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the bioavailability of ledipasvir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should amphotericin B dosing be adjusted for a patient with a specific variant in the AMB-binding ergosterol synthesis pathway?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nephrotoxicity with amphotericin B in individuals with genetic predispositions to renal dysfunction?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for amphotericin B based on a patient's genetic risk score for kidney injury?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with amphotericin B-induced infusion reactions?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for liposomal amphotericin B in pediatric patients with a genetic susceptibility to renal damage?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fluconazole for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with fluconazole in individuals with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma fluconazole concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP2C9 define a poor metabolizer in the context of fluconazole therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic clearance of fluconazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should itraconazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular events (e.g., heart failure) with itraconazole in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma itraconazole concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for itraconazole therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of itraconazole's potent inhibition of the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of posaconazole for a patient with a UGT1A4*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of subtherapeutic posaconazole levels in individuals with high-activity UGT1A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for posaconazole in a patient with a low-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes map to posaconazole clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 enzyme in the glucuronidation and elimination of posaconazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should caspofungin dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of elevated liver enzymes with caspofungin in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma caspofungin concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with caspofungin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of caspofungin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of acyclovir for a patient with a specific organic anion transporter (OAT1/SLC22A6) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nephrotoxicity with high-dose intravenous acyclovir in individuals with low-function OAT1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for acyclovir in a patient with a high-function OAT1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6 genotypes map to acyclovir renal secretion phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OAT1 transporter in the active tubular secretion of acyclovir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ganciclovir dosing be adjusted for a patient with a specific organic anion transporter (OAT1/SLC22A6) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myelosuppression with ganciclovir in individuals with low-function OAT1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ganciclovir concentrations in a patient with a high-function OAT1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6 genotypes correlate with ganciclovir renal clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for valganciclovir (prodrug of ganciclovir) in transplant patients with known SLC22A6 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of oseltamivir for a patient with a CES1 G143E variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of oseltamivir in individuals with high-activity CES1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of oseltamivir carboxylate (active metabolite) in a patient with a low-activity CES1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES1 genotype correlate with the hydrolysis of oseltamivir to its active form?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 1 (CES1) in the bioactivation of the prodrug oseltamivir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should zanamivir dosing be adjusted for a patient with a specific neuraminidase (NA) gene variant in the infecting influenza virus?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with zanamivir in infections caused by influenza with the H275Y NA mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target IC50 value for zanamivir against an influenza strain with a known NA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do viral NA genotypes correlate with zanamivir resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the viral neuraminidase enzyme and how do its genetic alterations confer resistance to zanamivir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of linezolid for a patient with a specific MAOA uVNTR polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of serotonin syndrome when linezolid is co-administered with an SSRI in a patient with a low-activity MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for linezolid to avoid hematologic toxicity based on MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA genotypes correlate with the risk of linezolid-induced hypertension?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of linezolid's weak, reversible inhibition of Monoamine Oxidase A?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should daptomycin dosing be adjusted for a patient with a genetic predisposition to rhabdomyolysis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of elevated creatine phosphokinase (CPK) with daptomycin in individuals with underlying muscular dystrophy gene mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested CPK monitoring frequency for a daptomycin-treated patient based on their genetic risk score for myopathy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors (e.g., in carnitine metabolism) correlate with daptomycin-induced muscle toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for daptomycin in patients on statin therapy with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of tigecycline for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe nausea and vomiting with tigecycline in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for tigecycline in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to tigecycline clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the minor metabolic pathway of tigecycline?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should erythromycin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with erythromycin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma erythromycin concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for erythromycin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of erythromycin's potent inhibition of the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of clarithromycin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular mortality with clarithromycin in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for clarithromycin in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to clarithromycin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for clarithromycin in patients with known CYP3A4 variants who are also taking other CYP3A4 substrates?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should azithromycin dosing be adjusted for a patient with a KCNH2 (hERG) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Torsades de Pointes with azithromycin in individuals with congenital long QT syndrome caused by KCNH2 mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested QTc interval limit for an azithromycin-treated patient based on their KCNH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KCNH2 genotypes correlate with azithromycin-induced cardiac arrhythmia phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the hERG potassium channel (encoded by KCNH2) and how is it affected by azithromycin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of doxycycline for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with doxycycline in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for doxycycline in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to doxycycline metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolic pathway of doxycycline?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should clindamycin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of C. difficile infection with clindamycin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma clindamycin concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for clindamycin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of clindamycin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of metronidazole for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of a disulfiram-like reaction with metronidazole and alcohol in individuals with CYP2C9 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for metronidazole in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C9 genotypes map to metronidazole clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic pathway of metronidazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should trimethoprim dosing be adjusted for a patient with a low-function MATE1 (SLC47A1) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperkalemia with trimethoprim in individuals with low-function MATE1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma trimethoprim concentrations in a patient with a high-function MATE1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC47A1 genotypes correlate with trimethoprim-induced renal toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MATE1 transporter in the renal secretion of trimethoprim?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nitrofurantoin for a patient with a specific variant in the nitroreductase gene (NfsA/NfsB)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pulmonary toxicity with long-term nitrofurantoin use in individuals with genetic predispositions to lung fibrosis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target urinary concentrations for nitrofurantoin based on the NfsA/NfsB genotype of the infecting E. coli?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do bacterial nitroreductase genotypes correlate with nitrofurantoin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of bacterial nitroreductases in the activation of the prodrug nitrofurantoin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fosfomycin dosing be adjusted for a patient with a specific variant in the MurA gene of the infecting bacteria?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with fosfomycin in infections caused by bacteria with MurA mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target urinary concentration for fosfomycin based on the MurA genotype of the infecting organism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do bacterial MurA genotypes correlate with fosfomycin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MurA enzyme in bacterial cell wall synthesis and how do its genetic alterations confer resistance to fosfomycin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cyclophosphamide for a patient who is a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of treatment failure with cyclophosphamide in individuals who are CYP2B6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of 4-hydroxycyclophosphamide in a patient with a CYP2B6 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2B6 genotypes map to cyclophosphamide bioactivation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the 4-hydroxylation (activation) of cyclophosphamide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ifosfamide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurotoxicity (encephalopathy) with ifosfamide in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma 4-hydroxyifosfamide in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ifosfamide therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the activation of ifosfamide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of etoposide for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe myelosuppression with etoposide in individuals with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for etoposide in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with etoposide clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the efflux and disposition of etoposide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should vincristine dosing be adjusted for a patient who is a CYP3A5 expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral neuropathy with vincristine in patients who are CYP3A5 non-expressers (*3/*3)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma vincristine concentrations in a CYP3A5 expresser versus a non-expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A5 intermediate metabolizer for vincristine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for vincristine in pediatric leukemia patients based on their CYP3A5 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of gefitinib for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea and rash with gefitinib in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for gefitinib in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to gefitinib metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the O-demethylation of gefitinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should erlotinib dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe skin toxicity with erlotinib in patients with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma erlotinib concentrations in a CYP1A2 rapid metabolizer (e.g., a heavy smoker)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of erlotinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for erlotinib in lung cancer patients who smoke, based on their CYP1A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lapatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with lapatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for lapatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to lapatinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the extensive metabolism of lapatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pazopanib dosing be adjusted for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with pazopanib in individuals with reduced UGT1A1 function (Gilbert's syndrome)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pazopanib concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with pazopanib-induced liver toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of pazopanib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sorafenib for a patient who is a UGT1A9 promoter polymorphism carrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hand-foot skin reaction with sorafenib in individuals with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for sorafenib in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes map to sorafenib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the metabolism of sorafenib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should vemurafenib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with vemurafenib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma vemurafenib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for vemurafenib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for vemurafenib in melanoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of crizotinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia and visual disorders with crizotinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for crizotinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to crizotinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of crizotinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should olaparib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hematologic toxicity with olaparib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma olaparib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for olaparib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for olaparib in ovarian cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of everolimus for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of stomatitis and non-infectious pneumonitis with everolimus in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for everolimus in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to everolimus clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for everolimus in transplant rejection prophylaxis based on a patient's CYP3A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sirolimus dosing be adjusted for a patient who is a CYP3A5 expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperlipidemia with sirolimus in patients who are CYP3A5 non-expressers (*3/*3)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic trough concentration for sirolimus in a CYP3A5 expresser versus a non-expresser?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A5 intermediate metabolizer for sirolimus therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sirolimus in pediatric transplant recipients based on their CYP3A5 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of temsirolimus for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperglycemia and hyperlipidemia with temsirolimus in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of sirolimus (the active metabolite of temsirolimus) in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to temsirolimus conversion and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of temsirolimus to sirolimus?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pemetrexed dosing be adjusted for a patient with a MTHFR C677T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hematologic toxicity with pemetrexed in individuals with the MTHFR 677TT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pemetrexed concentrations based on MTHFR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MTHFR genotypes correlate with pemetrexed efficacy and toxicity phenotypes in non-small cell lung cancer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the MTHFR enzyme in folate metabolism and its impact on the action of the antifolate drug pemetrexed?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of gemcitabine for a patient with a CDA (cytidine deaminase) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe neutropenia with gemcitabine in individuals with low-activity CDA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of the inactive metabolite dFdU in a gemcitabine-treated patient with a high-activity CDA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CDA genotypes map to gemcitabine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of cytidine deaminase (CDA) in the inactivation of gemcitabine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fludarabine dosing be adjusted for a patient with a specific variant in a nucleoside transporter gene like SLC28A1?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurotoxicity with fludarabine in individuals with genetic variants affecting drug transport or metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested intracellular concentrations of fludarabine triphosphate based on a patient's transporter genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do nucleoside transporter genotypes correlate with fludarabine efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of nucleoside transporters in the uptake of fludarabine into target cells?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cladribine for a patient with a specific variant in the DCK (deoxycytidine kinase) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with cladribine in individuals with low-activity DCK variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target intracellular concentrations of cladribine triphosphate in a patient with a high-activity DCK genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do DCK genotypes map to cladribine activation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of deoxycytidine kinase (DCK) in the phosphorylation and activation of cladribine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cytarabine (Ara-C) dosing be adjusted for a patient with a CDA (cytidine deaminase) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cerebellar toxicity with high-dose cytarabine in individuals with low-activity CDA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cytarabine concentrations in a patient with a high-activity CDA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CDA genotypes correlate with cytarabine clearance and toxicity phenotypes in acute myeloid leukemia (AML)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cytarabine in pediatric AML patients based on their CDA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of hydroxyurea for a patient with a specific variant in a ribonucleotide reductase (RRM1) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to hydroxyurea for sickle cell disease in individuals with specific RRM1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target fetal hemoglobin (HbF) level for a hydroxyurea-treated patient based on their genetic profile?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do RRM1 genotypes correlate with hydroxyurea efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of ribonucleotide reductase, the target of hydroxyurea, and how do its variants alter drug sensitivity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should bleomycin dosing be adjusted for a patient with a BLMH (bleomycin hydrolase) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pulmonary fibrosis with bleomycin in individuals with low-activity BLMH variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for bleomycin based on a patient's BLMH genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do BLMH genotypes correlate with bleomycin-induced lung toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of bleomycin hydrolase (BLMH) in the inactivation and detoxification of bleomycin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mitomycin C for a patient with a specific variant in the NQO1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myelosuppression with mitomycin C in individuals with the NQO1*2 allele (low activity)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of DNA cross-linking in tumor cells for a mitomycin C-treated patient based on their NQO1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NQO1 genotypes correlate with mitomycin C bioactivation and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the NAD(P)H Quinone Dehydrogenase 1 (NQO1) enzyme in the reductive activation of mitomycin C?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should temozolomide dosing be adjusted for a patient with an unmethylated MGMT promoter in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment resistance to temozolomide in glioblastoma patients with a methylated MGMT promoter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for temozolomide based on the MGMT methylation status of the tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does MGMT promoter methylation status correlate with temozolomide efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the O-6-methylguanine-DNA methyltransferase (MGMT) enzyme in repairing DNA damage caused by temozolomide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of carmustine (BCNU) for a patient with a GSTP1 Ile105Val polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pulmonary toxicity with carmustine in individuals with low-activity GSTP1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for carmustine in a patient with a high-activity GSTP1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do GSTP1 genotypes correlate with carmustine resistance phenotypes in brain tumors?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Glutathione S-transferase Pi 1 (GSTP1) enzyme in the detoxification of carmustine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lomustine (CCNU) dosing be adjusted for a patient with an unmethylated MGMT promoter in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe myelosuppression with lomustine in patients with a methylated MGMT promoter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for lomustine based on the MGMT methylation status of the tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does MGMT promoter methylation status correlate with lomustine efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the MGMT enzyme in repairing DNA alkylation caused by lomustine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dacarbazine for a patient with an unmethylated MGMT promoter in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to dacarbazine in melanoma patients with a methylated MGMT promoter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target levels of DNA methylation in tumor cells for a dacarbazine-treated patient based on their MGMT status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does MGMT promoter methylation status correlate with dacarbazine resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MGMT enzyme in reversing the therapeutic DNA damage caused by dacarbazine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should procarbazine dosing be adjusted for a patient with a specific MAO (Monoamine Oxidase) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertensive crisis with procarbazine when tyramine-containing foods are consumed, based on MAO genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma procarbazine concentrations based on MAO genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA/MAOB genotypes correlate with procarbazine's side effect profile?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Monoamine Oxidase enzymes in the metabolism of procarbazine and its interaction with sympathomimetic amines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of altretamine for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurotoxicity with altretamine in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for altretamine in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes map to altretamine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the N-demethylation of altretamine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should bendamustine dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe skin reactions with bendamustine in patients with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma bendamustine concentrations in a CYP1A2 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of bendamustine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolism of bendamustine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of trabectedin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of rhabdomyolysis with trabectedin in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for trabectedin in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to trabectedin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for trabectedin in sarcoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should topotecan dosing be adjusted for a patient with a low-function ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea and neutropenia with topotecan in individuals with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma topotecan concentrations in a patient with a high-activity ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with topotecan clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the biliary and renal excretion of topotecan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of rituximab for a patient with a specific FCGR3A (Fc gamma receptor IIIa) V158F polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to rituximab in lymphoma patients who are homozygous for the low-affinity FCGR3A-158F allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of B-cell depletion for a rituximab-treated patient based on their FCGR3A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FCGR3A genotypes correlate with rituximab efficacy phenotypes in autoimmune diseases and cancer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the FCGR3A receptor on NK cells in mediating antibody-dependent cell-mediated cytotoxicity (ADCC) for rituximab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should trastuzumab dosing be adjusted for a patient with a specific FCGR2A (Fc gamma receptor IIa) H131R polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiotoxicity with trastuzumab in individuals with specific FCGR2A variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for trastuzumab in HER2-positive breast cancer based on FCGR2A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FCGR2A genotypes correlate with trastuzumab-mediated ADCC and clinical outcomes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the FCGR2A receptor on macrophages in the therapeutic mechanism of trastuzumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cetuximab for a patient with a specific KRAS gene mutation in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of complete non-response to cetuximab in colorectal cancer patients with a KRAS mutation in codon 12 or 13?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic strategy for a patient whose tumor has a KRAS G12D mutation, regarding cetuximab therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KRAS mutational statuses (wild-type vs. mutant) correlate with cetuximab efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which a KRAS mutation leads to constitutive activation of the EGFR pathway, rendering cetuximab ineffective?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should panitumumab dosing be adjusted for a patient with a specific NRAS gene mutation in their tumor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of non-response to panitumumab in colorectal cancer patients with an NRAS Q61K mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic strategy for a patient whose tumor has an NRAS mutation, regarding panitumumab therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do NRAS mutational statuses correlate with panitumumab resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of NRAS in the EGFR signaling pathway and how do its mutations bypass the need for EGFR activation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bevacizumab for a patient with a specific VEGF-A gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertension and proteinuria with bevacizumab in individuals with specific VEGF-A variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for bevacizumab based on a patient's germline VEGF-A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do VEGF-A genotypes correlate with bevacizumab efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Vascular Endothelial Growth Factor A (VEGF-A) and how might its genetic variants alter response to anti-VEGF therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ipilimumab dosing be adjusted for a patient with a specific CTLA-4 gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe immune-related adverse events (irAEs) with ipilimumab in individuals with specific CTLA-4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for ipilimumab in melanoma based on a patient's CTLA-4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CTLA-4 genotypes correlate with ipilimumab efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4), the target of ipilimumab, and how do its variants alter immune response?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nivolumab for a patient with a specific PD-L1 (CD274) gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to nivolumab in patients whose tumors have low PD-L1 expression, and is this associated with germline CD274 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of T-cell activation for a nivolumab-treated patient based on their PD-L1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do germline CD274 genotypes correlate with nivolumab efficacy and immune-related adverse event phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the PD-L1 ligand and its interaction with the PD-1 receptor, which is blocked by nivolumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pembrolizumab dosing be adjusted for a patient with a specific PD-1 (PDCD1) gene polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pneumonitis with pembrolizumab in individuals with specific PDCD1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for pembrolizumab based on a patient's germline PDCD1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PDCD1 genotypes correlate with pembrolizumab efficacy and toxicity phenotypes across different cancers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Programmed Cell Death Protein 1 (PD-1), the target of pembrolizumab, and how do its variants alter immune checkpoint regulation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bortezomib for a patient with a specific variant in a proteasome subunit gene (e.g., PSMB5)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral neuropathy with bortezomib in individuals with specific PSMB5 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of proteasome inhibition for a bortezomib-treated patient based on their proteasome subunit genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do proteasome subunit genotypes correlate with bortezomib resistance phenotypes in multiple myeloma?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the proteasome beta-5 subunit (PSMB5), the primary target of bortezomib, and how do its mutations confer resistance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should carfilzomib dosing be adjusted for a patient with a specific variant in a proteasome subunit gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiotoxicity with carfilzomib in individuals with genetic predispositions to heart failure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for carfilzomib based on a patient's proteasome subunit genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do proteasome subunit genotypes correlate with carfilzomib efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for carfilzomib in multiple myeloma patients with a history of bortezomib resistance due to a PSMB5 mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of thalidomide for a patient with a specific variant in the CRBN (cereblon) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to thalidomide in multiple myeloma patients with low-expression CRBN variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of Ikaros/Aiolos degradation for a thalidomide-treated patient based on their CRBN genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CRBN genotypes correlate with thalidomide efficacy and teratogenicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Cereblon (CRBN) as the primary target of thalidomide and its role in protein degradation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lenalidomide dosing be adjusted for a patient with a specific variant in the CRBN (cereblon) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myelosuppression with lenalidomide in individuals with specific CRBN variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for lenalidomide in myelodysplastic syndromes based on CRBN genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CRBN genotypes correlate with lenalidomide resistance phenotypes in multiple myeloma?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for lenalidomide in patients with del(5q) MDS based on their CRBN expression level?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pomalidomide for a patient with a specific variant in the CRBN (cereblon) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with pomalidomide in lenalidomide-refractory myeloma patients with acquired CRBN mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of protein degradation for a pomalidomide-treated patient based on their CRBN genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CRBN genotypes correlate with pomalidomide efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Cereblon (CRBN) and how do its mutations affect the binding and activity of pomalidomide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should interferon alfa dosing be adjusted for a patient with a specific variant in the STAT1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing severe depression with interferon alfa in individuals with specific STAT1 gain-of-function mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of STAT1 phosphorylation to monitor in an interferon alfa-treated patient based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do STAT1 genotypes correlate with interferon alfa efficacy and side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Signal Transducer and Activator of Transcription 1 (STAT1) in the interferon signaling pathway?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of interleukin-2 (IL-2) for a patient with a specific variant in the IL2RA (CD25) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of capillary leak syndrome with high-dose IL-2 in individuals with specific IL2RA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for IL-2 in renal cell carcinoma based on a patient's IL2RA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do IL2RA genotypes correlate with IL-2 efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the IL-2 receptor alpha chain (IL2RA), and how do its variants alter T-cell response to IL-2 therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should denosumab dosing be adjusted for a patient with a specific variant in the RANKL (TNFSF11) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of osteonecrosis of the jaw with denosumab in individuals with specific RANKL variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of bone turnover marker suppression for a denosumab-treated patient based on their RANKL genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do RANKL genotypes correlate with denosumab efficacy phenotypes in osteoporosis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of RANKL, the target of denosumab, in osteoclast differentiation and function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of zoledronic acid for a patient with a specific variant in the FDPS (farnesyl diphosphate synthase) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of acute phase reactions with zoledronic acid in individuals with specific FDPS variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for zoledronic acid in bone metastases based on a patient's FDPS genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FDPS genotypes correlate with zoledronic acid efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of FDPS in the mevalonate pathway, which is inhibited by zoledronic acid?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pamidronate dosing be adjusted for a patient with a specific variant in the FDPS gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of renal toxicity with pamidronate in individuals with genetic predispositions to kidney disease?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of serum calcium reduction for a pamidronate-treated patient with hypercalcemia of malignancy, based on their FDPS genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FDPS genotypes correlate with pamidronate efficacy in treating Paget's disease of bone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of farnesyl diphosphate synthase (FDPS) inhibition in the mechanism of action of pamidronate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of G-CSF (filgrastim) for a patient with a specific variant in the CSF3R (G-CSF receptor) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor hematopoietic recovery with G-CSF in individuals with low-function CSF3R variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target absolute neutrophil count (ANC) for a G-CSF-treated patient based on their CSF3R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CSF3R genotypes correlate with G-CSF response phenotypes in congenital neutropenia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the G-CSF receptor (CSF3R) in mediating the effects of filgrastim on neutrophil production?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should erythropoietin (EPO) dosing be adjusted for a patient with a specific variant in the EPOR (EPO receptor) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of thrombosis with erythropoietin in individuals with specific EPOR gain-of-function mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested target hemoglobin level for an EPO-treated patient with chronic kidney disease, based on their EPOR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do EPOR genotypes correlate with erythropoietin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the erythropoietin receptor (EPOR) in erythropoiesis and how do its variants alter response to EPO therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of romiplostim for a patient with a specific variant in the TPO-R (thrombopoietin receptor, MPL) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with romiplostim in immune thrombocytopenia (ITP) patients with MPL mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target platelet count for a romiplostim-treated patient based on their MPL genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MPL genotypes correlate with romiplostim efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the thrombopoietin receptor (MPL), the target of romiplostim, in megakaryopoiesis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should eltrombopag dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with eltrombopag in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma eltrombopag concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with eltrombopag clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for eltrombopag in ITP patients of East Asian ancestry, considering their higher prevalence of specific SLCO1B1 and ABCG2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of anagrelide for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular events (e.g., palpitations, tachycardia) with anagrelide in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of anagrelide's active metabolite, 3-hydroxy anagrelide, in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes map to anagrelide metabolism and efficacy phenotypes in essential thrombocythemia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolism of anagrelide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ruxolitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of thrombocytopenia and anemia with ruxolitinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ruxolitinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ruxolitinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ruxolitinib in myelofibrosis patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bosutinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea and liver enzyme elevation with bosutinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for bosutinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to bosutinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the BCR-ABL inhibitor bosutinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should nilotinib dosing be adjusted for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia with nilotinib in individuals with reduced UGT1A1 function (Gilbert's syndrome)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma nilotinib concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with nilotinib-induced liver toxicity and QTc prolongation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation and elimination of nilotinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dasatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pleural effusion with dasatinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma dasatinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for dasatinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for dasatinib in CML patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ponatinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of arterial occlusive events with ponatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ponatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to ponatinib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the pan-BCR-ABL inhibitor ponatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ibrutinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding and atrial fibrillation with ibrutinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ibrutinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ibrutinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ibrutinib in CLL patients with known CYP3A4 variants who are also on a moderate CYP3A4 inhibitor?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should idelalisib dosing be adjusted for a patient with a UGT1A4*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea/colitis and hepatotoxicity with idelalisib in individuals with low-activity UGT1A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of idelalisib's main metabolite, GS-563117, in a patient with a high-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes map to idelalisib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 enzyme in the metabolism of idelalisib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of venetoclax for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of tumor lysis syndrome (TLS) with venetoclax in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for venetoclax during the dose ramp-up phase in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to venetoclax clearance and TLS risk phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for venetoclax in CLL patients with known CYP3A4 variants, especially during co-administration with strong CYP3A4 inhibitors?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should midostaurin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nausea, vomiting, and mucositis with midostaurin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma concentrations of midostaurin's active metabolites (CGP62221 and CGP52421) in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for midostaurin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the FLT3 inhibitor midostaurin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of enasidenib for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of non-infectious leukocytosis and differentiation syndrome with enasidenib in individuals with reduced UGT1A1 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for enasidenib in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with enasidenib-induced hyperbilirubinemia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the metabolism of the IDH2 inhibitor enasidenib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should glasdegib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with glasdegib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma glasdegib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to glasdegib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for glasdegib in AML patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of vismodegib for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of muscle spasms and alopecia with vismodegib in individuals with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for vismodegib in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C9 genotypes map to vismodegib metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic pathway of the Hedgehog pathway inhibitor vismodegib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sonidegib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of rhabdomyolysis with sonidegib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma sonidegib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for sonidegib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sonidegib in basal cell carcinoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of regorafenib for a patient with a UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hand-foot skin reaction and hepatotoxicity with regorafenib in individuals with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of regorafenib's active metabolites (M-2 and M-5) in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes map to regorafenib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the glucuronidation of regorafenib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cabozantinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertension, diarrhea, and fatigue with cabozantinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cabozantinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to cabozantinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cabozantinib in renal cell carcinoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lenvatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hypertension and proteinuria with lenvatinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma lenvatinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for lenvatinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the multi-kinase inhibitor lenvatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should axitinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertension and fatigue with axitinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for axitinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to axitinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for axitinib in advanced renal cell carcinoma patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of vandetanib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation and skin reactions with vandetanib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma vandetanib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for vandetanib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the RET/VEGFR/EGFR inhibitor vandetanib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should palbociclib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neutropenia with palbociclib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for palbociclib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to palbociclib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for palbociclib in breast cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ribociclib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation and hepatotoxicity with ribociclib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ribociclib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for ribociclib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the CDK4/6 inhibitor ribociclib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should abemaciclib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea with abemaciclib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for abemaciclib and its active metabolites in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to abemaciclib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for abemaciclib in breast cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of osimertinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of interstitial lung disease with osimertinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma osimertinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for osimertinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the EGFR T790M inhibitor osimertinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should alectinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia and myalgia with alectinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for alectinib and its active metabolite M4 in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to alectinib clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for alectinib in ALK-positive lung cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of brigatinib for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of early-onset pulmonary events with brigatinib in individuals with reduced CYP2C8 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for brigatinib in a patient with a CYP2C8 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes map to brigatinib metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C8 enzyme in the metabolic pathway of the ALK inhibitor brigatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lorlatinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperlipidemia and CNS effects with lorlatinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma lorlatinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for lorlatinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for lorlatinib in ALK-positive lung cancer patients with known CYP3A4 variants, especially when co-administered with strong CYP3A4 inducers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of entrectinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cognitive impairment and congestive heart failure with entrectinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for entrectinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to entrectinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the ROS1/TRK inhibitor entrectinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should larotrectinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dizziness and liver enzyme elevation with larotrectinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma larotrectinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for larotrectinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for larotrectinib in pediatric patients with NTRK fusion-positive tumors and known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of capmatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral edema and interstitial lung disease with capmatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for capmatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to capmatinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the MET inhibitor capmatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tepotinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral edema with tepotinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma tepotinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for tepotinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for tepotinib in METex14 skipping lung cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of selpercatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertension and QTc prolongation with selpercatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for selpercatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to selpercatinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the RET inhibitor selpercatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pralsetinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pneumonitis and hypertension with pralsetinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pralsetinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for pralsetinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for pralsetinib in RET fusion-positive lung cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ripretinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of palmar-plantar erythrodysesthesia with ripretinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ripretinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to ripretinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the KIT/PDGFRA inhibitor ripretinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should avapritinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cognitive effects and intracranial hemorrhage with avapritinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma avapritinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for avapritinib therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for avapritinib in GIST patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pemigatinib for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperphosphatemia and serous retinal detachment with pemigatinib in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for pemigatinib in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to pemigatinib clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the FGFR inhibitor pemigatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should infigratinib dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperphosphatemia and retinal pigment epithelial detachment with infigratinib in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma infigratinib concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of albuterol for a patient with the ADRB2 Arg16Gly polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of tachyphylaxis with albuterol in individuals with the ADRB2 Gly16 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target FEV1 improvement for an albuterol-treated patient based on their ADRB2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADRB2 haplotypes correspond to bronchodilator response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the beta-2 adrenergic receptor (ADRB2) and how do its variants alter albuterol binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for albuterol in pediatric asthma patients with the ADRB2 Arg16 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should metformin dosing be adjusted for a patient with a specific variant in the ATM gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of poor glycemic response to metformin in individuals with ATM gene variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested target HbA1c for a metformin-treated patient based on their ATM genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ATM genotypes correlate with metformin efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the ATM gene in the cellular response to metformin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cisplatin for a patient with a specific variant in the ERCC1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment resistance to cisplatin in non-small cell lung cancer patients with high ERCC1 expression?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for cisplatin based on the tumor's ERCC1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ERCC1 polymorphisms correlate with cisplatin efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ERCC1 enzyme in repairing cisplatin-induced DNA adducts?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should paclitaxel dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe neuropathy with paclitaxel in individuals with CYP2C8*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for paclitaxel in a patient with a CYP2C8 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes map to paclitaxel clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C8 enzyme in the metabolic pathway of paclitaxel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fluoxetine for a patient with a BDNF Val66Met polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor antidepressant response to fluoxetine in individuals carrying the BDNF Met allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response timeline for a fluoxetine-treated patient based on their BDNF genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do BDNF genotypes correlate with fluoxetine efficacy phenotypes in major depressive disorder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Brain-Derived Neurotrophic Factor (BDNF) and its potential role in the mechanism of action of fluoxetine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should losartan dosing be adjusted for a patient with a specific variant in the AGTR1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of poor blood pressure control with losartan in individuals with the AGTR1 1166A>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for a losartan-treated patient based on their AGTR1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do AGTR1 genotypes correlate with antihypertensive response phenotypes to losartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Angiotensin II Receptor Type 1 (AGTR1), the target of losartan, and how do its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of atorvastatin for a patient who is a UGT1A1 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy with atorvastatin in individuals with reduced UGT1A1 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for atorvastatin lactone in a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes map to atorvastatin metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation of atorvastatin metabolites?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should morphine dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of central respiratory depression with morphine in individuals with ABCB1 variants that reduce efflux from the brain?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target cerebrospinal fluid concentrations of morphine in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with morphine dose requirements for analgesia?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the blood-brain barrier penetration of morphine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of glimepiride for a patient with a specific variant in the KCNJ11 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of secondary failure of glimepiride therapy in individuals with the KCNJ11 E23K polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested target for glucose reduction in a glimepiride-treated patient based on their KCNJ11 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KCNJ11 genotypes correlate with glimepiride efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Kir6.2 potassium channel (KCNJ11), a component of the sulfonylurea receptor, and how do its variants alter glimepiride's action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should risperidone dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperprolactinemia with risperidone in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for risperidone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to risperidone clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolic pathway of risperidone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of omeprazole for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to omeprazole in individuals with high-activity ABCB1 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target intragastric pH for an omeprazole-treated patient based on their ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with omeprazole efficacy phenotypes in treating GERD?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the disposition of omeprazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should apixaban dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with apixaban in individuals with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested anti-Factor Xa activity level for an apixaban-treated patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C9 genotypes map to apixaban metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the minor metabolic pathway of apixaban?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of acetaminophen for a patient with a SULT1A1*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with acetaminophen overdose in individuals with low-activity SULT1A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of acetaminophen sulfate in a patient with a high-activity SULT1A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SULT1A1 genotypes map to acetaminophen sulfation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the SULT1A1 enzyme in the detoxification pathway of acetaminophen?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should olanzapine dosing be adjusted for a patient with a UGT1A4*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of metabolic side effects with olanzapine in individuals with low-activity UGT1A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma olanzapine concentrations in a patient with a high-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes correlate with olanzapine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 enzyme in the glucuronidation of olanzapine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of donepezil for a patient with a specific variant in the ACHE (acetylcholinesterase) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor cognitive response to donepezil in individuals with ACHE variants that alter enzyme structure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of acetylcholinesterase inhibition for a donepezil-treated patient based on their ACHE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ACHE genotypes correlate with donepezil efficacy phenotypes in Alzheimer's disease?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of acetylcholinesterase (ACHE), the target of donepezil, and how might its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should rivaroxaban dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with rivaroxaban in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma rivaroxaban concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with rivaroxaban exposure phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (SLCO1B1) in the hepatic disposition of rivaroxaban?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of salmeterol for a patient with the ADRB2 Arg16Gly polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of asthma-related death with long-acting beta-agonists like salmeterol in individuals homozygous for the Arg16 variant of ADRB2?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target bronchodilator response for a salmeterol-treated patient based on their ADRB2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADRB2 genotypes define response phenotypes to long-term salmeterol therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for salmeterol/fluticasone combination therapy in pediatric patients with the ADRB2 Gly16Gly genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should theophylline dosing be adjusted for a patient who is a CYP2E1 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of subtherapeutic theophylline levels in individuals with high CYP2E1 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for theophylline in a patient with a specific CYP2E1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2E1 genotypes map to theophylline clearance phenotypes, especially in smokers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2E1 enzyme in the metabolic pathway of theophylline?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of haloperidol for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of extrapyramidal symptoms with haloperidol in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for haloperidol in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of haloperidol therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for haloperidol in geriatric patients with a CYP2D6 decreased function allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should valproic acid dosing be adjusted for a patient with a UGT2B7*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperammonemic encephalopathy with valproic acid in individuals with low-activity UGT2B7 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma valproic acid concentrations in a patient with a high-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT2B7 genotypes correlate with valproic acid clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT2B7 enzyme in the glucuronidation of valproic acid?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ropinirole for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hallucinations and somnolence with ropinirole in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ropinirole in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes map to ropinirole clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolism of the dopamine agonist ropinirole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pramipexole dosing be adjusted for a patient with a low-function SLC22A2 (OCT2) genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with pramipexole in individuals with SLC22A2 variants that reduce renal clearance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pramipexole concentrations in a patient with a high-function SLC22A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A2 genotypes correlate with pramipexole elimination phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT2 transporter (SLC22A2) in the renal secretion of pramipexole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of levodopa for a patient with a COMT Val158Met polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of 'wearing-off' phenomena with levodopa in individuals with the high-activity COMT 'Val' allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for levodopa in a patient with the low-activity COMT 'Met/Met' genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do COMT genotypes correlate with levodopa response and the need for COMT inhibitors?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Catechol-O-methyltransferase (COMT) in the peripheral metabolism of levodopa?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should selegiline dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of insomnia and confusion with selegiline in individuals with reduced CYP2B6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma concentrations of selegiline's amphetamine metabolites in a CYP2B6 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2B6 genotypes correlate with selegiline clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nebivolol for a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia with nebivolol in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for nebivolol in a patient with a CYP2D6 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define a poor metabolizer for the purposes of nebivolol therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic clearance of nebivolol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for nebivolol in geriatric patients with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should metoprolol dosing be adjusted based on a patient's ADRB1 Ser49Gly polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of a blunted heart rate response to metoprolol in individuals homozygous for the ADRB1 Gly49 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target heart rate for a metoprolol-treated patient based on their ADRB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ADRB1 genotypes correlate with metoprolol efficacy phenotypes in heart failure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the beta-1 adrenergic receptor (ADRB1) and how do its variants alter metoprolol's effects?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lurasidone for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of akathisia for lurasidone users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for lurasidone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as intermediate metabolizers in the context of lurasidone treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for lurasidone involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should rivastigmine dosing be adjusted for a patient with a low-activity BCHE (butyrylcholinesterase) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe gastrointestinal side effects with rivastigmine in patients with BCHE deficiency?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma rivastigmine concentrations in a patient with a specific BCHE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do BCHE genotypes correspond to rivastigmine hydrolysis and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the BCHE enzyme in the metabolism of rivastigmine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of pantoprazole for a patient who is a CYP2C19 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Clostridium difficile infection with pantoprazole in CYP2C19 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target intragastric pH for a pantoprazole-treated patient who is a CYP2C19 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C19 rapid metabolizer for pantoprazole therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for pantoprazole in pediatric GERD patients with the CYP2C19*17 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lansoprazole for a patient who is a CYP2C19 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure for H. pylori eradication with lansoprazole in CYP2C19 ultrarapid metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for lansoprazole in a CYP2C19 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C19 genotypes map to lansoprazole efficacy phenotypes for erosive esophagitis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the metabolic clearance of lansoprazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should oxybutynin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of anticholinergic side effects (e.g., dry mouth, confusion) with oxybutynin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma concentrations of N-desethyloxybutynin in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for oxybutynin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for extended-release oxybutynin in elderly patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for tolterodine based on a patient's CYP2D6 ultrarapid metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of QTc prolongation with tolterodine in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for 5-hydroxymethyltolterodine (the active metabolite) in a CYP2D6 normal metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes are associated with increased tolterodine exposure phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP2D6 in the bioactivation of tolterodine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should solifenacin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe constipation with solifenacin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for solifenacin in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with solifenacin efficacy phenotypes for overactive bladder?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for solifenacin in patients with renal impairment and a known CYP3A4 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of naproxen for a patient identified as a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of gastrointestinal bleeding for naproxen users with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for naproxen in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 genotypes are classified as poor metabolizers in the context of naproxen treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for naproxen involving the CYP2C9 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ziprasidone dosing be adjusted for a patient who is a CYP3A4 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with ziprasidone in a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ziprasidone concentrations in a patient with combined CYP3A4 and CYP1A2 decreased function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP3A4 and CYP1A2 define a poor metabolizer phenotype for ziprasidone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 and CYP1A2 in the metabolic clearance of ziprasidone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of asenapine for a patient with the UGT1A4*3/*3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of oral hypoesthesia with asenapine in individuals who are CYP1A2 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of asenapine in a patient with a high-activity UGT1A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A4 genotypes map to asenapine glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A4 and CYP1A2 enzymes in the detoxification of asenapine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should dutasteride dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gynecomastia with dutasteride in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum dihydrotestosterone (DHT) suppression levels for a dutasteride-treated patient based on their SRD5A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with dutasteride clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the dual 5-alpha reductase inhibitor dutasteride?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of aprepitant for a patient identified as a CYP3A4 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of aprepitant in patients with high CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for aprepitant in a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correspond to aprepitant metabolism and chemotherapy-induced nausea prevention phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for aprepitant in pediatric patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should valsartan dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with valsartan in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma valsartan concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with valsartan antihypertensive response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter (encoded by SLCO1B1) in the hepatic uptake of valsartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of candesartan for a patient with a specific variant in the AGTR1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor blood pressure control with candesartan in individuals with the AGTR1 1166A>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for a candesartan-treated patient based on their AGTR1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do AGTR1 genotypes correlate with candesartan efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Angiotensin II Receptor Type 1 (AGTR1), the target of candesartan, and how do its variants alter drug affinity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tadalafil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of headache and back pain with tadalafil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma tadalafil concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for tadalafil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for tadalafil for pulmonary hypertension in patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose adjustment for desipramine based on a patient's CYP1A2 metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of anticholinergic toxicity with desipramine in CYP1A2 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for desipramine in a CYP1A2 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes correspond to desipramine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the CYP1A2 enzyme in the N-demethylation of desipramine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should galantamine dosing be adjusted for a patient who is both a CYP2D6 and CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of syncope with galantamine in patients with combined reduced function of CYP2D6 and CYP3A4?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma galantamine concentrations in a CYP2D6 ultrarapid metabolizer who is also a CYP3A4 normal metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What combination of CYP2D6 and CYP3A4 diplotypes would predict the highest galantamine exposure?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for galantamine in elderly Alzheimer's patients with known CYP2D6 and CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dasatinib for a patient with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing severe adverse effects to dasatinib in individuals with the ABCG2 421C>A polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for a dasatinib-treated patient based on their ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with dasatinib response phenotypes in chronic myeloid leukemia (CML)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the efflux and bioavailability of dasatinib?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should abiraterone acetate dosing be adjusted for a patient with a specific SULT2A1 gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of mineralocorticoid excess with abiraterone in individuals with low-activity SULT2A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma abiraterone concentrations based on SULT2A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SULT2A1 genotypes correlate with abiraterone efficacy and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the SULT2A1 enzyme in the sulfation and clearance of abiraterone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of enzalutamide for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of seizures with enzalutamide in individuals with reduced CYP2C8 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of N-desmethylenzalutamide (active metabolite) in a patient who is a CYP2C8 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes map to enzalutamide metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for enzalutamide in prostate cancer patients with a known CYP2C8*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should montelukast dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neuropsychiatric events with montelukast in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma montelukast concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with montelukast exposure and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter in the hepatic uptake of montelukast?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of diclofenac for a patient with a UGT2B7*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with diclofenac in individuals with low-activity UGT2B7 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of diclofenac-acyl-glucuronide in a patient with a high-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT2B7 genotypes map to diclofenac clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT2B7 enzyme in the glucuronidation of diclofenac?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should indomethacin dosing be adjusted for a patient with a UGT2B7*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS side effects with indomethacin in individuals who are poor metabolizers via UGT2B7?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma indomethacin concentrations in a patient with a high-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for UGT2B7 define a poor metabolizer in the context of indomethacin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of UGT2B7-mediated glucuronidation in the elimination of indomethacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ketorolac for a patient identified as a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of acute kidney injury for ketorolac users with the CYP2C9*2/*3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ketorolac in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 genotypes are classified as intermediate metabolizers in the context of ketorolac treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for ketorolac involving the CYP2C9 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ondansetron dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of headache with ondansetron in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ondansetron concentrations in a CYP1A2 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP1A2 genotypes correlate with ondansetron clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP1A2 enzyme in the metabolism of ondansetron?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of granisetron for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of granisetron in CYP2D6 ultrarapid metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for granisetron in a patient with a CYP2D6 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define a normal metabolizer for the purpose of granisetron therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for transdermal granisetron in patients with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tropisetron dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with tropisetron in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma tropisetron concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for tropisetron therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the hydroxylation of tropisetron?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fentanyl for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of life-threatening respiratory depression with fentanyl in patients with severely reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for fentanyl in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to fentanyl clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for transdermal fentanyl in cancer patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should alfentanil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of prolonged postoperative respiratory depression with alfentanil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma alfentanil concentrations in a CYP3A4 rapid metabolizer during surgery?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for alfentanil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the N-dealkylation of alfentanil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of sufentanil for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of bradycardia for sufentanil users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for sufentanil in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of sufentanil treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for sufentanil involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should methadone dosing be adjusted for a patient who is a CYP2B6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with methadone in patients with reduced CYP2B6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma methadone concentrations in a CYP2B6 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2B6 intermediate metabolizer for methadone therapy according to CPIC?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for methadone for opioid use disorder in patients with a CYP2B6*6 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of buprenorphine for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of respiratory depression with buprenorphine in individuals with reduced CYP3A4 function, especially when combined with benzodiazepines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for norbuprenorphine in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to buprenorphine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the N-dealkylation of buprenorphine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should propofol dosing be adjusted for a patient with a UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of propofol infusion syndrome in individuals with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma propofol concentrations during anesthesia in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which UGT1A9 genotypes are associated with altered propofol glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the primary metabolic pathway of propofol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of midazolam for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of prolonged sedation with midazolam in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for alpha-hydroxymidazolam in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to midazolam clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for oral midazolam in pediatric sedation based on their CYP3A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should atorvastatin dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy with atorvastatin when co-administered with a strong CYP3A4 inhibitor in a patient with already reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma atorvastatin concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for atorvastatin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of atorvastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of lovastatin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of rhabdomyolysis for lovastatin users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for lovastatin in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of lovastatin treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for lovastatin involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should pioglitazone dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of edema and fluid retention with pioglitazone in individuals with CYP2C8*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma pioglitazone concentrations in a CYP2C8 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C8 poor metabolizer for pioglitazone therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C8 enzyme in the metabolic clearance of pioglitazone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of rosiglitazone for a patient identified as a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular events with rosiglitazone in CYP2C8 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for rosiglitazone in a patient with a CYP2C8 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C8 diplotypes define a normal metabolizer for the purposes of rosiglitazone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for rosiglitazone in patients with a CYP2C8*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should gliclazide dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of prolonged hypoglycemia with gliclazide in patients with CYP2C9*2 or *3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma gliclazide concentrations in a CYP2C9 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C9 genotypes map to gliclazide clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of the sulfonylurea gliclazide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nateglinide for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypoglycemia with nateglinide in individuals with reduced CYP2C9 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for nateglinide in a patient with a CYP2C9 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 intermediate metabolizer for nateglinide therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2C9 in the primary metabolic pathway of nateglinide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sitagliptin dosing be adjusted for a patient with a specific organic anion transporter (OAT3/SLC22A8) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with sitagliptin in individuals with low-function OAT3 transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma sitagliptin concentrations in a patient with a high-function OAT3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A8 genotypes correlate with sitagliptin renal clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OAT3 transporter in the active tubular secretion of sitagliptin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of saxagliptin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of heart failure hospitalization with saxagliptin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of saxagliptin's active metabolite in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to saxagliptin bioactivation and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for saxagliptin in type 2 diabetes patients with a known CYP3A4 variant and moderate renal impairment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should linagliptin dosing be adjusted based on ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of altered linagliptin exposure in patients with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target therapeutic range for plasma linagliptin in a patient with a low-function ABCB1 haplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 haplotypes correspond to linagliptin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the biliary excretion of linagliptin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of canagliflozin for a patient with a UGT1A9*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of euglycemic diabetic ketoacidosis with canagliflozin in individuals with low-activity UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for canagliflozin in a patient with a high-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes map to canagliflozin glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of UGT1A9 in the metabolic clearance of the SGLT2 inhibitor canagliflozin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should dapagliflozin dosing be adjusted for a patient with a UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of genital mycotic infections with dapagliflozin in individuals with specific UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target urinary glucose excretion for a dapagliflozin-treated patient based on their UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes correlate with dapagliflozin efficacy and safety phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A9 enzyme in the metabolism of dapagliflozin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of empagliflozin for a patient with a specific UGT2B7 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced cardiovascular benefit with empagliflozin in individuals with high-activity UGT2B7 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for empagliflozin in a patient with a low-activity UGT2B7 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT2B7 genotypes map to empagliflozin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for empagliflozin in heart failure patients based on their UGT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should quinine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cinchonism with quinine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma quinine concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for quinine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the 3-hydroxylation of quinine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of chloroquine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of retinopathy with long-term chloroquine use in CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for desethylchloroquine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to chloroquine metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2D6 in the metabolic clearance of chloroquine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should proguanil dosing be adjusted for a patient who is a CYP2C19 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of malaria prophylaxis failure with proguanil in individuals who are CYP2C19 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cycloguanil (active metabolite) concentrations in a CYP2C19 normal metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C19 diplotypes define a poor metabolizer for the purpose of proguanil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the bioactivation of the prodrug proguanil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of artemether-lumefantrine for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with artemether-lumefantrine in individuals who are CYP3A4 rapid metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for lumefantrine in a patient with a CYP3A4 poor metabolizer genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with clearance phenotypes for both artemether and lumefantrine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for artemether-lumefantrine in pediatric malaria patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should praziquantel dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse CNS effects with praziquantel in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma praziquantel concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for praziquantel therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the extensive first-pass metabolism of praziquantel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ivermectin for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurotoxicity with ivermectin in individuals with ABCB1 variants that compromise the blood-brain barrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ivermectin in a patient with a high-activity ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes map to ivermectin safety and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in limiting the CNS penetration of ivermectin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should albendazole dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bone marrow suppression with albendazole in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma albendazole sulfoxide (active metabolite) in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with the conversion of albendazole to its active metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the primary metabolic pathway of albendazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ketoconazole for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with ketoconazole in individuals with pre-existing CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of CYP3A4 inhibition for a patient treated with ketoconazole, based on their own CYP3A4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to the severity of drug-drug interactions caused by ketoconazole?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of ketoconazole's potent inhibition of the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should terbinafine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of taste disturbance with terbinafine in patients with reduced CYP2D6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma terbinafine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer for terbinafine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of terbinafine and its potential for inhibiting the metabolism of other drugs?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of leflunomide for a patient identified as a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of liver injury for leflunomide users with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for teriflunomide (active metabolite) in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 genotypes are classified as poor metabolizers in the context of leflunomide treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2C9 in the metabolic pathway of leflunomide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should teriflunomide dosing be adjusted for a patient who is a CYP2C8 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of peripheral neuropathy with teriflunomide in individuals with reduced CYP2C8 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma teriflunomide concentrations in a CYP2C8 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2C8 genotypes map to teriflunomide clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for teriflunomide in multiple sclerosis patients with a known CYP2C8*3 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fingolimod for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bradycardia upon first dose of fingolimod in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for fingolimod-phosphate (active metabolite) in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with fingolimod phosphorylation and clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP3A4 in the metabolism of fingolimod?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should dimethyl fumarate dosing be adjusted for a patient with a specific variant in the HCAR2 (GPR109A) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of flushing with dimethyl fumarate in individuals with specific HCAR2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma monomethyl fumarate based on a patient's HCAR2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do HCAR2 genotypes correlate with dimethyl fumarate tolerability phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the HCAR2 receptor in mediating the flushing side effect of dimethyl fumarate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of natalizumab for a patient with a specific variant in the ITGA4 (integrin alpha 4) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of developing progressive multifocal leukoencephalopathy (PML) with natalizumab based on a patient's host genetic factors?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of alpha-4 integrin saturation for a natalizumab-treated patient based on their ITGA4 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ITGA4 genotypes correlate with natalizumab efficacy phenotypes in multiple sclerosis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the alpha-4 integrin (ITGA4), the target of natalizumab, and how might its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ocrelizumab dosing be adjusted for a patient with a specific FCGR3A V158F polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of infusion-related reactions with ocrelizumab in individuals with specific FCGR3A variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of B-cell depletion for an ocrelizumab-treated patient based on their FCGR3A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FCGR3A genotypes correlate with ocrelizumab treatment response in primary progressive multiple sclerosis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the FCGR3A receptor in mediating the antibody-dependent cell-mediated cytotoxicity of ocrelizumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dalfampridine for a patient with a low-function SLC22A2 (OCT2) genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of seizures with dalfampridine in individuals with SLC22A2 variants that reduce renal clearance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration ranges for dalfampridine in a patient with a high-function SLC22A2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A2 genotypes map to dalfampridine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OCT2 transporter (SLC22A2) in the renal elimination of dalfampridine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sildenafil dosing be adjusted for a patient with a PDE5A gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of non-response to sildenafil in individuals with specific variants in the phosphodiesterase type 5 (PDE5A) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of PDE5A inhibition for a sildenafil-treated patient based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PDE5A genotypes correlate with sildenafil efficacy phenotypes for erectile dysfunction?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the PDE5A enzyme, the target of sildenafil, and how might its variants alter drug binding and efficacy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of vardenafil for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of visual disturbances with vardenafil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma vardenafil concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for vardenafil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for vardenafil in elderly patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tamsulosin dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of orthostatic hypotension with tamsulosin in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for tamsulosin in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of tamsulosin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2D6 in the metabolic clearance of tamsulosin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of alfuzosin for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of symptomatic hypotension with alfuzosin in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma alfuzosin concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to alfuzosin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of alfuzosin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ramelteon dosing be adjusted for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of next-day somnolence with ramelteon in individuals with reduced CYP1A2 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of ramelteon's active metabolite in a patient with a CYP1A2 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of ramelteon therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ramelteon in patients who are heavy smokers (CYP1A2 inducers)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of eszopiclone for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of next-day cognitive impairment for eszopiclone users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for eszopiclone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as intermediate metabolizers in the context of eszopiclone treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for eszopiclone involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should zaleplon dosing be adjusted for a patient with a specific aldehyde oxidase (AOX1) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with zaleplon in individuals with low-activity AOX1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma zaleplon concentrations in a patient with a high-activity AOX1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do AOX1 genotypes correlate with zaleplon clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the AOX1 enzyme in the primary metabolic pathway of zaleplon?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of modafinil for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Stevens-Johnson Syndrome with modafinil in individuals with specific HLA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for modafinil acid in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to modafinil metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for modafinil in patients with known CYP3A4 variants who are also taking oral contraceptives?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should armodafinil dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of anxiety and insomnia with armodafinil in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma armodafinil concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for armodafinil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of the R-enantiomer of modafinil (armodafinil)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of methylphenidate for a patient with a specific CES1 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of poor response to methylphenidate in individuals with high-activity CES1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for ritalinic acid in a patient with a low-activity CES1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES1 genotype correlate with the hydrolysis of methylphenidate to its inactive metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 1 (CES1) in the metabolic pathway of methylphenidate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should lisdexamfetamine dosing be adjusted for a patient with a specific variant in a red blood cell enzyme responsible for its conversion?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of delayed onset of action with lisdexamfetamine in individuals with genetic variants affecting its hydrolysis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma d-amphetamine concentrations following lisdexamfetamine administration based on a patient's genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with the conversion rate of lisdexamfetamine to dextroamphetamine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of lisdexamfetamine's enzymatic conversion in the blood?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of atomoxetine for a patient with a CYP2D6 gene duplication and comorbid anxiety?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of suicidal ideation with atomoxetine in pediatric patients who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for 4-hydroxyatomoxetine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of atomoxetine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for atomoxetine in adults with ADHD and a known CYP2D6 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should guanfacine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of sedation and hypotension with guanfacine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma guanfacine concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to guanfacine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of guanfacine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of clonidine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe hypotension with clonidine in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for clonidine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to clonidine metabolism phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the CYP2D6 enzyme in the metabolic pathway of clonidine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should felodipine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gingival hyperplasia with felodipine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma felodipine concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for felodipine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for felodipine in elderly hypertensive patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of nifedipine for a patient identified as a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of peripheral edema for nifedipine users with decreased CYP3A4 activity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough concentrations for nifedipine in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 genotypes are classified as poor metabolizers in the context of nifedipine treatment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway for nifedipine involving the CYP3A4 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should diltiazem dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of atrioventricular block with diltiazem in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma desacetyldiltiazem concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with the severity of drug-drug interactions caused by diltiazem?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP3A4 in the N-demethylation of diltiazem?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of verapamil for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of constipation with verapamil in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for norverapamil in a patient with a CYP3A4 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP3A4 diplotypes define an intermediate metabolizer for the purposes of verapamil therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the extensive first-pass metabolism of verapamil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should quinidine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Torsades de Pointes with quinidine in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma quinidine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes map to quinidine clearance phenotypes and its inhibition of P-glycoprotein?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of quinidine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of flecainide for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of proarrhythmic effects with flecainide in patients with reduced CYP2D6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target trough plasma concentrations for flecainide in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for flecainide therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for flecainide in pediatric patients with supraventricular tachycardia and a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should propafenone dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS side effects (e.g., dizziness) with propafenone in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma propafenone concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2D6 genotypes correlate with propafenone efficacy and safety phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP2D6 in the 5-hydroxylation of propafenone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mexiletine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of neurological side effects with mexiletine in individuals with reduced CYP2D6 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for mexiletine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of mexiletine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the CYP2D6 enzyme in the metabolic clearance of mexiletine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should sotalol dosing be adjusted for a patient with a specific KCNH2 (hERG) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Torsades de Pointes with sotalol in individuals with congenital long QT syndrome caused by KCNH2 mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested QTc interval limit for a sotalol-treated patient based on their KCNH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KCNH2 genotypes correlate with sotalol-induced cardiac arrhythmia phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the hERG potassium channel (encoded by KCNH2) and how is it blocked by sotalol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dofetilide for a patient with a specific KCNH2 (hERG) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the absolute contraindication for dofetilide based on specific KCNH2 genotypes associated with Long QT Syndrome Type 2?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target QTc interval for a dofetilide-treated patient, and how is that decision influenced by KCNH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do KCNH2 genotypes map to dofetilide risk-stratification phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the mechanism by which KCNH2 variants increase the risk of dofetilide-induced Torsades de Pointes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should isosorbide dinitrate dosing be adjusted for a patient with a specific ALDH2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nitrate tolerance with isosorbide dinitrate in individuals with low-activity ALDH2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic effect (e.g., change in blood pressure) for isosorbide dinitrate based on a patient's ALDH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ALDH2 genotypes correlate with the hemodynamic response to isosorbide dinitrate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Aldehyde Dehydrogenase 2 (ALDH2) in the bioactivation of organic nitrates like isosorbide dinitrate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nitroglycerin for a patient with an ALDH2*2 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of sublingual nitroglycerin for angina in individuals with the ALDH2*2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of vasodilation for a nitroglycerin-treated patient based on their ALDH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ALDH2 genotypes define response phenotypes to nitroglycerin therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for continuous intravenous nitroglycerin in ICU patients with a known ALDH2 deficiency?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should edoxaban dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of major bleeding events with edoxaban in patients with specific ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested anti-Factor Xa activity level for an edoxaban-treated patient based on their ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with edoxaban peak concentration phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the absorption and clearance of edoxaban?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of prasugrel for a patient with a specific variant in the PON1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of stent thrombosis with prasugrel in patients with the PON1 192R allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target platelet reactivity unit (PRU) for a prasugrel-treated patient based on their PON1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the PON1 genotype correspond to prasugrel bioactivation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the paraoxonase 1 enzyme (PON1) in the metabolic pathway of prasugrel?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should fondaparinux dosing be adjusted for a patient with a specific antithrombin (SERPINC1) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with fondaparinux in individuals with congenital antithrombin deficiency?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested anti-Factor Xa activity level for a fondaparinux-treated patient based on their SERPINC1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SERPINC1 genotypes correlate with fondaparinux efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of antithrombin, the cofactor required for fondaparinux's activity, and how do its variants cause resistance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of argatroban for a patient with a specific variant affecting its hepatic metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of bleeding with argatroban in individuals with genetic variants causing severe hepatic impairment?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target aPTT for an argatroban-treated patient with HIT based on their genotype for a relevant metabolizing enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do hepatic function-related genotypes correlate with argatroban clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for argatroban in patients with a genetic predisposition to liver disease?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should torsemide dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of excessive diuresis and electrolyte imbalance with torsemide in patients with CYP2C9*2 or *3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma torsemide concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer for torsemide therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic inactivation of torsemide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bumetanide for a patient with a specific variant in the SLC12A1 (NKCC2) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of diuretic resistance to bumetanide in individuals with specific SLC12A1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target urinary sodium excretion for a bumetanide-treated patient based on their SLC12A1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC12A1 genotypes correlate with bumetanide response phenotypes in edema?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the NKCC2 cotransporter (encoded by SLC12A1) as the direct target of bumetanide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should indapamide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyponatremia with indapamide in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma indapamide concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to indapamide clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the metabolism of the thiazide-like diuretic indapamide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of chlorthalidone for a patient with a specific variant in the SLC12A3 (NCC) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypokalemia with chlorthalidone in individuals with gain-of-function variants in the NCC transporter?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure reduction for a chlorthalidone-treated patient based on their SLC12A3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC12A3 genotypes correlate with antihypertensive response phenotypes to chlorthalidone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the NCC transporter (encoded by SLC12A3), the direct target of chlorthalidone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should amiloride dosing be adjusted for a patient with a specific variant in the SCNN1A (ENaC alpha subunit) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hyperkalemia with amiloride in individuals with variants causing Liddle syndrome?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested serum potassium level to monitor in an amiloride-treated patient based on their SCNN1A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SCNN1A genotypes correlate with amiloride response phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ENaC channel, the target of amiloride, and how do its variants alter drug action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of benazepril for a patient with a specific variant in the ACE gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cough with benazepril in individuals with the ACE DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for benazeprilat based on a patient's ACE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the ACE I/D polymorphism correlate with benazepril antihypertensive efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the ACE gene in determining individual response to benazepril?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should quinapril dosing be adjusted for a patient with the ACE II genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of angioedema from quinapril in individuals with the ACE DD genotype compared to the II genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic effect for quinapril based on a patient's ACE genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which ACE genotypes are associated with poor response phenotypes to quinapril therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which the ACE I/D polymorphism influences quinapril's effect?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended starting dose of ramipril for a patient with the ACE DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of first-dose hypotension for ramipril users with the ACE DD genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of ramiprilat in a patient with the ACE II genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ACE genotypes map to ramipril efficacy phenotypes in preventing cardiovascular events?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ramipril in post-MI patients based on their ACE I/D polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should irbesartan dosing be adjusted for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with irbesartan in individuals with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma irbesartan concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer for irbesartan therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolic clearance of irbesartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of olmesartan for a patient with a specific variant in the CES1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of sprue-like enteropathy with olmesartan in individuals with specific CES1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for olmesartan in a patient with a low-activity CES1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES1 genotype correlate with the hydrolysis of the prodrug olmesartan medoxomil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 1 (CES1) in the bioactivation of olmesartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should telmisartan dosing be adjusted for a patient with a UGT1A1*28 allele?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with telmisartan in individuals with reduced UGT1A1 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma telmisartan concentrations in a patient with a specific UGT1A1 diplotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A1 genotypes correlate with telmisartan clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A1 enzyme in the glucuronidation of telmisartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of azilsartan for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypotension with azilsartan in patients with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for azilsartan in a patient with a CYP2C9 intermediate metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2C9 diplotypes define a normal metabolizer for the purposes of azilsartan therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2C9 in the metabolism of azilsartan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should aliskiren dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of diarrhea with aliskiren in individuals with the ABCB1 3435C>T polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma aliskiren concentrations in a patient with a high-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 haplotypes correspond to aliskiren bioavailability phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in the intestinal efflux of the direct renin inhibitor aliskiren?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pitavastatin for a patient with a UGT1A3 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy with pitavastatin in individuals with low-activity UGT1A3 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for pitavastatin in a patient with a high-activity UGT1A3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A3 genotypes map to pitavastatin glucuronidation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the UGT1A3 enzyme in the metabolic clearance of pitavastatin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should gemfibrozil dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of myopathy when gemfibrozil is co-administered with a statin in a patient with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma gemfibrozil concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with gemfibrozil safety and efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter in the hepatic uptake of gemfibrozil?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fenofibrate for a patient with a UGT1A9 promoter polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of pancreatitis with fenofibrate in individuals with specific UGT1A9 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations of fenofibric acid in a patient with a low-activity UGT1A9 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A9 genotypes map to fenofibric acid clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of UGT1A9 in the glucuronidation of fenofibrate's active metabolite?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should niacin dosing be adjusted for a patient with a specific HCAR2 (GPR109A) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe flushing with niacin in individuals with high-expression HCAR2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response (e.g., lipid reduction) for niacin based on a patient's HCAR2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do HCAR2 genotypes correlate with niacin's efficacy versus its flushing side effect?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the HCAR2 receptor in mediating both the therapeutic and adverse effects of niacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cholestyramine for a patient with a specific variant in the bile acid receptor (FXR/NR1H4) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gastrointestinal side effects with cholestyramine in individuals with specific FXR variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target LDL reduction for a cholestyramine-treated patient based on their FXR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FXR genotypes correlate with the lipid-lowering response to cholestyramine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the Farnesoid X receptor (FXR) in bile acid homeostasis and its relation to cholestyramine's mechanism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should diphenhydramine dosing be adjusted for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe anticholinergic effects (e.g., delirium) with diphenhydramine in elderly patients who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma diphenhydramine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for diphenhydramine therapy according to CPIC guidelines?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolic clearance of diphenhydramine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of promethazine for a patient who is a CYP2D6 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of excessive sedation with promethazine in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for promethazine in a patient with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which CYP2D6 diplotypes define an intermediate metabolizer for the purposes of promethazine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for promethazine in pediatric patients with a CYP2D6 gene duplication?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should hydroxyzine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of QTc prolongation with hydroxyzine in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma cetirizine (active metabolite) concentrations in a hydroxyzine-treated patient who is a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to hydroxyzine clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the metabolism of hydroxyzine to cetirizine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of pseudoephedrine for a patient with a specific MAOA variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypertensive crisis with pseudoephedrine in individuals taking an MAOI who also have a specific MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood pressure limit for a pseudoephedrine-treated patient based on their MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA genotypes correlate with the cardiovascular side effects of pseudoephedrine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Monoamine Oxidase A (MAOA) in the metabolism of catecholamines affected by pseudoephedrine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should dextromethorphan dosing be adjusted for a patient who is a CYP2D6 poor metabolizer to avoid psychoactive effects?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hallucinations with dextromethorphan in individuals who are CYP2D6 poor metabolizers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma dextrorphan (active metabolite) concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer for dextromethorphan antitussive therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of CYP2D6 in the O-demethylation of dextromethorphan to dextrorphan?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of guaifenesin for a patient with a genetic variant affecting its unknown metabolic pathway?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects from guaifenesin in individuals with genetic polymorphisms in hypothetical metabolizing enzymes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for guaifenesin in a patient with a hypothetical rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do theoretical genotypes map to guaifenesin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the primary metabolic pathway of guaifenesin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should cromolyn sodium dosing be adjusted for a patient with a genetic variant affecting mast cell stabilization?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to cromolyn sodium in individuals with specific variants in mast cell signaling pathways?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of mast cell degranulation inhibition for a cromolyn-treated patient based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with cromolyn efficacy phenotypes in asthma?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the molecular mechanism by which cromolyn sodium stabilizes mast cells, and are there known genetic modifiers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ipratropium for a patient with a specific cholinergic receptor (CHRM3) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced bronchodilation with ipratropium in individuals with specific CHRM3 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target FEV1 improvement for an ipratropium-treated patient based on their CHRM3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CHRM3 genotypes correlate with ipratropium response phenotypes in COPD?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the M3 muscarinic receptor (CHRM3), the target of ipratropium, and how do its variants alter drug affinity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tiotropium dosing be adjusted for a patient with a specific cholinergic receptor (CHRM3) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of anticholinergic side effects with tiotropium in individuals with specific CHRM variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response for tiotropium in COPD based on a patient's CHRM3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CHRM1/CHRM3 genotypes correlate with the efficacy and safety of tiotropium?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for tiotropium in patients with a history of poor response to other anticholinergics based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of fluticasone for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of systemic corticosteroid effects (e.g., adrenal suppression) with inhaled fluticasone in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma fluticasone concentrations in a CYP3A4 rapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 intermediate metabolizer for fluticasone therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for fluticasone nasal spray in pediatric allergic rhinitis patients with known CYP3A4 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should budesonide dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Cushing's syndrome with oral budesonide in individuals with severely reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for budesonide in an inhaled formulation for a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to budesonide clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the extensive first-pass metabolism of budesonide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mometasone for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of systemic side effects with topical mometasone in individuals with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for mometasone in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes correlate with the systemic bioavailability of inhaled mometasone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP3A4 in the metabolism of the corticosteroid mometasone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ciclesonide dosing be adjusted for a patient with a specific CES2 variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of reduced efficacy of inhaled ciclesonide in individuals with high-activity CES2 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target concentration of des-ciclesonide (active metabolite) in the lungs of a patient based on their CES2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How does the CES2 genotype correlate with the hydrolysis of the prodrug ciclesonide to its active form?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of Carboxylesterase 2 (CES2) in the bioactivation of ciclesonide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of zafirlukast for a patient who is a CYP2C9 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hepatotoxicity with zafirlukast in patients with CYP2C9*3 alleles?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma zafirlukast concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer for zafirlukast therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of CYP2C9 in the metabolism of zafirlukast and its potential to inhibit other CYP enzymes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should omalizumab dosing be adjusted for a patient with a specific variant in the high-affinity IgE receptor (FCER1A) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to omalizumab in individuals with FCER1A variants that alter IgE binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of free IgE for an omalizumab-treated patient based on their FCER1A genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FCER1A genotypes correlate with omalizumab efficacy phenotypes in severe allergic asthma?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the FCER1A receptor and how might its variants impact the pharmacodynamics of omalizumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of mepolizumab for a patient with a specific variant in the IL5RA (interleukin-5 receptor alpha) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of non-response to mepolizumab in severe eosinophilic asthma patients with low-affinity IL5RA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target blood eosinophil count reduction for a mepolizumab-treated patient based on their IL5RA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do IL5RA genotypes correlate with mepolizumab efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the IL5RA, the target of mepolizumab, and how do its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should benralizumab dosing be adjusted for a patient with a specific variant in the IL5RA gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with benralizumab in individuals with specific IL5RA variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested level of eosinophil depletion for a benralizumab-treated patient based on their IL5RA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do IL5RA genotypes correlate with benralizumab-mediated antibody-dependent cell-mediated cytotoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the IL-5 receptor alpha chain (IL5RA) on eosinophils, the target of benralizumab?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of dupilumab for a patient with a specific variant in the IL4R (interleukin-4 receptor) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor response to dupilumab for atopic dermatitis in individuals with IL4R variants that affect signaling?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target reduction in Eczema Area and Severity Index (EASI) score for a dupilumab-treated patient based on their IL4R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do IL4R genotypes correlate with dupilumab efficacy phenotypes across Type 2 inflammatory diseases?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the IL-4 receptor alpha subunit (IL4R), the target of dupilumab, in mediating IL-4 and IL-13 signaling?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should loperamide dosing be adjusted for a patient with a low-function ABCB1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of central nervous system toxicity with high-dose loperamide abuse in individuals with ABCB1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for loperamide in a patient with a low-function ABCB1 genotype to avoid cardiac toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCB1 genotypes correlate with the risk of CNS side effects from standard doses of loperamide?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of P-glycoprotein (ABCB1) in preventing loperamide from crossing the blood-brain barrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of bismuth subsalicylate for a patient with a specific genetic variant affecting salicylate metabolism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of salicylate toxicity with bismuth subsalicylate in individuals with UGT1A6 poor metabolizer status?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma salicylate concentrations in a patient taking high doses of bismuth subsalicylate based on their UGT1A6 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do UGT1A6 genotypes map to salicylate clearance phenotypes following bismuth subsalicylate administration?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of UGT1A6 in the glucuronidation of the salicylate moiety from bismuth subsalicylate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should famotidine dosing be adjusted for a patient with a low-function MATE1 (SLC47A1) variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of adverse effects with famotidine in individuals with MATE1 variants that reduce renal clearance?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma famotidine concentrations in a patient with a high-function MATE1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC47A1 genotypes correlate with famotidine elimination phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the MATE1 transporter in the renal secretion of famotidine?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of sucralfate for a patient with a genetic predisposition to aluminum toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of aluminum overload with long-term sucralfate use in renal failure patients with specific transporter gene variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma aluminum concentration limits for a sucralfate-treated patient based on their genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with sucralfate efficacy phenotypes for duodenal ulcers?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for sucralfate in pediatric patients with genetic renal disorders?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should misoprostol dosing be adjusted for a patient with a specific prostaglandin receptor (PTGER3) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of severe diarrhea with misoprostol in individuals with specific PTGER3 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of gastric acid suppression for a misoprostol-treated patient based on their PTGER3 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PTGER3 genotypes correlate with the uterotonic effects of misoprostol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the EP3 receptor (PTGER3), a target of misoprostol, and how might its variants alter drug action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of orlistat for a patient with a specific variant in the pancreatic lipase (PNLIP) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor weight loss response to orlistat in individuals with PNLIP variants that are resistant to inhibition?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target level of fecal fat excretion for an orlistat-treated patient based on their PNLIP genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do PNLIP genotypes correlate with orlistat efficacy and gastrointestinal side effect phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of pancreatic lipase (PNLIP), the target of orlistat, and how might its variants alter drug binding?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should phentermine dosing be adjusted for a patient with a specific FTO gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of cardiovascular side effects with phentermine in individuals with the FTO risk allele for obesity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested weight loss target for a phentermine-treated patient based on their FTO genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do FTO genotypes correlate with phentermine efficacy phenotypes for weight management?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the role of the FTO gene in appetite regulation and its potential interaction with phentermine's mechanism of action?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of liraglutide for a patient with a specific variant in the GLP-1 receptor (GLP1R) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of poor glycemic or weight loss response to liraglutide in individuals with low-function GLP1R variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for liraglutide in type 2 diabetes or obesity based on GLP1R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do GLP1R genotypes correlate with liraglutide efficacy and its risk for pancreatitis?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the GLP-1 receptor, the target of liraglutide, and how do its variants alter drug signaling?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should semaglutide dosing be adjusted for a patient with a specific variant in the GLP-1 receptor (GLP1R) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of gastrointestinal side effects (e.g., nausea) with semaglutide in individuals with specific GLP1R variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target HbA1c or weight reduction for a semaglutide-treated patient based on their GLP1R genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do GLP1R genotypes define response phenotypes to semaglutide therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for oral semaglutide in patients with a genotype known to affect absorption?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of calcium carbonate for a patient with a specific variant in the calcium-sensing receptor (CASR) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypercalcemia with calcium carbonate supplements in individuals with inactivating mutations in the CASR gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target serum calcium level for a patient taking calcium carbonate based on their CASR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CASR genotypes correlate with the risk of milk-alkali syndrome from calcium carbonate?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the calcium-sensing receptor (CASR) in calcium homeostasis and its relevance to calcium supplementation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should vitamin D (cholecalciferol) dosing be adjusted for a patient with a specific variant in the CYP2R1 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of failing to achieve adequate 25-hydroxyvitamin D levels with standard vitamin D supplementation in individuals with low-function CYP2R1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum 25(OH)D concentrations for a patient based on their CYP2R1 and GC (VDBP) genotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP2R1 genotypes correlate with vitamin D bioactivation phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP2R1 enzyme in the 25-hydroxylation of vitamin D?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of calcitriol for a patient with a specific variant in the vitamin D receptor (VDR) gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of hypercalciuria with calcitriol in individuals with gain-of-function VDR polymorphisms?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic response metric for calcitriol in secondary hyperparathyroidism based on VDR genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do VDR genotypes (e.g., FokI, BsmI, TaqI) correlate with calcitriol efficacy and safety phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the vitamin D receptor (VDR) in mediating the genomic effects of calcitriol?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should levofloxacin dosing be adjusted for a patient with a specific variant in a DNA gyrase (gyrA) or topoisomerase IV (parC) gene of the infecting bacteria?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with levofloxacin in infections caused by bacteria with gyrA mutations?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target minimum inhibitory concentration (MIC) for levofloxacin based on the gyrA/parC genotype of the infecting organism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do bacterial gyrA and parC genotypes correlate with levofloxacin resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of DNA gyrase and topoisomerase IV, and how do their genetic alterations confer resistance to levofloxacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ciprofloxacin for a patient who is a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of drug interactions (e.g., with theophylline) when ciprofloxacin is used by a CYP1A2 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ciprofloxacin concentrations in a CYP1A2 ultrarapid metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes for CYP1A2 define a poor metabolizer in the context of ciprofloxacin therapy and its DDI potential?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of ciprofloxacin's inhibition of the CYP1A2 enzyme?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should moxifloxacin dosing be adjusted for a patient with a specific KCNH2 (hERG) gene variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of Torsades de Pointes with moxifloxacin in individuals with congenital long QT syndrome?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested QTc interval limit for a moxifloxacin-treated patient based on their KCNH2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host KCNH2 genotypes correlate with moxifloxacin-induced cardiotoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the hERG potassium channel and how is it affected by moxifloxacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of linezolid for a patient with a genetic predisposition to myelosuppression?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of thrombocytopenia with long-term linezolid use in individuals with variants in mitochondrial protein synthesis genes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested platelet count monitoring thresholds for a linezolid-treated patient based on their genetic risk?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with linezolid-induced hematologic toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the mechanism by which linezolid impacts mitochondrial protein synthesis, leading to potential toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tedizolid dosing be adjusted for a patient with a specific MAOA uVNTR polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of serotonin syndrome when tedizolid is co-administered with an SSRI in a patient with a low-activity MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for tedizolid to avoid hematologic toxicity based on MAOA genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MAOA genotypes correlate with the risk of tedizolid-induced adverse effects?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism of tedizolid's weak, reversible inhibition of Monoamine Oxidase A?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cefuroxime for a patient with a specific variant in a penicillin-binding protein (PBP) gene of the infecting bacteria?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the risk of treatment failure with cefuroxime in infections caused by bacteria with altered PBP genes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target minimum inhibitory concentration (MIC) for cefuroxime based on the PBP genotype of the infecting organism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do bacterial PBP genotypes correlate with cefuroxime resistance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of penicillin-binding proteins and how do their genetic alterations confer resistance to cefuroxime?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should ceftriaxone dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of biliary pseudolithiasis with ceftriaxone in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma ceftriaxone concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with ceftriaxone clearance and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter in the hepatic uptake of ceftriaxone?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of cefepime for a patient with a genetic predisposition to neurotoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nonconvulsive status epilepticus with cefepime in individuals with genetic variants affecting renal clearance or the blood-brain barrier?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for cefepime in a patient based on their genetic risk score for neurotoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors (e.g., in ABCB1) correlate with cefepime-induced encephalopathy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for cefepime in elderly patients with renal impairment and a genotype predisposing to CNS toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should meropenem dosing be adjusted for a patient with a specific variant affecting renal tubular secretion transporters like OAT1/OAT3?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of seizures with meropenem in individuals with low-function OAT transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the target time above MIC for a meropenem-treated patient based on their OAT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6/SLC22A8 genotypes correlate with meropenem clearance and neurotoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of organic anion transporters (OATs) in the renal elimination of meropenem?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of ertapenem for a patient with a genetic predisposition to seizures?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of CNS adverse effects with ertapenem in individuals with genetic variants affecting GABAergic pathways?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the suggested plasma concentration limits for ertapenem based on a patient's genetic risk score for neurotoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do host genetic factors correlate with ertapenem-induced seizures?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for ertapenem in elderly patients with a genetic susceptibility to CNS toxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should piperacillin-tazobactam dosing be adjusted for a patient with a specific variant in a renal transporter gene like OAT1/OAT3?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of nephrotoxicity with piperacillin-tazobactam in individuals with low-function OAT transporter variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma piperacillin concentrations in a patient with a high-function OAT genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6/SLC22A8 genotypes correlate with piperacillin clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of organic anion transporters (OATs) in the active tubular secretion of piperacillin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of gentamicin for a patient with a specific variant in a mitochondrial rRNA gene (e.g., MT-RNR1)?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of irreversible ototoxicity (hearing loss) with gentamicin in individuals with the m.1555A>G mutation in MT-RNR1?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic monitoring strategy for a gentamicin-treated patient with a known MT-RNR1 risk variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MT-RNR1 genotypes correlate with aminoglycoside-induced ototoxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the basic mechanism by which MT-RNR1 variants increase susceptibility to the ototoxic effects of aminoglycosides?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should tobramycin dosing be adjusted for a patient with the MT-RNR1 m.1555A>G mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the quantified risk of aminoglycoside-induced deafness for tobramycin users with the MT-RNR1 m.1555A>G variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the alternative antibiotic recommendations for a patient with a life-threatening infection who has a high-risk MT-RNR1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "Which MT-RNR1 variants are considered high-risk for aminoglycoside-induced ototoxicity?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for inhaled tobramycin in cystic fibrosis patients with a known MT-RNR1 risk variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of amikacin for a patient with the MT-RNR1 m.1555A>G mutation?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of vestibulotoxicity with amikacin in individuals with MT-RNR1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target peak and trough concentrations for amikacin in a patient with a high-risk MT-RNR1 genotype, assuming the drug must be used?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do MT-RNR1 genotypes map to aminoglycoside-induced toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the mitochondrial ribosome and how do MT-RNR1 variants increase its affinity for amikacin?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should remdesivir dosing be adjusted for a patient with a SLCO1B1 low-function genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of transaminase elevation with remdesivir in individuals with the SLCO1B1 c.521T>C polymorphism?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma remdesivir concentrations in a patient with a high-function SLCO1B1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLCO1B1 genotypes correlate with remdesivir safety and efficacy phenotypes in COVID-19?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OATP1B1 transporter in the hepatic uptake of remdesivir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of nirmatrelvir/ritonavir (Paxlovid) for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of dysgeusia with nirmatrelvir/ritonavir in patients with reduced CYP3A4 function?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target plasma concentrations for nirmatrelvir in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do CYP3A4 genotypes map to nirmatrelvir clearance phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of nirmatrelvir, and how is it inhibited by ritonavir?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should colchicine dosing be adjusted for a patient who is a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of fatal toxicity when colchicine is co-administered with a strong CYP3A4 inhibitor in a patient who is also a CYP3A4 poor metabolizer?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested therapeutic range for plasma colchicine concentrations in a patient with a CYP3A4 rapid metabolizer phenotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What diplotypes define a CYP3A4 poor metabolizer for colchicine therapy?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the dosing recommendation for colchicine in patients with renal impairment and a known CYP3A4 poor metabolizer genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended dose of febuxostat for a patient with a specific variant in the ABCG2 gene?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of liver function abnormalities with febuxostat in individuals with the ABCG2 Q141K variant?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What are the target serum urate levels for a febuxostat-treated patient based on their ABCG2 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do ABCG2 genotypes correlate with febuxostat response and toxicity phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the ABCG2 transporter in the excretion of febuxostat?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How should probenecid dosing be adjusted for a patient with a low-function OAT1 (SLC22A6) genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the increased risk of hypersensitivity reactions with probenecid in individuals with specific OAT1 variants?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the suggested target for serum urate reduction in a probenecid-treated patient based on their OAT1 genotype?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "How do SLC22A6 genotypes map to probenecid efficacy phenotypes?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the function of the OAT1 transporter in the uricosuric action of probenecid?",
    "answer": "No CPIC guideline information available."
  },
  {
    "question": "What is the recommended ivacaftor dose for a patient with the CFTR G551D mutation?",
    "answer": {
      "Drug Name": "ivacaftor",
      "Gene Name": "CFTR",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
      "Content to Search": "Recommended ivacaftor dosage for patients with the CFTR G551D genotype."
    }
  },
  {
    "question": "What is the risk of elevated transaminases for patients with a responsive CFTR genotype taking ivacaftor?",
    "answer": {
      "Drug Name": "ivacaftor",
      "Gene Name": "CFTR",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
      "Content to Search": "Incidence rates or quantified risk of elevated transaminases in patients on ivacaftor therapy."
    }
  },
  {
    "question": "What is the target for sweat chloride concentration reduction with ivacaftor therapy in responsive CFTR genotypes?",
    "answer": {
      "Drug Name": "ivacaftor",
      "Gene Name": "CFTR",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
      "Content to Search": "Pharmacodynamic data on expected sweat chloride reduction following ivacaftor treatment."
    }
  },
  {
    "question": "Which CFTR genotypes are considered responsive to ivacaftor therapy according to the CPIC guideline?",
    "answer": {
      "Drug Name": "ivacaftor",
      "Gene Name": "CFTR",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
      "Content to Search": "List of CFTR genotypes for which ivacaftor therapy is recommended."
    }
  },
  {
    "question": "What is the mechanism of action of ivacaftor on the CFTR protein channel?",
    "answer": {
      "Drug Name": "ivacaftor",
      "Gene Name": "CFTR",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
      "Content to Search": "Description of ivacaftor's function as a CFTR potentiator."
    }
  },
  {
    "question": "What is the recommended ivacaftor dose for a pediatric patient aged 6-11 with a responsive CFTR genotype?",
    "answer": {
      "Drug Name": "ivacaftor",
      "Gene Name": "CFTR",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype (March 2014).pdf",
      "Content to Search": "Pediatric dosing protocol for ivacaftor in children aged 6 to 11 years."
    }
  },
  {
    "question": "What is the recommended efavirenz dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "efavirenz",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
      "Content to Search": "Dose adjustment protocol for efavirenz in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of CNS adverse effects for a CYP2B6 poor metabolizer taking efavirenz?",
    "answer": {
      "Drug Name": "efavirenz",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
      "Content to Search": "Quantified risk data for CNS adverse effects in CYP2B6 poor metabolizers using efavirenz."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma efavirenz concentrations to minimize toxicity?",
    "answer": {
      "Drug Name": "efavirenz",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
      "Content to Search": "Therapeutic window or plasma concentration range for efavirenz."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "efavirenz",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
      "Content to Search": "Diplotype definitions corresponding to the CYP2B6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6*6 allele in efavirenz metabolism?",
    "answer": {
      "Drug Name": "efavirenz",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
      "Content to Search": "Description of the CYP2B6*6 allele's impact on enzyme function and efavirenz metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for efavirenz in children weighing <40kg with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "efavirenz",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy (April 2019).pdf",
      "Content to Search": "Pediatric dosing guidance for efavirenz in children under 40kg who are CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "How should the starting dose of methadone be adjusted for a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for methadone initiation in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the risk of opioid overdose for a CYP2B6 poor metabolizer on a standard methadone dose?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for toxicity or overdose in CYP2B6 poor metabolizers using methadone."
    }
  },
  {
    "question": "What is the expected impact of the CYP2B6 ultrarapid metabolizer phenotype on (R)-methadone plasma concentrations?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
      "Content to Search": "Pharmacokinetic data on (R)-methadone plasma levels in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "Which diplotypes correspond to the CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions for the CYP2B6 poor metabolizer category."
    }
  },
  {
    "question": "How does the CYP2B6 enzyme contribute to the metabolism of methadone?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2B6's role in methadone's metabolic pathway."
    }
  },
  {
    "question": "Are there specific methadone dosing recommendations for pregnant patients who are CYP2B6 poor metabolizers?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for methadone in pregnant patients with CYP2B6 poor metabolizer status."
    }
  },
  {
    "question": "What is the recommended therapeutic alternative to clopidogrel for a CYP2C19 poor metabolizer undergoing percutaneous coronary intervention (PCI)?",
    "answer": {
      "Drug Name": "clopidogrel",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
      "Content to Search": "Alternative antiplatelet therapy recommendations for CYP2C19 poor metabolizers post-PCI."
    }
  },
  {
    "question": "What is the increased risk of major adverse cardiovascular events (MACE) for a CYP2C19 poor metabolizer taking clopidogrel?",
    "answer": {
      "Drug Name": "clopidogrel",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
      "Content to Search": "Risk multipliers or incidence rates for MACE in CYP2C19 poor metabolizers on clopidogrel."
    }
  },
  {
    "question": "What is the expected plasma concentration of the active metabolite of clopidogrel in a CYP2C19 ultrarapid metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "clopidogrel",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
      "Content to Search": "Pharmacokinetic data comparing active metabolite concentrations of clopidogrel across CYP2C19 phenotypes."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "clopidogrel",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C19 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the bioactivation of clopidogrel?",
    "answer": {
      "Drug Name": "clopidogrel",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
      "Content to Search": "Explanation of CYP2C19's function in converting clopidogrel to its active metabolite."
    }
  },
  {
    "question": "Are there specific clopidogrel dosing recommendations for pediatric patients with a CYP2C19 loss-of-function allele?",
    "answer": {
      "Drug Name": "clopidogrel",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 update (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidance for clopidogrel based on CYP2C19 genotype."
    }
  },
  {
    "question": "What is the recommended dexlansoprazole dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "dexlansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Dose adjustment protocol for dexlansoprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the risk of treatment failure with standard dexlansoprazole dosing for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "dexlansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using dexlansoprazole."
    }
  },
  {
    "question": "What is the expected area under the curve (AUC) for dexlansoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "dexlansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pharmacokinetic data on dexlansoprazole exposure in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 rapid metabolizer?",
    "answer": {
      "Drug Name": "dexlansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 rapid metabolizer phenotype."
    }
  },
  {
    "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of dexlansoprazole?",
    "answer": {
      "Drug Name": "dexlansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Description of CYP2C19's role in dexlansoprazole's mechanism and metabolism."
    }
  },
  {
    "question": "Is dose adjustment for dexlansoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "dexlansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pediatric dosing guidance for dexlansoprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended esomeprazole dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "esomeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Dose adjustment protocol for esomeprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the risk of treatment failure with standard esomeprazole dosing for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "esomeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using esomeprazole."
    }
  },
  {
    "question": "What is the expected area under the curve (AUC) for esomeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "esomeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pharmacokinetic data on esomeprazole exposure in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "esomeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of esomeprazole?",
    "answer": {
      "Drug Name": "esomeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Description of CYP2C19's role in esomeprazole's mechanism and metabolism."
    }
  },
  {
    "question": "Is dose adjustment for esomeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "esomeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pediatric dosing guidance for esomeprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended lansoprazole dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "lansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Dose adjustment protocol for lansoprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the risk of treatment failure with standard lansoprazole dosing for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "lansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using lansoprazole."
    }
  },
  {
    "question": "What is the expected area under the curve (AUC) for lansoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "lansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pharmacokinetic data on lansoprazole exposure in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "lansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of lansoprazole?",
    "answer": {
      "Drug Name": "lansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Description of CYP2C19's role in lansoprazole's mechanism and metabolism."
    }
  },
  {
    "question": "Is dose adjustment for lansoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "lansoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pediatric dosing guidance for lansoprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended omeprazole dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "omeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Dose adjustment protocol for omeprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the risk of treatment failure with standard omeprazole dosing for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "omeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using omeprazole."
    }
  },
  {
    "question": "What is the expected area under the curve (AUC) for omeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "omeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pharmacokinetic data on omeprazole exposure in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "omeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 poor metabolizer phenotype."
    }
  },
  {
    "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of omeprazole?",
    "answer": {
      "Drug Name": "omeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Description of CYP2C19's role in omeprazole's mechanism and metabolism."
    }
  },
  {
    "question": "Is dose adjustment for omeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "omeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pediatric dosing guidance for omeprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended pantoprazole dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "pantoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Dose adjustment protocol for pantoprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the risk of treatment failure with standard pantoprazole dosing for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "pantoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using pantoprazole."
    }
  },
  {
    "question": "What is the expected area under the curve (AUC) for pantoprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "pantoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pharmacokinetic data on pantoprazole exposure in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 normal metabolizer?",
    "answer": {
      "Drug Name": "pantoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 normal metabolizer phenotype."
    }
  },
  {
    "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of pantoprazole?",
    "answer": {
      "Drug Name": "pantoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Description of CYP2C19's role in pantoprazole's mechanism and metabolism."
    }
  },
  {
    "question": "Is dose adjustment for pantoprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "pantoprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pediatric dosing guidance for pantoprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended rabeprazole dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "rabeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Dose adjustment protocol for rabeprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the risk of treatment failure with standard rabeprazole dosing for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "rabeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Quantified risk data for therapeutic failure in CYP2C19 ultrarapid metabolizers using rabeprazole."
    }
  },
  {
    "question": "What is the expected area under the curve (AUC) for rabeprazole in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "rabeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pharmacokinetic data on rabeprazole exposure in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 rapid metabolizer?",
    "answer": {
      "Drug Name": "rabeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Diplotype definitions corresponding to the CYP2C19 rapid metabolizer phenotype."
    }
  },
  {
    "question": "How does CYP2C19 polymorphism affect the first-pass metabolism of rabeprazole?",
    "answer": {
      "Drug Name": "rabeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Description of CYP2C19's role in rabeprazole's mechanism and metabolism."
    }
  },
  {
    "question": "Is dose adjustment for rabeprazole needed for pediatric patients who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "rabeprazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (August 2020).pdf",
      "Content to Search": "Pediatric dosing guidance for rabeprazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended initial intravenous voriconazole dose for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "voriconazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol for intravenous voriconazole in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the increased risk of hepatotoxicity for a CYP2C19 poor metabolizer taking a standard dose of voriconazole?",
    "answer": {
      "Drug Name": "voriconazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
      "Content to Search": "Quantified risk data for hepatotoxicity in CYP2C19 poor metabolizers using voriconazole."
    }
  },
  {
    "question": "What is the target trough plasma concentration for voriconazole to ensure efficacy and minimize toxicity?",
    "answer": {
      "Drug Name": "voriconazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
      "Content to Search": "Therapeutic drug monitoring values or target trough concentration range for voriconazole."
    }
  },
  {
    "question": "What diplotypes are classified as CYP2C19 intermediate metabolizers?",
    "answer": {
      "Drug Name": "voriconazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C19 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the primary metabolic pathway for voriconazole, and what is the role of CYP2C19?",
    "answer": {
      "Drug Name": "voriconazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
      "Content to Search": "Description of voriconazole's metabolism and the specific function of the CYP2C19 enzyme."
    }
  },
  {
    "question": "How should voriconazole dosing be adjusted for a pediatric patient who is a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "voriconazole",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Voriconazole Therapy (December 2016).pdf",
      "Content to Search": "Pediatric dosing adjustments for voriconazole in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended initial dose of aceclofenac for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for aceclofenac in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking aceclofenac?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using aceclofenac."
    }
  },
  {
    "question": "What is the expected increase in aceclofenac exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on aceclofenac exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of aceclofenac?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in aceclofenac's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for aceclofenac use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for aceclofenac in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for aceclofenac recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for aceclofenac based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with aceclofenac in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using aceclofenac."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of aceclofenac?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on aceclofenac exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of aceclofenac?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in aceclofenac's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aceclofenac dosing?",
    "answer": {
      "Drug Name": "aceclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for aceclofenac therapy."
    }
  },
  {
    "question": "Is a dose adjustment for low-dose aspirin recommended based on CYP2C9 genotype for cardioprotection?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing recommendations for low-dose aspirin based on CYP2C9 status."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with high-dose aspirin in patients with reduced-function CYP2C9 alleles?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Risk data for adverse effects with high-dose aspirin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "How does the CYP2C9*3 allele affect the pharmacokinetics of aspirin?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on aspirin related to the CYP2C9*3 allele."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the contribution of CYP2C9 to the overall clearance of aspirin?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's role in aspirin metabolism."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aspirin dosing in any special population?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for aspirin therapy in special populations."
    }
  },
  {
    "question": "Is a dose adjustment for aspirin recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for aspirin based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with aspirin in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using aspirin."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of aspirin?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on aspirin exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of aspirin?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in aspirin's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for aspirin dosing?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for aspirin therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of celecoxib for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for celecoxib in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of cardiovascular events for a CYP2C9 poor metabolizer taking celecoxib?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for cardiovascular events in CYP2C9 poor metabolizers using celecoxib."
    }
  },
  {
    "question": "What is the expected increase in celecoxib exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on celecoxib exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of celecoxib?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in celecoxib's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for celecoxib use in pediatric patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for celecoxib in pediatric CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for celecoxib recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for celecoxib based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with celecoxib in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using celecoxib."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of celecoxib?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on celecoxib exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of celecoxib?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in celecoxib's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for celecoxib dosing?",
    "answer": {
      "Drug Name": "celecoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for celecoxib therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of diclofenac for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for diclofenac in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of hepatotoxicity for a CYP2C9 poor metabolizer taking diclofenac?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for hepatotoxicity in CYP2C9 poor metabolizers using diclofenac."
    }
  },
  {
    "question": "What is the expected increase in diclofenac exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on diclofenac exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of diclofenac?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in diclofenac's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for diclofenac use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for diclofenac in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for diclofenac recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for diclofenac based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with diclofenac in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using diclofenac."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of diclofenac?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on diclofenac exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of diclofenac?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in diclofenac's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for diclofenac dosing?",
    "answer": {
      "Drug Name": "diclofenac",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for diclofenac therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of flurbiprofen for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for flurbiprofen in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking flurbiprofen?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using flurbiprofen."
    }
  },
  {
    "question": "What is the expected increase in flurbiprofen exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on flurbiprofen exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of flurbiprofen?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in flurbiprofen's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for flurbiprofen use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for flurbiprofen in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for flurbiprofen recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for flurbiprofen based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with flurbiprofen in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using flurbiprofen."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of flurbiprofen?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on flurbiprofen exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of flurbiprofen?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in flurbiprofen's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for flurbiprofen dosing?",
    "answer": {
      "Drug Name": "flurbiprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for flurbiprofen therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of ibuprofen for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for ibuprofen in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking ibuprofen?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using ibuprofen."
    }
  },
  {
    "question": "What is the expected increase in ibuprofen exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on ibuprofen exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of ibuprofen?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in ibuprofen's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for ibuprofen use in pediatric patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for ibuprofen in pediatric CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for ibuprofen recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for ibuprofen based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with ibuprofen in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using ibuprofen."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of ibuprofen?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on ibuprofen exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of ibuprofen?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in ibuprofen's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for ibuprofen dosing in pediatric patients?",
    "answer": {
      "Drug Name": "ibuprofen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for ibuprofen therapy in pediatric populations."
    }
  },
  {
    "question": "What is the recommended initial dose of indomethacin for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for indomethacin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking indomethacin?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using indomethacin."
    }
  },
  {
    "question": "What is the expected increase in indomethacin exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on indomethacin exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of indomethacin?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in indomethacin's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for indomethacin use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for indomethacin in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for indomethacin recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for indomethacin based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with indomethacin in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using indomethacin."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of indomethacin?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on indomethacin exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of indomethacin?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in indomethacin's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for indomethacin dosing?",
    "answer": {
      "Drug Name": "indomethacin",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for indomethacin therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of lornoxicam for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for lornoxicam in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking lornoxicam?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using lornoxicam."
    }
  },
  {
    "question": "What is the expected increase in lornoxicam exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on lornoxicam exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of lornoxicam?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in lornoxicam's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for lornoxicam use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for lornoxicam in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for lornoxicam recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for lornoxicam based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with lornoxicam in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using lornoxicam."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of lornoxicam?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on lornoxicam exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of lornoxicam?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in lornoxicam's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for lornoxicam dosing?",
    "answer": {
      "Drug Name": "lornoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for lornoxicam therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of lumiracoxib for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for lumiracoxib in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of hepatotoxicity for a CYP2C9 poor metabolizer taking lumiracoxib?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for hepatotoxicity in CYP2C9 poor metabolizers using lumiracoxib."
    }
  },
  {
    "question": "What is the expected increase in lumiracoxib exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on lumiracoxib exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of lumiracoxib?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in lumiracoxib's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for lumiracoxib use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for lumiracoxib in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for lumiracoxib recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for lumiracoxib based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with lumiracoxib in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using lumiracoxib."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of lumiracoxib?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on lumiracoxib exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of lumiracoxib?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in lumiracoxib's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for lumiracoxib dosing?",
    "answer": {
      "Drug Name": "lumiracoxib",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for lumiracoxib therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of meloxicam for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for meloxicam in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking meloxicam?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using meloxicam."
    }
  },
  {
    "question": "What is the expected increase in meloxicam exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on meloxicam exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of meloxicam?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in meloxicam's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for meloxicam use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for meloxicam in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for meloxicam recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for meloxicam based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with meloxicam in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using meloxicam."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of meloxicam?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on meloxicam exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of meloxicam?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in meloxicam's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for meloxicam dosing?",
    "answer": {
      "Drug Name": "meloxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for meloxicam therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of nabumetone for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for nabumetone in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking nabumetone?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using nabumetone."
    }
  },
  {
    "question": "What is the expected increase in exposure to nabumetone's active metabolite in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on nabumetone's active metabolite exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of nabumetone's active metabolite?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in the metabolic pathway of nabumetone's active metabolite."
    }
  },
  {
    "question": "Are there specific recommendations for nabumetone use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for nabumetone in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for nabumetone recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for nabumetone based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with nabumetone in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using nabumetone."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of nabumetone?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on nabumetone exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of nabumetone?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in nabumetone's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for nabumetone dosing?",
    "answer": {
      "Drug Name": "nabumetone",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for nabumetone therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of naproxen for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for naproxen in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking naproxen?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using naproxen."
    }
  },
  {
    "question": "What is the expected increase in naproxen exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on naproxen exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of naproxen?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in naproxen's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for naproxen use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for naproxen in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for naproxen recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for naproxen based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with naproxen in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using naproxen."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of naproxen?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on naproxen exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of naproxen?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in naproxen's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for naproxen dosing?",
    "answer": {
      "Drug Name": "naproxen",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for naproxen therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of piroxicam for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for piroxicam in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking piroxicam?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using piroxicam."
    }
  },
  {
    "question": "What is the expected increase in piroxicam exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on piroxicam exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of piroxicam?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in piroxicam's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for piroxicam use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for piroxicam in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for piroxicam recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for piroxicam based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with piroxicam in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using piroxicam."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of piroxicam?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on piroxicam exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of piroxicam?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in piroxicam's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for piroxicam dosing?",
    "answer": {
      "Drug Name": "piroxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for piroxicam therapy."
    }
  },
  {
    "question": "What is the recommended initial dose of tenoxicam for a patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for tenoxicam in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of gastrointestinal bleeding for a CYP2C9 poor metabolizer taking tenoxicam?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for GI bleeding in CYP2C9 poor metabolizers using tenoxicam."
    }
  },
  {
    "question": "What is the expected increase in tenoxicam exposure (AUC) in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on tenoxicam exposure in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Which diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in the metabolism of tenoxicam?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C9's function in tenoxicam's metabolic pathway."
    }
  },
  {
    "question": "Are there specific recommendations for tenoxicam use in elderly patients who are also CYP2C9 poor metabolizers?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dosing guidance for tenoxicam in elderly CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "Is a dose adjustment for tenoxicam recommended based on CYP2C8 genotype?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Dose adjustment protocol for tenoxicam based on CYP2C8 genotype."
    }
  },
  {
    "question": "Is there an increased risk of adverse events with tenoxicam in patients with reduced-function CYP2C8 alleles?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Quantified risk data for adverse events in patients with reduced-function CYP2C8 alleles using tenoxicam."
    }
  },
  {
    "question": "How does the CYP2C8*3 allele affect the pharmacokinetics of tenoxicam?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Pharmacokinetic data on tenoxicam exposure related to the CYP2C8*3 allele."
    }
  },
  {
    "question": "What are the known functional classifications of CYP2C8 alleles relevant to NSAID metabolism?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Allele function table or definitions for CYP2C8."
    }
  },
  {
    "question": "What is the contribution of CYP2C8 to the overall clearance of tenoxicam?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Description of CYP2C8's role in tenoxicam's metabolic pathway."
    }
  },
  {
    "question": "Are there combined CYP2C8 and CYP2C9 genotype considerations for tenoxicam dosing?",
    "answer": {
      "Drug Name": "tenoxicam",
      "Gene Name": "CYP2C8",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and NSAID Therapy (March 2020).pdf",
      "Content to Search": "Guidance on combined CYP2C8/CYP2C9 genotypes for tenoxicam therapy."
    }
  },
  {
    "question": "What is the recommended initial fosphenytoin dose for an adult who is a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Dose adjustment protocol for fosphenytoin in CYP2C9 intermediate metabolizers"
    }
  },
  {
    "question": "What is the increased risk of neurotoxicity from fosphenytoin in a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Quantified risk data for neurotoxicity in CYP2C9 poor metabolizers using fosphenytoin"
    }
  },
  {
    "question": "How does the CYP2C9 poor metabolizer phenotype affect the plasma concentration of phenytoin after fosphenytoin administration?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Plasma concentration data for phenytoin in CYP2C9 poor metabolizers after fosphenytoin administration"
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype"
    }
  },
  {
    "question": "How is fosphenytoin converted to phenytoin, and what is the role of CYP2C9 in the subsequent metabolism?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Mechanism of fosphenytoin conversion and the role of CYP2C9 in phenytoin metabolism"
    }
  },
  {
    "question": "What is the fosphenytoin dosing recommendation for a neonate with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for fosphenytoin in neonates with CYP2C9 poor metabolizer status"
    }
  },
  {
    "question": "What is the dosing recommendation for fosphenytoin in a patient who is positive for the HLA-B*15:02 allele?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Dosing recommendation or alternative therapy for fosphenytoin in HLA-B*15:02 positive individuals"
    }
  },
  {
    "question": "What is the quantified risk of fosphenytoin-induced toxic epidermal necrolysis (TEN) in an HLA-B*15:02 carrier?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Incidence rates or risk multipliers for TEN in HLA-B*15:02 carriers taking fosphenytoin"
    }
  },
  {
    "question": "Does the presence of the HLA-B*15:02 allele alter the pharmacokinetic profile of phenytoin derived from fosphenytoin?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Pharmacokinetic data (e.g., plasma concentration) of phenytoin based on HLA-B*15:02 status after fosphenytoin administration"
    }
  },
  {
    "question": "What is the correspondence between the HLA-B*15:02 genotype and the phenotype of high risk for fosphenytoin-induced SJS/TEN?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Definition of the high-risk phenotype associated with the HLA-B*15:02 allele for fosphenytoin use"
    }
  },
  {
    "question": "What is the mechanism by which the HLA-B*15:02 allele is thought to trigger an adverse immune response to fosphenytoin?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Immunological mechanism of HLA-B*15:02-mediated adverse reaction to fosphenytoin"
    }
  },
  {
    "question": "In which pediatric populations is HLA-B*15:02 screening recommended before initiating fosphenytoin therapy?",
    "answer": {
      "Drug Name": "fosphenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Recommendations for HLA-B*15:02 screening in specific pediatric or ethnic populations before fosphenytoin use"
    }
  },
  {
    "question": "What is the recommended initial phenytoin dose for a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Initial dose and adjustment protocol for phenytoin in CYP2C9 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of phenytoin toxicity for a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Quantified risk data for phenytoin toxicity in CYP2C9 intermediate metabolizers"
    }
  },
  {
    "question": "What is the target therapeutic range for plasma phenytoin concentrations?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Therapeutic window or plasma concentration range for phenytoin"
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the role of the CYP2C9 enzyme in phenytoin metabolism?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Function of CYP2C9 enzyme in the metabolic pathway of phenytoin"
    }
  },
  {
    "question": "What is the recommended phenytoin dosing adjustment for a pediatric patient who is a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for phenytoin based on CYP2C9 poor metabolizer status"
    }
  },
  {
    "question": "How should phenytoin dosing be managed for a patient who is a positive carrier of the HLA-B*15:02 allele?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Clinical recommendation for phenytoin use in HLA-B*15:02 positive patients"
    }
  },
  {
    "question": "What is the risk of developing Stevens-Johnson syndrome (SJS) when taking phenytoin for a patient with the HLA-B*15:02 allele?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Risk multiplier or incidence rate of SJS in HLA-B*15:02 carriers using phenytoin"
    }
  },
  {
    "question": "Is there an established therapeutic window for phenytoin that differs based on HLA-B genotype?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Information on whether HLA-B genotype affects the therapeutic range of phenytoin"
    }
  },
  {
    "question": "Which HLA-B allele is most strongly associated with phenytoin-induced severe cutaneous adverse reactions (SCARs)?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Specific HLA-B allele linked to high risk of SCARs with phenytoin"
    }
  },
  {
    "question": "What is the function of the HLA-B gene in the immune system?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Basic function and role of the HLA-B gene"
    }
  },
  {
    "question": "Are there specific recommendations regarding phenytoin use and HLA-B*15:02 testing in certain ethnic populations?",
    "answer": {
      "Drug Name": "phenytoin",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing (August 2020).pdf",
      "Content to Search": "Recommendations for HLA-B*15:02 screening in specific populations before phenytoin initiation"
    }
  },
  {
    "question": "How should the initial warfarin dose be adjusted for a patient with a CYP2C9 *3/*3 genotype (poor metabolizer)?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Dose adjustment protocol or dosing algorithm for warfarin in CYP2C9 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of bleeding for a warfarin patient who is a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Quantified risk data for bleeding events in CYP2C9 intermediate metabolizers on warfarin"
    }
  },
  {
    "question": "What is the target INR (International Normalized Ratio) range for a patient on warfarin, and how does CYP2C9 genotype affect the time to reach this range?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Data on time to stable INR based on CYP2C9 genotype"
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 intermediate metabolizer in the context of warfarin dosing?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Diplotype definitions for the CYP2C9 intermediate metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of warfarin?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Role of CYP2C9 in the metabolic pathway of S-warfarin"
    }
  },
  {
    "question": "What is the recommended warfarin dosing algorithm for a pediatric patient with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Pediatric-specific warfarin dosing guidance for CYP2C9 poor metabolizers"
    }
  },
  {
    "question": "How does the presence of the CYP4F2*3 allele influence the stable maintenance dose of warfarin?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP4F2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Percentage or numerical dose adjustment for warfarin in carriers of the CYP4F2*3 allele"
    }
  },
  {
    "question": "Is there a quantified risk of subtherapeutic INR associated with the CYP4F2*3 variant in patients taking warfarin?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP4F2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Risk data for achieving subtherapeutic INR in patients with the CYP4F2*3 variant"
    }
  },
  {
    "question": "What is the effect of the CYP4F2*3 variant on vitamin K plasma concentrations during warfarin therapy?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP4F2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Data on plasma vitamin K levels in relation to CYP4F2 genotype"
    }
  },
  {
    "question": "What CYP4F2 genotype is associated with a need for a higher warfarin dose?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP4F2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Definition of the CYP4F2 genotype that requires increased warfarin dosage"
    }
  },
  {
    "question": "What is the function of the CYP4F2 enzyme in relation to vitamin K metabolism?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP4F2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Role of the CYP4F2 enzyme in the vitamin K cycle"
    }
  },
  {
    "question": "Are there specific warfarin dosing considerations for patients with the CYP4F2*3 variant and comorbid liver disease?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "CYP4F2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Dosing adjustments for warfarin in patients with both CYP4F2*3 variant and liver comorbidities"
    }
  },
  {
    "question": "What is the recommended starting dose of warfarin for a patient with the VKORC1 -1639G>A (AA) genotype, indicating increased sensitivity?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "VKORC1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Specific starting dose or dose reduction percentage for warfarin in patients with VKORC1 -1639G>A (AA) genotype"
    }
  },
  {
    "question": "What is the relative risk of over-anticoagulation for a patient with a sensitive VKORC1 genotype when starting warfarin?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "VKORC1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Quantified risk data for supratherapeutic INR in patients with a sensitive VKORC1 genotype"
    }
  },
  {
    "question": "How does the VKORC1 -1639G>A genotype affect the pharmacodynamics of warfarin, specifically the dose-response relationship?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "VKORC1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Pharmacodynamic data describing the effect of VKORC1 genotype on warfarin dose-response"
    }
  },
  {
    "question": "What VKORC1 genotypes correspond to the 'high sensitivity' phenotype for warfarin?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "VKORC1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Genotype definitions for the high sensitivity warfarin phenotype related to VKORC1"
    }
  },
  {
    "question": "What is the role of the VKORC1 enzyme in the vitamin K cycle, and how does warfarin inhibit it?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "VKORC1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Mechanism of action of warfarin on the VKORC1 enzyme within the vitamin K cycle"
    }
  },
  {
    "question": "How is warfarin dosing adjusted for an elderly patient with a sensitive VKORC1 genotype?",
    "answer": {
      "Drug Name": "warfarin",
      "Gene Name": "VKORC1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenetics-guided Warfarin Dosing: 2016 Update.pdf",
      "Content to Search": "Dosing recommendations for warfarin in elderly patients with a sensitive VKORC1 genotype"
    }
  },
  {
    "question": "What is the recommended atomoxetine starting dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "atomoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
      "Content to Search": "Recommended starting dose and titration schedule for atomoxetine in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of cardiovascular adverse effects for a CYP2D6 poor metabolizer taking atomoxetine?",
    "answer": {
      "Drug Name": "atomoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
      "Content to Search": "Quantified risk data for adverse effects like increased blood pressure or tachycardia in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the expected plasma concentration (AUC) of atomoxetine in a CYP2D6 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "atomoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
      "Content to Search": "Pharmacokinetic data, specifically area under the curve (AUC) values, for atomoxetine in CYP2D6 poor vs. normal metabolizers"
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "atomoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
      "Content to Search": "Diplotype definitions and corresponding activity scores for the CYP2D6 ultrarapid metabolizer phenotype"
    }
  },
  {
    "question": "What is the primary metabolic pathway for atomoxetine, and what is the role of the CYP2D6 enzyme?",
    "answer": {
      "Drug Name": "atomoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
      "Content to Search": "Description of atomoxetine metabolism and the specific function of the CYP2D6 enzyme in that process"
    }
  },
  {
    "question": "What is the recommended atomoxetine dose for a child weighing over 70kg who is a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "atomoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine (February 2019).pdf",
      "Content to Search": "Specific dosing guidance for atomoxetine in pediatric patients >70kg with CYP2D6 poor metabolizer status"
    }
  },
  {
    "question": "What is the recommended ondansetron dosing adjustment for a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "ondansetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol or alternative therapy for ondansetron in CYP2D6 ultrarapid metabolizers"
    }
  },
  {
    "question": "What is the increased risk of treatment failure for a CYP2D6 ultrarapid metabolizer taking a standard dose of ondansetron?",
    "answer": {
      "Drug Name": "ondansetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Quantified risk data for lack of efficacy in CYP2D6 ultrarapid metabolizers using ondansetron"
    }
  },
  {
    "question": "What are the expected plasma concentrations of ondansetron in a CYP2D6 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "ondansetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Plasma concentration data or pharmacokinetic parameters for ondansetron in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "ondansetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype"
    }
  },
  {
    "question": "What is the role of the CYP2D6 enzyme in the metabolism of ondansetron?",
    "answer": {
      "Drug Name": "ondansetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Description of CYP2D6's metabolic pathway for ondansetron"
    }
  },
  {
    "question": "Are there specific ondansetron dosing recommendations for pediatric CYP2D6 ultrarapid metabolizers?",
    "answer": {
      "Drug Name": "ondansetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Pediatric dosing recommendations for ondansetron based on CYP2D6 ultrarapid metabolizer status"
    }
  },
  {
    "question": "How should tropisetron dosing be modified for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "tropisetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Dose modification protocol for tropisetron in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for CYP2D6 poor metabolizers when using tropisetron?",
    "answer": {
      "Drug Name": "tropisetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Incidence rates or risk multipliers for adverse effects in CYP2D6 poor metabolizers taking tropisetron"
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma tropisetron concentrations?",
    "answer": {
      "Drug Name": "tropisetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Therapeutic range for plasma tropisetron concentrations"
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "tropisetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the CYP2D6*4 allele in relation to drug metabolism?",
    "answer": {
      "Drug Name": "tropisetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Functional description of the non-functional CYP2D6*4 allele"
    }
  },
  {
    "question": "What is the recommended tropisetron dose for a pregnant patient who is a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "tropisetron",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron (December 2016).pdf",
      "Content to Search": "Dosing guidance for tropisetron in pregnant CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the recommended alternative therapy to tamoxifen for a CYP2D6 poor metabolizer with breast cancer?",
    "answer": {
      "Drug Name": "tamoxifen",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
      "Content to Search": "Alternative therapy recommendations for tamoxifen in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of breast cancer recurrence for a CYP2D6 intermediate metabolizer on tamoxifen therapy?",
    "answer": {
      "Drug Name": "tamoxifen",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
      "Content to Search": "Quantified risk of disease recurrence for CYP2D6 intermediate metabolizers taking tamoxifen"
    }
  },
  {
    "question": "What are the target plasma concentrations for endoxifen, the active metabolite of tamoxifen?",
    "answer": {
      "Drug Name": "tamoxifen",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
      "Content to Search": "Therapeutic plasma concentration range for endoxifen"
    }
  },
  {
    "question": "Which CYP2D6 diplotypes are classified as intermediate metabolizers?",
    "answer": {
      "Drug Name": "tamoxifen",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 intermediate metabolizer phenotype"
    }
  },
  {
    "question": "How does the CYP2D6 enzyme contribute to the bioactivation of tamoxifen?",
    "answer": {
      "Drug Name": "tamoxifen",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
      "Content to Search": "Mechanism of tamoxifen's metabolic activation to endoxifen by CYP2D6"
    }
  },
  {
    "question": "Are there specific tamoxifen dosing considerations for postmenopausal CYP2D6 poor metabolizers?",
    "answer": {
      "Drug Name": "tamoxifen",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy (January 2018).pdf",
      "Content to Search": "Dosing or therapy recommendations for postmenopausal CYP2D6 poor metabolizers on tamoxifen"
    }
  },
  {
    "question": "What is the recommended dosing adjustment for atazanavir in a patient with a UGT1A1 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "atazanavir",
      "Gene Name": "UGT1A1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
      "Content to Search": "Dosing adjustment protocol or alternative therapy recommendation for atazanavir in UGT1A1 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of hyperbilirubinemia for a UGT1A1 poor metabolizer taking atazanavir?",
    "answer": {
      "Drug Name": "atazanavir",
      "Gene Name": "UGT1A1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
      "Content to Search": "Quantified risk data (e.g., odds ratio, incidence rate) of hyperbilirubinemia in UGT1A1 poor metabolizers taking atazanavir."
    }
  },
  {
    "question": "What is the expected impact on bilirubin concentrations in a UGT1A1 poor metabolizer treated with atazanavir?",
    "answer": {
      "Drug Name": "atazanavir",
      "Gene Name": "UGT1A1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
      "Content to Search": "Expected bilirubin concentration levels or changes in UGT1A1 poor metabolizers on atazanavir therapy."
    }
  },
  {
    "question": "Which UGT1A1 diplotypes correspond to the intermediate metabolizer phenotype?",
    "answer": {
      "Drug Name": "atazanavir",
      "Gene Name": "UGT1A1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
      "Content to Search": "List of UGT1A1 diplotypes that define the intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the UGT1A1 enzyme in the metabolism of atazanavir?",
    "answer": {
      "Drug Name": "atazanavir",
      "Gene Name": "UGT1A1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
      "Content to Search": "Mechanism of UGT1A1-mediated atazanavir metabolism and its role in bilirubin conjugation."
    }
  },
  {
    "question": "Are there specific atazanavir dosing recommendations for pediatric patients with a UGT1A1 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "atazanavir",
      "Gene Name": "UGT1A1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for UGT1A1 and Atazanavir Prescribing (September 2015).pdf",
      "Content to Search": "Atazanavir dosing guidelines for pediatric patients with the UGT1A1 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the recommended starting dose of tacrolimus for a CYP3A5 expresser (intermediate metabolizer)?",
    "answer": {
      "Drug Name": "tacrolimus",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
      "Content to Search": "Recommended tacrolimus starting dose for CYP3A5 intermediate metabolizers"
    }
  },
  {
    "question": "What is the risk of supratherapeutic tacrolimus concentrations for a CYP3A5 non-expresser (poor metabolizer)?",
    "answer": {
      "Drug Name": "tacrolimus",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
      "Content to Search": "Quantified risk of toxicity or supratherapeutic concentrations in CYP3A5 poor metabolizers taking tacrolimus"
    }
  },
  {
    "question": "What is the target therapeutic trough concentration range for tacrolimus?",
    "answer": {
      "Drug Name": "tacrolimus",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
      "Content to Search": "Therapeutic trough concentration range for tacrolimus"
    }
  },
  {
    "question": "Which diplotypes correspond to a CYP3A5 non-expresser (poor metabolizer) phenotype?",
    "answer": {
      "Drug Name": "tacrolimus",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
      "Content to Search": "Diplotype definitions for the CYP3A5 poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the role of the CYP3A5 enzyme in tacrolimus metabolism?",
    "answer": {
      "Drug Name": "tacrolimus",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
      "Content to Search": "Function of CYP3A5 enzyme in the metabolic pathway of tacrolimus"
    }
  },
  {
    "question": "What is the recommended tacrolimus dosing for a pediatric kidney transplant recipient who is a CYP3A5 expresser?",
    "answer": {
      "Drug Name": "tacrolimus",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and Tacrolimus Dosing (July 2015).pdf",
      "Content to Search": "Pediatric dosing recommendations for tacrolimus in CYP3A5 expressers"
    }
  },
  {
    "question": "How should capecitabine dosing be adjusted for a DPYD intermediate metabolizer?",
    "answer": {
      "Drug Name": "capecitabine",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Dose adjustment protocol for capecitabine in DPYD intermediate metabolizers"
    }
  },
  {
    "question": "What is the increased risk of severe toxicity for a DPYD poor metabolizer taking capecitabine?",
    "answer": {
      "Drug Name": "capecitabine",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Quantified risk data for severe toxicity in DPYD poor metabolizers using capecitabine"
    }
  },
  {
    "question": "What is the effect of DPYD poor metabolizer status on fluorouracil (the active metabolite of capecitabine) clearance?",
    "answer": {
      "Drug Name": "capecitabine",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Pharmacokinetic data on fluorouracil clearance in DPYD poor metabolizers after capecitabine administration"
    }
  },
  {
    "question": "What diplotypes define a DPYD poor metabolizer?",
    "answer": {
      "Drug Name": "capecitabine",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Diplotype definitions for the DPYD poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the DPYD gene in fluoropyrimidine metabolism?",
    "answer": {
      "Drug Name": "capecitabine",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Role of the DPYD enzyme in the catabolism of fluoropyrimidines"
    }
  },
  {
    "question": "Are there specific capecitabine dosing recommendations for pediatric patients with DPYD deficiency?",
    "answer": {
      "Drug Name": "capecitabine",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Pediatric dosing guidance for capecitabine in patients with DPYD deficiency"
    }
  },
  {
    "question": "What is the recommended dose reduction for fluorouracil in a DPYD intermediate metabolizer?",
    "answer": {
      "Drug Name": "fluorouracil",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Specific dose reduction percentage or value for fluorouracil in DPYD intermediate metabolizers"
    }
  },
  {
    "question": "What is the incidence of grade 3 or higher toxicity in DPYD poor metabolizers treated with standard-dose fluorouracil?",
    "answer": {
      "Drug Name": "fluorouracil",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Incidence rates of severe toxicity for DPYD poor metabolizers on fluorouracil"
    }
  },
  {
    "question": "What is the expected plasma concentration of fluorouracil in a DPYD poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "fluorouracil",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Pharmacokinetic data comparing fluorouracil plasma concentrations between DPYD poor and normal metabolizers"
    }
  },
  {
    "question": "Which genotypes are associated with the DPYD intermediate metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluorouracil",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Genotype or diplotype definitions for the DPYD intermediate metabolizer phenotype"
    }
  },
  {
    "question": "How does the DPYD enzyme inactivate fluorouracil?",
    "answer": {
      "Drug Name": "fluorouracil",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Mechanism of action for DPYD enzyme in the inactivation of fluorouracil"
    }
  },
  {
    "question": "Are there specific fluorouracil dosing guidelines for patients with renal impairment and DPYD deficiency?",
    "answer": {
      "Drug Name": "fluorouracil",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Dosing adjustments for fluorouracil in patients with both renal impairment and DPYD deficiency"
    }
  },
  {
    "question": "What is the recommended dosing adjustment for tegafur in patients with a DPYD poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "tegafur",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Dose adjustment protocol for tegafur in DPYD poor metabolizers"
    }
  },
  {
    "question": "What is the quantified risk of life-threatening toxicity when administering tegafur to a DPYD poor metabolizer?",
    "answer": {
      "Drug Name": "tegafur",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Quantified risk data or incidence rates of severe toxicity in DPYD poor metabolizers using tegafur"
    }
  },
  {
    "question": "How does DPYD deficiency affect the pharmacokinetics of tegafur's active metabolite, 5-fluorouracil?",
    "answer": {
      "Drug Name": "tegafur",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Pharmacokinetic parameters of 5-fluorouracil in DPYD deficient individuals after tegafur administration"
    }
  },
  {
    "question": "What DPYD activity score corresponds to an intermediate metabolizer phenotype?",
    "answer": {
      "Drug Name": "tegafur",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "DPYD activity score definitions for the intermediate metabolizer phenotype"
    }
  },
  {
    "question": "What is the mechanism by which tegafur is converted to fluorouracil and subsequently metabolized by DPYD?",
    "answer": {
      "Drug Name": "tegafur",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Metabolic pathway of tegafur to 5-fluorouracil and its subsequent catabolism by DPYD"
    }
  },
  {
    "question": "Are there specific dosing recommendations for tegafur in elderly patients with reduced DPYD activity?",
    "answer": {
      "Drug Name": "tegafur",
      "Gene Name": "DPYD",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update (October 2017).pdf",
      "Content to Search": "Dosing guidance for tegafur in elderly patients with DPYD intermediate or poor metabolizer status"
    }
  },
  {
    "question": "What is the dosing recommendation for carbamazepine in a patient positive for the HLA-A*31:01 allele?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Clinical dosing recommendation for carbamazepine in HLA-A*31:01 positive individuals"
    }
  },
  {
    "question": "What is the increased risk of maculopapular exanthema (MPE) for an HLA-A*31:01 carrier taking carbamazepine?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Quantified risk or odds ratio for MPE in HLA-A*31:01 carriers using carbamazepine"
    }
  },
  {
    "question": "Is there a known pharmacokinetic mechanism linking HLA-A*31:01 to carbamazepine-induced adverse reactions?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Pharmacokinetic data or mechanism linking HLA-A*31:01 and carbamazepine adverse events"
    }
  },
  {
    "question": "What is the clinical implication of testing positive for the HLA-A*31:01 allele before starting carbamazepine?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Definition of the clinical phenotype or implication for a patient with the HLA-A*31:01 allele regarding carbamazepine use"
    }
  },
  {
    "question": "What is the function of the HLA-A gene in the immune response related to drug hypersensitivity?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Basic function of the HLA-A gene and its role in antigen presentation leading to drug hypersensitivity"
    }
  },
  {
    "question": "Are there different carbamazepine recommendations for pediatric patients with the HLA-A*31:01 allele?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Specific dosing or clinical recommendations for carbamazepine in pediatric HLA-A*31:01 carriers"
    }
  },
  {
    "question": "What is the clinical recommendation for carbamazepine use in a patient who tests positive for the HLA-B*15:02 allele?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Dosing recommendation or contraindication for carbamazepine in HLA-B*15:02 positive individuals"
    }
  },
  {
    "question": "What is the quantified risk of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in an HLA-B*15:02 positive individual taking carbamazepine?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Risk multiplier or incidence rate of SJS/TEN in HLA-B*15:02 carriers taking carbamazepine"
    }
  },
  {
    "question": "Is there a defined therapeutic window for carbamazepine that changes based on HLA-B*15:02 status?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Therapeutic drug monitoring values or plasma concentration ranges for carbamazepine in relation to HLA-B*15:02 status"
    }
  },
  {
    "question": "Which populations have a higher prevalence of the HLA-B*15:02 allele, impacting carbamazepine prescribing?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Definition of populations with high HLA-B*15:02 allele frequency"
    }
  },
  {
    "question": "What is the proposed immunological mechanism for HLA-B*15:02-mediated carbamazepine hypersensitivity?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Mechanism of HLA-B*15:02 involvement in the immune response to carbamazepine"
    }
  },
  {
    "question": "What is the carbamazepine dosing recommendation for a child of Southeast Asian ancestry who is positive for HLA-B*15:02?",
    "answer": {
      "Drug Name": "carbamazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Pediatric dosing recommendations for carbamazepine in HLA-B*15:02 positive children, particularly of specific ancestries"
    }
  },
  {
    "question": "What is the dosing recommendation for oxcarbazepine in a patient who is a carrier of the HLA-A*31:01 allele?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Clinical dosing recommendation for oxcarbazepine in HLA-A*31:01 positive individuals"
    }
  },
  {
    "question": "What is the risk of oxcarbazepine-induced cutaneous adverse reactions in individuals with the HLA-A*31:01 allele?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Quantified risk data for cutaneous adverse reactions with oxcarbazepine in HLA-A*31:01 carriers"
    }
  },
  {
    "question": "Does the HLA-A*31:01 allele affect the pharmacokinetics of oxcarbazepine or its active metabolite?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Pharmacokinetic data for oxcarbazepine in relation to HLA-A*31:01 status"
    }
  },
  {
    "question": "What is the clinical significance of the HLA-A*31:01 allele for oxcarbazepine therapy?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Definition of clinical phenotype or implication of HLA-A*31:01 positivity for oxcarbazepine use"
    }
  },
  {
    "question": "How does the HLA-A gene's role in antigen presentation relate to potential oxcarbazepine hypersensitivity?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Basic mechanism of HLA-A in immune-mediated reactions to oxcarbazepine"
    }
  },
  {
    "question": "Are there specific guidelines for using oxcarbazepine in pediatric patients with the HLA-A*31:01 allele?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Pediatric dosing or clinical guidance for oxcarbazepine in HLA-A*31:01 positive children"
    }
  },
  {
    "question": "How should oxcarbazepine be prescribed for a patient who is positive for the HLA-B*15:02 allele?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Dosing recommendation or contraindication for oxcarbazepine in HLA-B*15:02 positive individuals"
    }
  },
  {
    "question": "What is the risk of SJS/TEN when using oxcarbazepine in an HLA-B*15:02 positive patient?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Quantified risk of SJS/TEN for oxcarbazepine use in HLA-B*15:02 carriers"
    }
  },
  {
    "question": "Are there any therapeutic drug monitoring recommendations for oxcarbazepine based on HLA-B*15:02 status?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Therapeutic drug monitoring guidance for oxcarbazepine in relation to HLA-B*15:02 status"
    }
  },
  {
    "question": "Does the presence of the HLA-B*15:02 allele have the same predictive value for oxcarbazepine as it does for carbamazepine?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Comparison of predictive value of HLA-B*15:02 for hypersensitivity between oxcarbazepine and carbamazepine"
    }
  },
  {
    "question": "What is the mechanism of cross-reactivity between carbamazepine and oxcarbazepine in HLA-B*15:02 positive individuals?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Mechanism of immunological cross-reactivity for carbamazepine and oxcarbazepine in HLA-B*15:02 carriers"
    }
  },
  {
    "question": "What is the recommendation for initiating oxcarbazepine in a pregnant patient who is an HLA-B*15:02 carrier?",
    "answer": {
      "Drug Name": "oxcarbazepine",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update (December 2017).pdf",
      "Content to Search": "Guidance for oxcarbazepine use during pregnancy in HLA-B*15:02 positive individuals"
    }
  },
  {
    "question": "What is the dosing recommendation for abacavir in a patient who is positive for the HLA-B*57:01 allele?",
    "answer": {
      "Drug Name": "abacavir",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
      "Content to Search": "Clinical recommendation and dosing guidance for abacavir in HLA-B*57:01 positive individuals"
    }
  },
  {
    "question": "What is the quantified risk of abacavir hypersensitivity syndrome (AHS) in an individual carrying the HLA-B*57:01 allele?",
    "answer": {
      "Drug Name": "abacavir",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
      "Content to Search": "Quantified risk, odds ratio, or incidence rate of AHS in HLA-B*57:01 carriers"
    }
  },
  {
    "question": "Is there a known pharmacokinetic interaction between abacavir and the HLA-B*57:01 allele, or is the mechanism purely immunological?",
    "answer": {
      "Drug Name": "abacavir",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
      "Content to Search": "Pharmacokinetic data or description of the immunological mechanism for abacavir hypersensitivity related to HLA-B*57:01"
    }
  },
  {
    "question": "What is the clinical phenotype associated with being an HLA-B*57:01 carrier in the context of abacavir therapy?",
    "answer": {
      "Drug Name": "abacavir",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
      "Content to Search": "Definition of the clinical implication or phenotype for an HLA-B*57:01 carrier regarding abacavir use"
    }
  },
  {
    "question": "What is the immunological mechanism by which the HLA-B*57:01 allele leads to abacavir hypersensitivity?",
    "answer": {
      "Drug Name": "abacavir",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
      "Content to Search": "Description of the immunological mechanism involving HLA-B*57:01 and abacavir"
    }
  },
  {
    "question": "Are there specific guidelines for abacavir use in pediatric patients who are HLA-B*57:01 positive?",
    "answer": {
      "Drug Name": "abacavir",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing (April 2012).pdf",
      "Content to Search": "Clinical recommendations for abacavir use in pediatric HLA-B*57:01 carriers"
    }
  },
  {
    "question": "What is the dosing recommendation for allopurinol in a patient who tests positive for the HLA-B*58:01 allele?",
    "answer": {
      "Drug Name": "allopurinol",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
      "Content to Search": "Clinical recommendation and dosing guidance for allopurinol in HLA-B*58:01 positive individuals"
    }
  },
  {
    "question": "What is the increased risk of severe cutaneous adverse reactions (SCARs) for an HLA-B*58:01 carrier taking allopurinol?",
    "answer": {
      "Drug Name": "allopurinol",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
      "Content to Search": "Quantified risk or odds ratio for SCARs in HLA-B*58:01 carriers taking allopurinol"
    }
  },
  {
    "question": "Does the HLA-B*58:01 allele affect the pharmacokinetics of allopurinol or its active metabolite, oxypurinol?",
    "answer": {
      "Drug Name": "allopurinol",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
      "Content to Search": "Pharmacokinetic data for allopurinol or oxypurinol in relation to HLA-B*58:01 status"
    }
  },
  {
    "question": "In which ethnic populations is the HLA-B*58:01 allele most prevalent, necessitating pre-screening for allopurinol therapy?",
    "answer": {
      "Drug Name": "allopurinol",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
      "Content to Search": "Information on ethnic populations with high prevalence of the HLA-B*58:01 allele"
    }
  },
  {
    "question": "What is the proposed mechanism for HLA-B*58:01-mediated allopurinol-induced SCARs?",
    "answer": {
      "Drug Name": "allopurinol",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
      "Content to Search": "Description of the immunological mechanism involving HLA-B*58:01 and allopurinol"
    }
  },
  {
    "question": "What is the allopurinol dosing recommendation for a patient with chronic kidney disease who is also an HLA-B*58:01 carrier?",
    "answer": {
      "Drug Name": "allopurinol",
      "Gene Name": "HLA-B",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing (February 2013).pdf",
      "Content to Search": "Dosing recommendations for allopurinol in patients with both chronic kidney disease and HLA-B*58:01 positive status"
    }
  },
  {
    "question": "What is the recommended dosing for amikacin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "amikacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for amikacin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering amikacin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "amikacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for amikacin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for amikacin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "amikacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for amikacin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "amikacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to amikacin-induced ototoxicity?",
    "answer": {
      "Drug Name": "amikacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with amikacin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for amikacin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "amikacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for amikacin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for dibekacin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "dibekacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for dibekacin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering dibekacin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "dibekacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for dibekacin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for dibekacin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "dibekacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for dibekacin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "dibekacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to dibekacin-induced ototoxicity?",
    "answer": {
      "Drug Name": "dibekacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with dibekacin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for dibekacin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "dibekacin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for dibekacin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for gentamicin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "gentamicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for gentamicin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering gentamicin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "gentamicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for gentamicin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for gentamicin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "gentamicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for gentamicin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "gentamicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to gentamicin-induced ototoxicity?",
    "answer": {
      "Drug Name": "gentamicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with gentamicin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for gentamicin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "gentamicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for gentamicin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for kanamycin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "kanamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for kanamycin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering kanamycin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "kanamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for kanamycin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for kanamycin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "kanamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for kanamycin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "kanamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to kanamycin-induced ototoxicity?",
    "answer": {
      "Drug Name": "kanamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with kanamycin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for kanamycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "kanamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for kanamycin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for neomycin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "neomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for neomycin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering neomycin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "neomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for neomycin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for neomycin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "neomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for neomycin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "neomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to neomycin-induced ototoxicity?",
    "answer": {
      "Drug Name": "neomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with neomycin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for neomycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "neomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for neomycin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for netilmicin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "netilmicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for netilmicin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering netilmicin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "netilmicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for netilmicin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for netilmicin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "netilmicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for netilmicin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "netilmicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to netilmicin-induced ototoxicity?",
    "answer": {
      "Drug Name": "netilmicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with netilmicin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for netilmicin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "netilmicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for netilmicin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for paromomycin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "paromomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for paromomycin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering paromomycin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "paromomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for paromomycin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for paromomycin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "paromomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for paromomycin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "paromomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to paromomycin-induced ototoxicity?",
    "answer": {
      "Drug Name": "paromomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with paromomycin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for paromomycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "paromomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for paromomycin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for plazomicin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "plazomicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for plazomicin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering plazomicin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "plazomicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for plazomicin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for plazomicin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "plazomicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for plazomicin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "plazomicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to plazomicin-induced ototoxicity?",
    "answer": {
      "Drug Name": "plazomicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with plazomicin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for plazomicin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "plazomicin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for plazomicin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for ribostamycin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "ribostamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for ribostamycin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering ribostamycin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "ribostamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for ribostamycin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for ribostamycin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "ribostamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for ribostamycin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "ribostamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to ribostamycin-induced ototoxicity?",
    "answer": {
      "Drug Name": "ribostamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with ribostamycin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for ribostamycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "ribostamycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for ribostamycin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for streptomycin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "streptomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for streptomycin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering streptomycin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "streptomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for streptomycin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for streptomycin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "streptomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for streptomycin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "streptomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to streptomycin-induced ototoxicity?",
    "answer": {
      "Drug Name": "streptomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with streptomycin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for streptomycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "streptomycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for streptomycin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for tobramycin in an individual with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "tobramycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Dosing recommendations or alternative therapies for tobramycin in patients with pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the quantified risk of ototoxicity when administering tobramycin to a patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "tobramycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Incidence rates or risk multipliers for tobramycin-induced ototoxicity in MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What are the target therapeutic plasma concentrations for tobramycin, and how are they affected by MT-RNR1 status?",
    "answer": {
      "Drug Name": "tobramycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Therapeutic drug monitoring ranges for tobramycin and any specific considerations for MT-RNR1 variant carriers."
    }
  },
  {
    "question": "What MT-RNR1 variants define a high-risk phenotype for aminoglycoside-induced hearing loss?",
    "answer": {
      "Drug Name": "tobramycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "List of specific MT-RNR1 variants or diplotypes associated with increased risk of ototoxicity."
    }
  },
  {
    "question": "What is the mechanism by which MT-RNR1 variants increase susceptibility to tobramycin-induced ototoxicity?",
    "answer": {
      "Drug Name": "tobramycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Functional explanation of how MT-RNR1 variants interact with tobramycin to cause cellular damage."
    }
  },
  {
    "question": "What is the dosing recommendation for tobramycin in a pediatric patient with a pathogenic MT-RNR1 variant?",
    "answer": {
      "Drug Name": "tobramycin",
      "Gene Name": "MT-RNR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for MT-RNR1 and Aminoglycosides (May 2021).pdf",
      "Content to Search": "Specific dosing guidance for tobramycin in pediatric populations carrying pathogenic MT-RNR1 variants."
    }
  },
  {
    "question": "What is the recommended dosing for desflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for desflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering desflurane to a patient with a pathogenic RYR1 variant?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for desflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for desflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for desflurane in the context of RYR1-MHS."
    }
  },
  {
    "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the RYR1 gene in the mechanism of desflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of desflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for desflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for desflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering desflurane to a patient with a pathogenic CACNA1S variant?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for desflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for desflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for desflurane in the context of CACNA1S-MHS."
    }
  },
  {
    "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the CACNA1S gene in the mechanism of desflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of desflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "desflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for enflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for enflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering enflurane to a patient with a pathogenic RYR1 variant?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for enflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for enflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for enflurane in the context of RYR1-MHS."
    }
  },
  {
    "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the RYR1 gene in the mechanism of enflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of enflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for enflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for enflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering enflurane to a patient with a pathogenic CACNA1S variant?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for enflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for enflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for enflurane in the context of CACNA1S-MHS."
    }
  },
  {
    "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the CACNA1S gene in the mechanism of enflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of enflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "enflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for halothane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for halothane in patients with RYR1-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering halothane to a patient with a pathogenic RYR1 variant?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for halothane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for halothane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for halothane in the context of RYR1-MHS."
    }
  },
  {
    "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the RYR1 gene in the mechanism of halothane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of halothane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for halothane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for halothane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering halothane to a patient with a pathogenic CACNA1S variant?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for halothane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for halothane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for halothane in the context of CACNA1S-MHS."
    }
  },
  {
    "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the CACNA1S gene in the mechanism of halothane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of halothane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "halothane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for isoflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for isoflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering isoflurane to a patient with a pathogenic RYR1 variant?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for isoflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for isoflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for isoflurane in the context of RYR1-MHS."
    }
  },
  {
    "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the RYR1 gene in the mechanism of isoflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of isoflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for isoflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for isoflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering isoflurane to a patient with a pathogenic CACNA1S variant?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for isoflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for isoflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for isoflurane in the context of CACNA1S-MHS."
    }
  },
  {
    "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the CACNA1S gene in the mechanism of isoflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of isoflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "isoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for methoxyflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for methoxyflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering methoxyflurane to a patient with a pathogenic RYR1 variant?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for methoxyflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for methoxyflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for methoxyflurane in the context of RYR1-MHS."
    }
  },
  {
    "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the RYR1 gene in the mechanism of methoxyflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of methoxyflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for methoxyflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for methoxyflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering methoxyflurane to a patient with a pathogenic CACNA1S variant?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for methoxyflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for methoxyflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for methoxyflurane in the context of CACNA1S-MHS."
    }
  },
  {
    "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the CACNA1S gene in the mechanism of methoxyflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of methoxyflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "methoxyflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for sevoflurane in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for sevoflurane in patients with RYR1-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering sevoflurane to a patient with a pathogenic RYR1 variant?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for sevoflurane-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for sevoflurane in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for sevoflurane in the context of RYR1-MHS."
    }
  },
  {
    "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the RYR1 gene in the mechanism of sevoflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of sevoflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for sevoflurane in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for sevoflurane in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering sevoflurane to a patient with a pathogenic CACNA1S variant?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for sevoflurane-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for sevoflurane in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for sevoflurane in the context of CACNA1S-MHS."
    }
  },
  {
    "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the CACNA1S gene in the mechanism of sevoflurane-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of sevoflurane-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "sevoflurane",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for succinylcholine in a patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for succinylcholine in patients with RYR1-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering succinylcholine to a patient with a pathogenic RYR1 variant?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for succinylcholine-triggered malignant hyperthermia in patients with pathogenic RYR1 variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for succinylcholine in a patient with RYR1-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for succinylcholine in the context of RYR1-MHS."
    }
  },
  {
    "question": "Which RYR1 genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for RYR1 that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the RYR1 gene in the mechanism of succinylcholine-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the RYR1 gene function and its role in the pathophysiology of succinylcholine-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a RYR1 genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "RYR1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with RYR1-MHS."
    }
  },
  {
    "question": "What is the recommended dosing for succinylcholine in a patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Dosing protocol or avoidance recommendation for succinylcholine in patients with CACNA1S-Malignant Hyperthermia Susceptibility."
    }
  },
  {
    "question": "What is the quantified risk of malignant hyperthermia when administering succinylcholine to a patient with a pathogenic CACNA1S variant?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Incidence rates or risk data for succinylcholine-triggered malignant hyperthermia in patients with pathogenic CACNA1S variants."
    }
  },
  {
    "question": "Are there specific PK/PD parameters to monitor for succinylcholine in a patient with CACNA1S-related Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Pharmacokinetic or pharmacodynamic monitoring parameters for succinylcholine in the context of CACNA1S-MHS."
    }
  },
  {
    "question": "Which CACNA1S genotypes are associated with Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Diplotype or allele definitions for CACNA1S that correspond to the Malignant Hyperthermia Susceptible phenotype."
    }
  },
  {
    "question": "What is the role of the CACNA1S gene in the mechanism of succinylcholine-triggered malignant hyperthermia?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Explanation of the CACNA1S gene function and its role in the pathophysiology of succinylcholine-induced malignant hyperthermia."
    }
  },
  {
    "question": "What are the anesthetic recommendations for a pediatric patient with a CACNA1S genotype conferring Malignant Hyperthermia Susceptibility?",
    "answer": {
      "Drug Name": "succinylcholine",
      "Gene Name": "CACNA1S",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes.pdf",
      "Content to Search": "Anesthetic agent selection and dosing for pediatric patients with CACNA1S-MHS."
    }
  },
  {
    "question": "Does the recommended dosing of peginterferon alfa-2a change for a patient with a favorable IFNL3 genotype (e.g., rs12979860 CC)?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Dose adjustment protocol or clinical recommendation for peginterferon alfa-2a based on IFNL3 favorable response genotype"
    }
  },
  {
    "question": "What is the probability of achieving sustained virologic response (SVR) with peginterferon alfa-2a in a patient with an unfavorable IFNL3 genotype?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Quantified SVR rates for peginterferon alfa-2a therapy in patients with unfavorable IFNL3 genotypes"
    }
  },
  {
    "question": "How does the IFNL3 genotype affect the viral kinetics during treatment with peginterferon alfa-2a?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Pharmacodynamic data on viral load reduction based on IFNL3 genotype during peginterferon alfa-2a treatment"
    }
  },
  {
    "question": "Which genotypes for the IFNL3 SNP rs12979860 define a favorable response phenotype to peginterferon alfa-2a therapy?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Genotype definitions for the IFNL3 favorable response phenotype"
    }
  },
  {
    "question": "What is the function of the IFNL3 gene that influences the efficacy of peginterferon alfa-2a in treating Hepatitis C?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Role of the IFNL3 gene product in the immune response to HCV and interferon-based therapy"
    }
  },
  {
    "question": "Are there different treatment recommendations with peginterferon alfa-2a for patients with HIV/HCV coinfection based on their IFNL3 genotype?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Specific recommendations for peginterferon alfa-2a in HIV/HCV coinfected patients stratified by IFNL3 genotype"
    }
  },
  {
    "question": "Is the dosing of peginterferon alfa-2a modified based on the IFNL4-\u0394G/TT genotype (rs368234815)?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Dose adjustment protocol for peginterferon alfa-2a based on IFNL4 genotype"
    }
  },
  {
    "question": "What is the likelihood of treatment failure with peginterferon alfa-2a for a patient with the unfavorable IFNL4-\u0394G allele?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Quantified risk of non-response or relapse in patients with the IFNL4-\u0394G allele treated with peginterferon alfa-2a"
    }
  },
  {
    "question": "Is there a correlation between IFNL4 genotype and interferon-stimulated gene (ISG) expression levels before peginterferon alfa-2a treatment?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Pharmacodynamic data linking IFNL4 genotype to baseline ISG expression levels"
    }
  },
  {
    "question": "Which IFNL4 genotype (rs368234815) corresponds to a favorable response to peginterferon alfa-2a?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Genotype definition (e.g., TT/TT) for the IFNL4 favorable response phenotype"
    }
  },
  {
    "question": "What is the function of the IFNL4-\u0394G variant that leads to impaired viral clearance during peginterferon alfa-2a therapy?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Mechanism of the IFNL4-\u0394G variant and its impact on interferon signaling or response"
    }
  },
  {
    "question": "Are there specific peginterferon alfa-2a treatment duration guidelines for African-American patients based on their IFNL4 genotype?",
    "answer": {
      "Drug Name": "peginterferon alfa-2a",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Treatment duration recommendations for peginterferon alfa-2a in African-American patients stratified by IFNL4 genotype"
    }
  },
  {
    "question": "Is the dose of peginterferon alfa-2b adjusted based on a patient's IFNL3 genotype?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Dosing recommendations for peginterferon alfa-2b based on IFNL3 genotype"
    }
  },
  {
    "question": "What is the relative chance of achieving SVR with peginterferon alfa-2b for a patient with IFNL3 rs12979860 CC versus CT/TT genotypes?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Odds ratio or comparative SVR rates for peginterferon alfa-2b based on IFNL3 rs12979860 genotypes"
    }
  },
  {
    "question": "How does IFNL3 genotype influence the rapid virologic response (RVR) to peginterferon alfa-2b therapy?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Pharmacodynamic data on RVR rates stratified by IFNL3 genotype for patients on peginterferon alfa-2b"
    }
  },
  {
    "question": "What IFNL3 genotype is considered to predict an unfavorable response to peginterferon alfa-2b?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Genotype definitions (e.g., rs12979860 CT or TT) for the IFNL3 unfavorable response phenotype"
    }
  },
  {
    "question": "How does peginterferon alfa-2b's mechanism of action interact with the IFNL3-mediated immune pathway?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Interaction between peginterferon alfa-2b's antiviral effect and the IFNL3 signaling pathway"
    }
  },
  {
    "question": "Are there specific recommendations for peginterferon alfa-2b treatment duration in HCV genotype 1 patients based on IFNL3 status?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Guidance on peginterferon alfa-2b treatment duration for HCV genotype 1 patients stratified by IFNL3 genotype"
    }
  },
  {
    "question": "Should the dose of peginterferon alfa-2b be altered for a patient with the IFNL4-\u0394G/TT genotype?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Dose adjustment protocol for peginterferon alfa-2b based on IFNL4 genotype"
    }
  },
  {
    "question": "What is the SVR rate for patients with the favorable IFNL4 TT/TT genotype when treated with peginterferon alfa-2b?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Quantified SVR rates for peginterferon alfa-2b therapy in patients with the favorable IFNL4 genotype"
    }
  },
  {
    "question": "Is there a difference in the clearance of peginterferon alfa-2b based on a patient's IFNL4 genotype?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Pharmacokinetic data on peginterferon alfa-2b clearance stratified by IFNL4 genotype"
    }
  },
  {
    "question": "Which IFNL4 genotypes are linked to a poor response to peginterferon alfa-2b therapy?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Genotype definitions (e.g., containing the \u0394G allele) for the IFNL4 unfavorable response phenotype"
    }
  },
  {
    "question": "What is the biological function of the protein encoded by IFNL4 that impacts peginterferon alfa-2b treatment outcome?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Function of the IFNL4 gene product and its role in interferon signaling"
    }
  },
  {
    "question": "Are there specific guidelines for using peginterferon alfa-2b in patients of Asian descent based on their IFNL4 genotype?",
    "answer": {
      "Drug Name": "peginterferon alfa-2b",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Treatment recommendations for peginterferon alfa-2b in Asian patients stratified by IFNL4 genotype"
    }
  },
  {
    "question": "Is the dose of ribavirin adjusted based on a patient's IFNL3 genotype when used in combination with peginterferon?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Ribavirin dose adjustment protocol based on IFNL3 genotype"
    }
  },
  {
    "question": "What is the likelihood of achieving SVR with a peginterferon/ribavirin regimen in a patient with a favorable IFNL3 genotype?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Quantified SVR rates for combination therapy with ribavirin in patients with favorable IFNL3 genotypes"
    }
  },
  {
    "question": "Does IFNL3 genotype influence the risk of ribavirin-induced anemia?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Pharmacodynamic or safety data linking IFNL3 genotype to the incidence of ribavirin-induced anemia"
    }
  },
  {
    "question": "How is the IFNL3 genotype used to define the overall response phenotype for peginterferon/ribavirin combination therapy?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Definition of response phenotypes for combination therapy based on IFNL3 genotype"
    }
  },
  {
    "question": "What is the mechanism of action of ribavirin and how does it synergize with the IFNL3-related interferon response?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Interaction between ribavirin's mechanism and the IFNL3-mediated immune pathway"
    }
  },
  {
    "question": "Are there specific ribavirin dosing guidelines for pediatric patients based on their IFNL3 genotype?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL3",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Pediatric dosing recommendations for ribavirin stratified by IFNL3 genotype"
    }
  },
  {
    "question": "Should ribavirin dosing be modified in a peginterferon regimen based on the patient's IFNL4 genotype?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Ribavirin dose adjustment protocol based on IFNL4 genotype"
    }
  },
  {
    "question": "What is the SVR probability for a peginterferon/ribavirin regimen in a patient with the unfavorable IFNL4-\u0394G allele?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Quantified SVR rates for combination therapy with ribavirin in patients with the unfavorable IFNL4 genotype"
    }
  },
  {
    "question": "Is there a correlation between IFNL4 genotype and the therapeutic plasma concentration of ribavirin?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Pharmacokinetic data on ribavirin concentrations stratified by IFNL4 genotype"
    }
  },
  {
    "question": "How does the IFNL4 genotype contribute to the overall response prediction for peginterferon/ribavirin therapy?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Definition of response phenotypes for combination therapy based on IFNL4 genotype"
    }
  },
  {
    "question": "How does the IFNL4-\u0394G variant, which produces a disruptive protein, affect the antiviral activity of ribavirin?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Interaction between the IFNL4-\u0394G gene product and the mechanism of action of ribavirin"
    }
  },
  {
    "question": "Are there specific recommendations for ribavirin use in patients with liver transplants based on their IFNL4 genotype?",
    "answer": {
      "Drug Name": "ribavirin",
      "Gene Name": "IFNL4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG interferon-alpha-based Regimens (February 2014).pdf",
      "Content to Search": "Guidance for ribavirin use in liver transplant recipients stratified by IFNL4 genotype"
    }
  },
  {
    "question": "What is the recommended starting dose of azathioprine for a NUDT15 intermediate metabolizer?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Dose adjustment protocol or percentage reduction for azathioprine in NUDT15 intermediate metabolizers"
    }
  },
  {
    "question": "What is the risk of severe hematologic toxicity for a NUDT15 poor metabolizer taking a standard dose of azathioprine?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Quantified risk or incidence rate of severe myelosuppression in NUDT15 poor metabolizers using azathioprine"
    }
  },
  {
    "question": "How does NUDT15 poor metabolizer status affect the accumulation of active thioguanine nucleotide (TGN) metabolites from azathioprine?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Pharmacokinetic data on TGN concentrations in NUDT15 poor metabolizers after azathioprine administration"
    }
  },
  {
    "question": "Which diplotypes define a NUDT15 poor metabolizer?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Diplotype definitions for the NUDT15 poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the NUDT15 enzyme in the metabolic pathway of azathioprine?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Role of the NUDT15 enzyme in deactivating thiopurine metabolites"
    }
  },
  {
    "question": "What is the recommended azathioprine dosing for a pediatric patient with acute lymphoblastic leukemia (ALL) who is a NUDT15 intermediate metabolizer?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Pediatric dosing guidance for azathioprine in ALL patients with NUDT15 intermediate metabolizer status"
    }
  },
  {
    "question": "How should azathioprine dosing be adjusted for a TPMT intermediate metabolizer?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Dose adjustment protocol or percentage reduction for azathioprine in TPMT intermediate metabolizers"
    }
  },
  {
    "question": "What is the quantified risk of myelosuppression in a TPMT poor metabolizer treated with a standard dose of azathioprine?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Incidence rate or risk multiplier for myelosuppression in TPMT poor metabolizers using azathioprine"
    }
  },
  {
    "question": "What is the target therapeutic range for 6-thioguanine nucleotide (6-TGN) concentrations when treating inflammatory bowel disease with azathioprine?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Therapeutic window or target concentration range for 6-TGN metabolites"
    }
  },
  {
    "question": "Which diplotypes define a TPMT intermediate metabolizer?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Diplotype definitions for the TPMT intermediate metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the TPMT enzyme in shunting azathioprine metabolites away from the active cytotoxic pathway?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Role of the TPMT enzyme in the inactivation pathway of azathioprine metabolites"
    }
  },
  {
    "question": "What is the azathioprine dosing recommendation for a patient who is a TPMT intermediate metabolizer AND a NUDT15 intermediate metabolizer?",
    "answer": {
      "Drug Name": "azathioprine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Dosing guidance for azathioprine in patients with combined TPMT and NUDT15 intermediate metabolizer status"
    }
  },
  {
    "question": "What is the recommended starting dose of mercaptopurine for a NUDT15 poor metabolizer?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Specific dose reduction or alternative therapy recommendation for mercaptopurine in NUDT15 poor metabolizers"
    }
  },
  {
    "question": "What is the incidence of leukopenia in Asian patients with the NUDT15 risk allele when treated with mercaptopurine?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Incidence rates of leukopenia in Asian populations with NUDT15 variants taking mercaptopurine"
    }
  },
  {
    "question": "How does NUDT15 deficiency impact the ratio of 6-TGN to 6-MMPN metabolites during mercaptopurine therapy?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Pharmacokinetic data on the ratio of active to inactive metabolites in NUDT15 deficient individuals on mercaptopurine"
    }
  },
  {
    "question": "Which NUDT15 alleles are most commonly associated with an intermediate metabolizer phenotype?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Allele definitions for the NUDT15 intermediate metabolizer phenotype"
    }
  },
  {
    "question": "How does mercaptopurine exert its cytotoxic effect, and how does NUDT15 activity mitigate this?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Mechanism of action of mercaptopurine and the protective role of the NUDT15 enzyme"
    }
  },
  {
    "question": "What is the mercaptopurine dosing recommendation for a pediatric ALL patient who is a NUDT15 poor metabolizer?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Pediatric dosing guidance for mercaptopurine in ALL patients with NUDT15 poor metabolizer status"
    }
  },
  {
    "question": "What is the recommended dose reduction of mercaptopurine for a TPMT poor metabolizer?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Specific dose reduction (e.g., percentage) for mercaptopurine in TPMT poor metabolizers"
    }
  },
  {
    "question": "What is the threshold for 6-TGN concentration that is associated with an increased risk of toxicity from mercaptopurine?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Toxicity threshold for 6-thioguanine nucleotide concentrations"
    }
  },
  {
    "question": "What are the expected 6-TGN levels in a TPMT intermediate metabolizer on a standard mercaptopurine dose compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Comparative pharmacokinetic data on 6-TGN levels between TPMT intermediate and normal metabolizers"
    }
  },
  {
    "question": "Which TPMT alleles are combined to define a poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Allele or diplotype definitions for the TPMT poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the primary metabolic pathway for mercaptopurine inactivation that is catalyzed by TPMT?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Biochemical reaction catalyzed by TPMT in the metabolism of mercaptopurine"
    }
  },
  {
    "question": "What is the mercaptopurine dosing recommendation for a patient with Crohn's disease who is a TPMT intermediate metabolizer?",
    "answer": {
      "Drug Name": "mercaptopurine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Dosing guidance for mercaptopurine in Crohn's disease patients with TPMT intermediate metabolizer status"
    }
  },
  {
    "question": "What is the recommended starting dose of thioguanine for a patient who is a NUDT15 intermediate metabolizer?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Dose adjustment protocol for thioguanine in NUDT15 intermediate metabolizers"
    }
  },
  {
    "question": "What is the risk of life-threatening myelosuppression when administering standard-dose thioguanine to a NUDT15 poor metabolizer?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Quantified risk data for severe toxicity in NUDT15 poor metabolizers using thioguanine"
    }
  },
  {
    "question": "How does NUDT15 genotype affect the intracellular concentration of thioguanine triphosphate (TGTP)?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Pharmacokinetic data on TGTP levels in relation to NUDT15 metabolizer status"
    }
  },
  {
    "question": "What is the phenotype assignment for a patient with one normal function and one no function NUDT15 allele?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Phenotype category for a heterozygous NUDT15 no function allele carrier"
    }
  },
  {
    "question": "What is the specific biochemical reaction catalyzed by NUDT15 that deactivates thioguanine's active metabolites?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Mechanism of NUDT15 enzyme in hydrolyzing active thioguanine metabolites"
    }
  },
  {
    "question": "Are there specific thioguanine dosing recommendations for patients of East Asian ancestry due to higher prevalence of NUDT15 variants?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "NUDT15",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Dosing guidance for thioguanine in East Asian populations considering NUDT15 genotype"
    }
  },
  {
    "question": "What is the recommended dose adjustment for thioguanine in a patient who is a TPMT intermediate metabolizer?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Dose reduction protocol for thioguanine in TPMT intermediate metabolizers"
    }
  },
  {
    "question": "What is the risk of developing hepatotoxicity (nodular regenerative hyperplasia) in a TPMT normal metabolizer on long-term thioguanine therapy?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Risk data for thioguanine-induced hepatotoxicity in TPMT normal metabolizers"
    }
  },
  {
    "question": "What is the expected level of 6-methylmercaptopurine (6-MMP) metabolites in a TPMT normal metabolizer taking thioguanine?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Pharmacokinetic data on 6-MMP levels in TPMT normal metabolizers on thioguanine"
    }
  },
  {
    "question": "What is the phenotype assignment for a patient with a TPMT*1/*3A diplotype?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Phenotype category (intermediate metabolizer) for the TPMT*1/*3A diplotype"
    }
  },
  {
    "question": "How does the metabolic pathway of thioguanine differ from azathioprine and mercaptopurine with respect to TPMT's role?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Comparison of thiopurine metabolic pathways and the specific role of TPMT for thioguanine"
    }
  },
  {
    "question": "What is the thioguanine dosing recommendation for a patient with IBD who is a TPMT poor metabolizer?",
    "answer": {
      "Drug Name": "thioguanine",
      "Gene Name": "TPMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guidelines for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update (November 2018).pdf",
      "Content to Search": "Dosing guidance or contraindication for thioguanine in IBD patients with TPMT poor metabolizer status"
    }
  },
  {
    "question": "What is the recommended dosing adjustment for amitriptyline in a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol for amitriptyline in CYP2C19 ultrarapid metabolizers"
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking amitriptyline?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using amitriptyline"
    }
  },
  {
    "question": "What is the expected plasma concentration of amitriptyline in a CYP2C19 poor metabolizer compared to a normal metabolizer?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pharmacokinetic data comparing amitriptyline plasma concentrations between CYP2C19 poor and normal metabolizers"
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C19 ultrarapid metabolizer phenotype"
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the metabolism of amitriptyline?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Function of CYP2C19 enzyme in the metabolic pathway of amitriptyline"
    }
  },
  {
    "question": "Are there specific amitriptyline dosing recommendations for pediatric patients who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pediatric dosing guidance for amitriptyline in CYP2C19 poor metabolizers"
    }
  },
  {
    "question": "What is the recommended starting dose of amitriptyline for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Recommended starting dose and titration protocol for amitriptyline in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the risk of cardiotoxicity for a CYP2D6 poor metabolizer taking amitriptyline?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of cardiotoxicity or QTc prolongation in CYP2D6 poor metabolizers on amitriptyline"
    }
  },
  {
    "question": "What is the suggested therapeutic range for the sum of amitriptyline and nortriptyline concentrations, and how is it affected by CYP2D6 status?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Therapeutic drug monitoring range for amitriptyline plus nortriptyline and its relation to CYP2D6 phenotype"
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 poor metabolizer phenotype"
    }
  },
  {
    "question": "How does the CYP2D6 enzyme metabolize amitriptyline to its active metabolite, nortriptyline?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Mechanism of CYP2D6-mediated metabolism of amitriptyline to nortriptyline"
    }
  },
  {
    "question": "What is the amitriptyline dosing recommendation for an elderly patient who is a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "amitriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Geriatric dosing recommendations for amitriptyline in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the recommended dose adjustment for clomipramine in a patient who is a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol for clomipramine in CYP2C19 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of anticholinergic side effects in a CYP2C19 poor metabolizer taking clomipramine?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of anticholinergic effects in CYP2C19 poor metabolizers on clomipramine"
    }
  },
  {
    "question": "How does CYP2C19 ultrarapid metabolizer status affect the plasma concentration of clomipramine?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pharmacokinetic data on clomipramine plasma concentrations in CYP2C19 ultrarapid metabolizers"
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C19 intermediate metabolizer phenotype"
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the demethylation of clomipramine?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Function of CYP2C19 in the metabolic pathway of clomipramine"
    }
  },
  {
    "question": "Are there specific clomipramine dosing guidelines for adolescents with OCD who are CYP2C19 ultrarapid metabolizers?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Adolescent dosing recommendations for clomipramine in CYP2C19 ultrarapid metabolizers"
    }
  },
  {
    "question": "What is the recommended clomipramine dose for a patient who is a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dosing recommendation for clomipramine in CYP2D6 ultrarapid metabolizers"
    }
  },
  {
    "question": "What is the risk of therapeutic failure for a CYP2D6 ultrarapid metabolizer on a standard dose of clomipramine?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of non-response or therapeutic failure in CYP2D6 ultrarapid metabolizers taking clomipramine"
    }
  },
  {
    "question": "What is the target plasma concentration for the sum of clomipramine and desmethylclomipramine, and how is it influenced by CYP2D6 phenotype?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Therapeutic drug monitoring range for clomipramine plus its metabolite and its relation to CYP2D6 status"
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the hydroxylation of clomipramine?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Role of CYP2D6 in the metabolic pathway of clomipramine"
    }
  },
  {
    "question": "What is the clomipramine dosing recommendation for a patient who is both a CYP2D6 poor metabolizer and a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "clomipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dosing guidance for clomipramine in patients with combined CYP2D6 and CYP2C19 poor metabolizer status"
    }
  },
  {
    "question": "Is there any recommended dosing adjustment for desipramine based on CYP2C19 genotype?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol for desipramine based on CYP2C19 status"
    }
  },
  {
    "question": "Is there a documented increased risk of adverse effects from desipramine in CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using desipramine"
    }
  },
  {
    "question": "Does CYP2C19 genotype significantly alter the plasma concentrations of desipramine?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pharmacokinetic data on the impact of CYP2C19 genotype on desipramine plasma levels"
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C19 poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the role, if any, of the CYP2C19 enzyme in the metabolism of desipramine?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Function of CYP2C19 enzyme in the metabolic pathway of desipramine"
    }
  },
  {
    "question": "Are there any special considerations for pediatric patients on desipramine with a known CYP2C19 variant?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pediatric dosing or safety considerations for desipramine related to CYP2C19 status"
    }
  },
  {
    "question": "What is the recommended dose reduction for desipramine in a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Specific dose reduction percentage for desipramine in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of QTc prolongation for a CYP2D6 poor metabolizer taking desipramine?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of QTc prolongation in CYP2D6 poor metabolizers on desipramine"
    }
  },
  {
    "question": "What is the target plasma concentration range for desipramine, and how is it affected by CYP2D6 ultrarapid metabolizer status?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Therapeutic drug monitoring range for desipramine and its relation to CYP2D6 ultrarapid metabolizer status"
    }
  },
  {
    "question": "Which diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 intermediate metabolizer phenotype"
    }
  },
  {
    "question": "What is the primary metabolic pathway for desipramine clearance involving the CYP2D6 enzyme?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Role of CYP2D6-mediated hydroxylation in desipramine metabolism"
    }
  },
  {
    "question": "Are there specific desipramine dosing guidelines for geriatric patients who are CYP2D6 intermediate metabolizers?",
    "answer": {
      "Drug Name": "desipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Geriatric dosing recommendations for desipramine in CYP2D6 intermediate metabolizers"
    }
  },
  {
    "question": "How should doxepin dosing be adjusted for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol for doxepin in CYP2C19 poor metabolizers"
    }
  },
  {
    "question": "What is the risk of excessive sedation in a CYP2C19 poor metabolizer taking doxepin?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of sedation or other CNS effects in CYP2C19 poor metabolizers on doxepin"
    }
  },
  {
    "question": "What is the expected plasma concentration of doxepin in a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pharmacokinetic data on doxepin plasma concentrations in CYP2C19 ultrarapid metabolizers"
    }
  },
  {
    "question": "Which genotypes correspond to the CYP2C19 normal metabolizer phenotype?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Genotype or diplotype definitions for the CYP2C19 normal metabolizer phenotype"
    }
  },
  {
    "question": "What is the role of CYP2C19 in the metabolism of doxepin to nordoxepin?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Function of CYP2C19 in the N-demethylation of doxepin"
    }
  },
  {
    "question": "Are there specific doxepin dosing recommendations for patients with comorbid anxiety who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dosing guidance for doxepin in patients with anxiety and CYP2C19 poor metabolizer status"
    }
  },
  {
    "question": "What is the recommended starting dose of doxepin for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Recommended starting dose for doxepin in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of adverse events in a CYP2D6 poor metabolizer taking doxepin?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of adverse events in CYP2D6 poor metabolizers on doxepin"
    }
  },
  {
    "question": "What is the therapeutic range for the sum of doxepin and nordoxepin concentrations?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Therapeutic drug monitoring range for doxepin plus its active metabolite"
    }
  },
  {
    "question": "Which diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of doxepin?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Role of CYP2D6 in the metabolic clearance of doxepin"
    }
  },
  {
    "question": "What is the doxepin dosing recommendation for a patient who is both a CYP2D6 ultrarapid metabolizer and a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "doxepin",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dosing guidance for doxepin in patients with combined CYP2D6 and CYP2C19 ultrarapid metabolizer status"
    }
  },
  {
    "question": "What is the recommended dosing adjustment for imipramine in a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol for imipramine in CYP2C19 ultrarapid metabolizers"
    }
  },
  {
    "question": "What is the risk of therapeutic failure for a CYP2C19 ultrarapid metabolizer on a standard dose of imipramine?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of non-response in CYP2C19 ultrarapid metabolizers taking imipramine"
    }
  },
  {
    "question": "How does CYP2C19 poor metabolizer status affect the plasma concentration of imipramine?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pharmacokinetic data on imipramine plasma concentrations in CYP2C19 poor metabolizers"
    }
  },
  {
    "question": "Which diplotypes define a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C19 poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the N-demethylation of imipramine to desipramine?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Function of CYP2C19 in the metabolic conversion of imipramine to desipramine"
    }
  },
  {
    "question": "Are there specific imipramine dosing recommendations for pediatric patients with enuresis who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pediatric dosing guidance for imipramine in CYP2C19 poor metabolizers with enuresis"
    }
  },
  {
    "question": "What is the recommended starting dose of imipramine for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Recommended starting dose for imipramine in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of toxicity in a CYP2D6 poor metabolizer taking imipramine?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of toxicity in CYP2D6 poor metabolizers on imipramine"
    }
  },
  {
    "question": "What is the therapeutic range for the sum of imipramine and desipramine concentrations?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Therapeutic drug monitoring range for imipramine plus its active metabolite, desipramine"
    }
  },
  {
    "question": "Which diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 ultrarapid metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the hydroxylation of imipramine?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Role of CYP2D6 in the metabolic clearance of imipramine"
    }
  },
  {
    "question": "What is the imipramine dosing recommendation for a patient who is a CYP2D6 poor metabolizer and also has renal impairment?",
    "answer": {
      "Drug Name": "imipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dosing guidance for imipramine in patients with both CYP2D6 poor metabolizer status and renal impairment"
    }
  },
  {
    "question": "Is there a recommended dosing adjustment for nortriptyline based on CYP2C19 genotype?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol for nortriptyline based on CYP2C19 status"
    }
  },
  {
    "question": "Is there a documented increased risk of adverse effects from nortriptyline in CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using nortriptyline"
    }
  },
  {
    "question": "Does CYP2C19 genotype significantly alter the plasma concentrations of nortriptyline?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pharmacokinetic data on the impact of CYP2C19 genotype on nortriptyline plasma levels"
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 normal metabolizer?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2C19 normal metabolizer phenotype"
    }
  },
  {
    "question": "What is the role, if any, of the CYP2C19 enzyme in the metabolism of nortriptyline?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Function of CYP2C19 enzyme in the metabolic pathway of nortriptyline"
    }
  },
  {
    "question": "Are there any special considerations for using nortriptyline for smoking cessation in patients with known CYP2C19 variants?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dosing or safety considerations for nortriptyline in smoking cessation related to CYP2C19 status"
    }
  },
  {
    "question": "What is the recommended dose reduction for nortriptyline in a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Specific dose reduction percentage for nortriptyline in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of adverse events for a CYP2D6 poor metabolizer taking nortriptyline?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of adverse events in CYP2D6 poor metabolizers on nortriptyline"
    }
  },
  {
    "question": "What is the target plasma concentration range for nortriptyline?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Therapeutic drug monitoring range for nortriptyline"
    }
  },
  {
    "question": "Which diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 poor metabolizer phenotype"
    }
  },
  {
    "question": "What is the primary metabolic pathway for nortriptyline clearance involving the CYP2D6 enzyme?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Role of CYP2D6-mediated hydroxylation in nortriptyline metabolism"
    }
  },
  {
    "question": "Are there specific nortriptyline dosing guidelines for geriatric patients who are CYP2D6 ultrarapid metabolizers?",
    "answer": {
      "Drug Name": "nortriptyline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Geriatric dosing recommendations for nortriptyline in CYP2D6 ultrarapid metabolizers"
    }
  },
  {
    "question": "How should trimipramine dosing be adjusted for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dose adjustment protocol for trimipramine in CYP2C19 poor metabolizers"
    }
  },
  {
    "question": "What is the risk of toxicity in a CYP2C19 poor metabolizer taking trimipramine?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of toxicity in CYP2C19 poor metabolizers on trimipramine"
    }
  },
  {
    "question": "How does CYP2C19 ultrarapid metabolizer status affect the plasma concentration of trimipramine?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Pharmacokinetic data on trimipramine plasma concentrations in CYP2C19 ultrarapid metabolizers"
    }
  },
  {
    "question": "Which genotypes correspond to the CYP2C19 intermediate metabolizer phenotype?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Genotype or diplotype definitions for the CYP2C19 intermediate metabolizer phenotype"
    }
  },
  {
    "question": "What is the role of CYP2C19 in the metabolism of trimipramine?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Function of CYP2C19 in the metabolic pathway of trimipramine"
    }
  },
  {
    "question": "Are there specific trimipramine dosing recommendations for pregnant patients who are CYP2C19 poor metabolizers?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dosing guidance for trimipramine during pregnancy for CYP2C19 poor metabolizers"
    }
  },
  {
    "question": "What is the recommended starting dose of trimipramine for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Recommended starting dose for trimipramine in CYP2D6 poor metabolizers"
    }
  },
  {
    "question": "What is the increased risk of adverse events in a CYP2D6 poor metabolizer taking trimipramine?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Quantified risk of adverse events in CYP2D6 poor metabolizers on trimipramine"
    }
  },
  {
    "question": "Is there a recommended therapeutic range for trimipramine concentrations?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Therapeutic drug monitoring range for trimipramine"
    }
  },
  {
    "question": "Which diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Diplotype definitions for the CYP2D6 normal metabolizer phenotype"
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of trimipramine?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Role of CYP2D6 in the metabolic clearance of trimipramine"
    }
  },
  {
    "question": "What is the trimipramine dosing recommendation for a patient who is a CYP2D6 poor metabolizer and is taking a concurrent CYP2D6 inhibitor?",
    "answer": {
      "Drug Name": "trimipramine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC\u00ae) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update (December 2016).pdf",
      "Content to Search": "Dosing guidance for trimipramine in CYP2D6 poor metabolizers with a drug-drug interaction involving a CYP2D6 inhibitor"
    }
  },
  {
    "question": "What is the recommended alfentanil dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for alfentanil in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking alfentanil?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for alfentanil in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma alfentanil concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for alfentanil stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'low-activity' phenotype?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to alfentanil?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and alfentanil's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for alfentanil in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for alfentanil adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "How should alfentanil dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for alfentanil in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking alfentanil?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using alfentanil."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma alfentanil concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for alfentanil in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of alfentanil?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in alfentanil metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for alfentanil in children with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for alfentanil in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should alfentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for alfentanil based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking alfentanil?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of alfentanil in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma alfentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for alfentanil stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered opioid response or dose requirements?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on opioid response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of alfentanil therapy?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for alfentanil."
    }
  },
  {
    "question": "What is the dosing recommendation for alfentanil in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "alfentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for alfentanil in cancer patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended buprenorphine dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for buprenorphine in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking buprenorphine?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for buprenorphine in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma buprenorphine concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for buprenorphine stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'high-activity' phenotype?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to buprenorphine?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and buprenorphine's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for buprenorphine in pediatric patients with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for buprenorphine adjusted for COMT low-activity genotype."
    }
  },
  {
    "question": "How should buprenorphine dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for buprenorphine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking buprenorphine?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using buprenorphine."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma buprenorphine concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for buprenorphine in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of buprenorphine?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in buprenorphine metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for buprenorphine in children with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for buprenorphine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "How should buprenorphine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for buprenorphine based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking buprenorphine?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of buprenorphine in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma buprenorphine concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for buprenorphine stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered buprenorphine response?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on buprenorphine response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of buprenorphine therapy?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, a primary target for buprenorphine."
    }
  },
  {
    "question": "What is the dosing recommendation for buprenorphine in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "buprenorphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for buprenorphine in opioid use disorder patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended codeine dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for codeine in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking codeine?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for codeine in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma morphine concentrations (from codeine) in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for morphine (active metabolite of codeine) stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'normal-activity' phenotype?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to codeine?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and codeine's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for codeine in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for codeine adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "What is the recommended codeine dose for a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Specific dosing recommendation or contraindication for codeine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the increased risk of morphine toxicity for a CYP2D6 ultrarapid metabolizer taking codeine?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk, incidence rate, or odds ratio for morphine toxicity in CYP2D6 UMs using codeine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of morphine in a CYP2D6 poor metabolizer after a standard dose of codeine?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration data for morphine (the active metabolite of codeine) in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and corresponding activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of codeine?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in converting codeine to its active metabolite, morphine."
    }
  },
  {
    "question": "What is the dosing recommendation for codeine in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing recommendations or contraindications for codeine in lactating mothers with a CYP2D6 UM phenotype."
    }
  },
  {
    "question": "How should codeine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for codeine based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking codeine?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of codeine in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma morphine concentrations (from codeine) in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for morphine (active metabolite of codeine) stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered codeine response?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on codeine response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of codeine therapy?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for codeine's active metabolite, morphine."
    }
  },
  {
    "question": "What is the dosing recommendation for codeine in pediatric patients post-tonsillectomy with an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "codeine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for codeine in pediatric post-tonsillectomy patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended fentanyl dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for fentanyl in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking fentanyl?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for fentanyl in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma fentanyl concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for fentanyl stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'low-activity' phenotype?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to fentanyl?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and fentanyl's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for fentanyl in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for fentanyl adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "How should fentanyl dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for fentanyl in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking fentanyl?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using fentanyl."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma fentanyl concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for fentanyl in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of fentanyl?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in fentanyl metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for fentanyl in children with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for fentanyl in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should fentanyl dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for fentanyl based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking fentanyl?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of fentanyl in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma fentanyl concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for fentanyl stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered fentanyl response?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on fentanyl response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of fentanyl therapy?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for fentanyl."
    }
  },
  {
    "question": "What is the dosing recommendation for fentanyl in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "fentanyl",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for fentanyl in cancer patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended hydrocodone dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for hydrocodone in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking hydrocodone?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for hydrocodone in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma hydromorphone concentrations (from hydrocodone) in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for hydromorphone (active metabolite of hydrocodone) stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'normal-activity' phenotype?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to hydrocodone?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and hydrocodone's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for hydrocodone in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for hydrocodone adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "What is the recommended hydrocodone dose for a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Specific dosing recommendation or contraindication for hydrocodone in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the increased risk of hydromorphone toxicity for a CYP2D6 ultrarapid metabolizer taking hydrocodone?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk, incidence rate, or odds ratio for hydromorphone toxicity in CYP2D6 UMs using hydrocodone."
    }
  },
  {
    "question": "What are the expected plasma concentrations of hydromorphone in a CYP2D6 poor metabolizer after a standard dose of hydrocodone?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration data for hydromorphone (the active metabolite of hydrocodone) in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and corresponding activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of hydrocodone?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in converting hydrocodone to its active metabolite, hydromorphone."
    }
  },
  {
    "question": "What is the dosing recommendation for hydrocodone in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing recommendations or contraindications for hydrocodone in lactating mothers with a CYP2D6 UM phenotype."
    }
  },
  {
    "question": "How should hydrocodone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for hydrocodone based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking hydrocodone?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of hydrocodone in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma hydromorphone concentrations (from hydrocodone) in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for hydromorphone (active metabolite of hydrocodone) stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered hydrocodone response?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on hydrocodone response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of hydrocodone therapy?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for hydrocodone's active metabolite, hydromorphone."
    }
  },
  {
    "question": "What is the dosing recommendation for hydrocodone in pediatric patients with an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "hydrocodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for hydrocodone in pediatric patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended hydromorphone dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for hydromorphone in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking hydromorphone?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for hydromorphone in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma hydromorphone concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for hydromorphone stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'high-activity' phenotype?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to hydromorphone?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and hydromorphone's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for hydromorphone in pediatric patients with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for hydromorphone adjusted for COMT low-activity genotype."
    }
  },
  {
    "question": "How should hydromorphone dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for hydromorphone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking hydromorphone?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using hydromorphone."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma hydromorphone concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for hydromorphone in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of hydromorphone?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in hydromorphone metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for hydromorphone in children with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for hydromorphone in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "How should hydromorphone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for hydromorphone based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking hydromorphone?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of hydromorphone in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma hydromorphone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for hydromorphone stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered hydromorphone response?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on hydromorphone response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of hydromorphone therapy?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for hydromorphone."
    }
  },
  {
    "question": "What is the dosing recommendation for hydromorphone in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "hydromorphone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for hydromorphone in cancer patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended levomethadone dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for levomethadone in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking levomethadone?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for levomethadone in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma levomethadone concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for levomethadone stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'low-activity' phenotype?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to levomethadone?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and levomethadone's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for levomethadone in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for levomethadone adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "How should levomethadone dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for levomethadone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking levomethadone?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using levomethadone."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma levomethadone concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for levomethadone in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of levomethadone?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in levomethadone metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for levomethadone in children with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for levomethadone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should levomethadone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for levomethadone based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking levomethadone?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of levomethadone in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma levomethadone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for levomethadone stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered levomethadone response?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on levomethadone response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of levomethadone therapy?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for levomethadone."
    }
  },
  {
    "question": "What is the dosing recommendation for levomethadone in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "levomethadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for levomethadone in opioid use disorder patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended methadone dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for methadone in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking methadone?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for methadone in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma methadone concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for methadone stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'normal-activity' phenotype?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to methadone?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and methadone's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for methadone in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for methadone adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "How should methadone dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for methadone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking methadone?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using methadone."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma methadone concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for methadone in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of methadone?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in methadone metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for methadone in children with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for methadone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should methadone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for methadone based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking methadone?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of methadone in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma methadone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for methadone stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered methadone response?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on methadone response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of methadone therapy?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for methadone."
    }
  },
  {
    "question": "What is the dosing recommendation for methadone in patients with opioid use disorder and an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "methadone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for methadone in opioid use disorder patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended morphine dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for morphine in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking morphine?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for morphine in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma morphine concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for morphine stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'high-activity' phenotype?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to morphine?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and morphine's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for morphine in pediatric patients with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for morphine adjusted for COMT low-activity genotype."
    }
  },
  {
    "question": "How should morphine dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for morphine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking morphine?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using morphine."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma morphine concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for morphine in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of morphine?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in morphine metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for morphine in children with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for morphine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "How should morphine dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for morphine based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking morphine?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of morphine in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma morphine concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for morphine stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered morphine response?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on morphine response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of morphine therapy?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for morphine."
    }
  },
  {
    "question": "What is the dosing recommendation for morphine in patients with cancer pain and an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "morphine",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for morphine in cancer patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended naltrexone dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for naltrexone in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking naltrexone?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for naltrexone in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma naltrexone concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for naltrexone stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'low-activity' phenotype?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to naltrexone?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and naltrexone's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for naltrexone in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for naltrexone adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "How should naltrexone dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for naltrexone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking naltrexone?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using naltrexone."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma naltrexone concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for naltrexone in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of naltrexone?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in naltrexone metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for naltrexone in children with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for naltrexone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should naltrexone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for naltrexone based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of altered therapeutic effect for individuals with the OPRM1 A118G variant when taking naltrexone?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for altered therapeutic efficacy of naltrexone in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma naltrexone concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for naltrexone stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered naltrexone response?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on naltrexone response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of naltrexone therapy?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for naltrexone."
    }
  },
  {
    "question": "What is the dosing recommendation for naltrexone in patients with alcohol use disorder and an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "naltrexone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for naltrexone in alcohol use disorder patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended oxycodone dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for oxycodone in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking oxycodone?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for oxycodone in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma oxymorphone concentrations (from oxycodone) in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for oxymorphone (active metabolite of oxycodone) stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'normal-activity' phenotype?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to oxycodone?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and oxycodone's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for oxycodone in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for oxycodone adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "What is the recommended oxycodone dose for a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Specific dosing recommendation or contraindication for oxycodone in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the increased risk of oxymorphone toxicity for a CYP2D6 ultrarapid metabolizer taking oxycodone?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk, incidence rate, or odds ratio for oxymorphone toxicity in CYP2D6 UMs using oxycodone."
    }
  },
  {
    "question": "What are the expected plasma concentrations of oxymorphone in a CYP2D6 poor metabolizer after a standard dose of oxycodone?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration data for oxymorphone (the active metabolite of oxycodone) in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of oxycodone?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in converting oxycodone to its active metabolite, oxymorphone."
    }
  },
  {
    "question": "What is the dosing recommendation for oxycodone in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing recommendations or contraindications for oxycodone in lactating mothers with a CYP2D6 UM phenotype."
    }
  },
  {
    "question": "How should oxycodone dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for oxycodone based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking oxycodone?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of oxycodone in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma oxymorphone concentrations (from oxycodone) in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for oxymorphone (active metabolite of oxycodone) stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered oxycodone response?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on oxycodone response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of oxycodone therapy?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for oxycodone's active metabolite, oxymorphone."
    }
  },
  {
    "question": "What is the dosing recommendation for oxycodone in pediatric patients with an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "oxycodone",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for oxycodone in pediatric patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended remifentanil dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for remifentanil in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking remifentanil?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for remifentanil in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma remifentanil concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for remifentanil stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'high-activity' phenotype?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT high-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to remifentanil?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and remifentanil's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for remifentanil in pediatric patients with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for remifentanil adjusted for COMT low-activity genotype."
    }
  },
  {
    "question": "How should remifentanil dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for remifentanil in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking remifentanil?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using remifentanil."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma remifentanil concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for remifentanil in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of remifentanil?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in remifentanil metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for remifentanil in children with a CYP2D6 ultrarapid metabolizer phenotype?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for remifentanil in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "How should remifentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for remifentanil based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking remifentanil?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of remifentanil in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma remifentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for remifentanil stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered remifentanil response?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on remifentanil response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of remifentanil therapy?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for remifentanil."
    }
  },
  {
    "question": "What is the dosing recommendation for remifentanil in patients undergoing surgery with an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "remifentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for remifentanil in surgical patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended sufentanil dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for sufentanil in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking sufentanil?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for sufentanil in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma sufentanil concentrations in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for sufentanil stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'normal-activity' phenotype?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT normal-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to sufentanil?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and sufentanil's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for sufentanil in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for sufentanil adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "How should sufentanil dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for sufentanil in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 ultrarapid metabolizer taking sufentanil?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 ultrarapid metabolizers using sufentanil."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma sufentanil concentrations in a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration ranges for sufentanil in CYP2D6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of sufentanil?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in sufentanil metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for sufentanil in children with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing adjustments for sufentanil in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should sufentanil dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for sufentanil based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking sufentanil?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of sufentanil in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma sufentanil concentrations in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for sufentanil stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered sufentanil response?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on sufentanil response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of sufentanil therapy?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for sufentanil."
    }
  },
  {
    "question": "What is the dosing recommendation for sufentanil in patients undergoing surgery with an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "sufentanil",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for sufentanil in surgical patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended tramadol dose for an individual with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for tramadol in individuals with a COMT low-activity genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for individuals with a COMT high-activity genotype when taking tramadol?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Risk multipliers or incidence rates of adverse effects for tramadol in patients with COMT high-activity genotype."
    }
  },
  {
    "question": "What are the expected plasma O-desmethyltramadol concentrations (from tramadol) in a patient with a COMT low-activity genotype?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic range or plasma concentration data for O-desmethyltramadol (active metabolite of tramadol) stratified by COMT genotype."
    }
  },
  {
    "question": "What genotypes define the COMT 'low-activity' phenotype?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Genotype definitions and corresponding diplotypes for the COMT low-activity phenotype."
    }
  },
  {
    "question": "What is the role of the COMT enzyme in the pharmacological response to tramadol?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Mechanism of interaction between COMT enzyme activity and tramadol's effects."
    }
  },
  {
    "question": "What is the dosing recommendation for tramadol in pediatric patients with a COMT high-activity genotype?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "COMT",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Pediatric dosing guidelines for tramadol adjusted for COMT high-activity genotype."
    }
  },
  {
    "question": "What is the recommended tramadol dose for a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Specific dosing recommendation or contraindication for tramadol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the increased risk of O-desmethyltramadol toxicity for a CYP2D6 ultrarapid metabolizer taking tramadol?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk, incidence rate, or odds ratio for O-desmethyltramadol toxicity in CYP2D6 UMs using tramadol."
    }
  },
  {
    "question": "What are the expected plasma concentrations of O-desmethyltramadol in a CYP2D6 poor metabolizer after a standard dose of tramadol?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Plasma concentration data for O-desmethyltramadol (the active metabolite of tramadol) in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of tramadol?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Description of CYP2D6's role in converting tramadol to its active metabolite, O-desmethyltramadol."
    }
  },
  {
    "question": "What is the dosing recommendation for tramadol in breastfeeding mothers who are CYP2D6 ultrarapid metabolizers?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing recommendations or contraindications for tramadol in lactating mothers with a CYP2D6 UM phenotype."
    }
  },
  {
    "question": "How should tramadol dosing be adjusted for an individual with an OPRM1 variant associated with decreased receptor function (e.g., A118G)?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dose adjustment protocol for tramadol based on OPRM1 variants affecting receptor function."
    }
  },
  {
    "question": "What is the risk of inadequate analgesia for individuals with the OPRM1 A118G variant when taking tramadol?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Quantified risk or clinical evidence for reduced analgesic efficacy of tramadol in patients with the OPRM1 A118G variant."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma O-desmethyltramadol concentrations (from tramadol) in a patient with an OPRM1 variant leading to increased receptor expression?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Therapeutic drug monitoring values for O-desmethyltramadol (active metabolite of tramadol) stratified by OPRM1 genotype."
    }
  },
  {
    "question": "What OPRM1 variants are associated with altered tramadol response?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "List and description of OPRM1 variants and their corresponding functional impact on tramadol response."
    }
  },
  {
    "question": "What is the function of the OPRM1 gene product in the context of tramadol therapy?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Explanation of OPRM1's role as the mu-opioid receptor, the primary target for tramadol's active metabolite, O-desmethyltramadol."
    }
  },
  {
    "question": "What is the dosing recommendation for tramadol in pediatric patients post-tonsillectomy with an OPRM1 variant associated with decreased receptor function?",
    "answer": {
      "Drug Name": "tramadol",
      "Gene Name": "OPRM1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy (December 2020).pdf",
      "Content to Search": "Dosing guidelines for tramadol in pediatric post-tonsillectomy patients, adjusted for OPRM1 genotype."
    }
  },
  {
    "question": "What is the recommended atorvastatin dose for an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for atorvastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What is the increased risk of statin-associated musculoskeletal symptoms (SAMS) for an individual with ABCG2 decreased function taking atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking atorvastatin."
    }
  },
  {
    "question": "What are the expected plasma atorvastatin concentrations in an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What genotypes define ABCG2 decreased function?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Genotype or diplotype definitions for the ABCG2 decreased function phenotype."
    }
  },
  {
    "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of ABCG2's role as an efflux transporter affecting atorvastatin disposition."
    }
  },
  {
    "question": "What is the dosing recommendation for atorvastatin in pediatric patients with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for atorvastatin adjusted for ABCG2 decreased function."
    }
  },
  {
    "question": "What is the recommended atorvastatin dose for a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for atorvastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using atorvastatin."
    }
  },
  {
    "question": "What are the expected plasma atorvastatin concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in CYP2C9 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP2C9's role in atorvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for atorvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for atorvastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended atorvastatin dose for a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for atorvastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using atorvastatin."
    }
  },
  {
    "question": "What are the expected plasma atorvastatin concentrations in a CYP3A4 intermediate metabolizer?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in CYP3A4 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A4's role in atorvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for atorvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for atorvastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended atorvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for atorvastatin in CYP3A5 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using atorvastatin."
    }
  },
  {
    "question": "What are the expected plasma atorvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A5 enzyme in the metabolism of atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A5's role in atorvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for atorvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for atorvastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What is the recommended atorvastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for atorvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking atorvastatin."
    }
  },
  {
    "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pharmacodynamic data (LDL-C reduction) for atorvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What HMGCR variants are associated with altered statin response?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
    }
  },
  {
    "question": "What is the function of HMGCR in the mechanism of action of atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of HMGCR as the pharmacological target of atorvastatin."
    }
  },
  {
    "question": "What is the dosing recommendation for atorvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for atorvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the recommended atorvastatin dose for an individual with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for atorvastatin in individuals with SLCO1B1 low function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking atorvastatin."
    }
  },
  {
    "question": "What are the expected plasma atorvastatin concentrations in an individual with SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for atorvastatin in individuals with SLCO1B1 intermediate function."
    }
  },
  {
    "question": "What diplotypes define SLCO1B1 low function?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype."
    }
  },
  {
    "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of atorvastatin?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting atorvastatin clearance."
    }
  },
  {
    "question": "What is the dosing recommendation for atorvastatin in pediatric patients with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "atorvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for atorvastatin adjusted for SLCO1B1 low function."
    }
  },
  {
    "question": "What is the recommended fluvastatin dose for an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for fluvastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking fluvastatin."
    }
  },
  {
    "question": "What are the expected plasma fluvastatin concentrations in an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What genotypes define ABCG2 normal function?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Genotype or diplotype definitions for the ABCG2 normal function phenotype."
    }
  },
  {
    "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of ABCG2's role as an efflux transporter affecting fluvastatin disposition."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvastatin in pediatric patients with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for fluvastatin adjusted for ABCG2 decreased function."
    }
  },
  {
    "question": "What is the recommended fluvastatin dose for a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for fluvastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using fluvastatin."
    }
  },
  {
    "question": "What are the expected plasma fluvastatin concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in CYP2C9 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP2C9's role in fluvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluvastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended fluvastatin dose for a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for fluvastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using fluvastatin."
    }
  },
  {
    "question": "What are the expected plasma fluvastatin concentrations in a CYP3A4 intermediate metabolizer?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in CYP3A4 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A4 normal metabolizer?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A4's role in fluvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluvastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended fluvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for fluvastatin in CYP3A5 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using fluvastatin."
    }
  },
  {
    "question": "What are the expected plasma fluvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A5 enzyme in the metabolism of fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A5's role in fluvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluvastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What is the recommended fluvastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for fluvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking fluvastatin."
    }
  },
  {
    "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pharmacodynamic data (LDL-C reduction) for fluvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What HMGCR variants are associated with altered statin response?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
    }
  },
  {
    "question": "What is the function of HMGCR in the mechanism of action of fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of HMGCR as the pharmacological target of fluvastatin."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the recommended fluvastatin dose for an individual with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for fluvastatin in individuals with SLCO1B1 low function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking fluvastatin."
    }
  },
  {
    "question": "What are the expected plasma fluvastatin concentrations in an individual with SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluvastatin in individuals with SLCO1B1 intermediate function."
    }
  },
  {
    "question": "What diplotypes define SLCO1B1 normal function?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 normal function phenotype."
    }
  },
  {
    "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of fluvastatin?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting fluvastatin clearance."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvastatin in pediatric patients with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "fluvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for fluvastatin adjusted for SLCO1B1 low function."
    }
  },
  {
    "question": "What is the recommended lovastatin dose for an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for lovastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking lovastatin."
    }
  },
  {
    "question": "What are the expected plasma lovastatin concentrations in an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What genotypes define ABCG2 decreased function?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Genotype or diplotype definitions for the ABCG2 decreased function phenotype."
    }
  },
  {
    "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of ABCG2's role as an efflux transporter affecting lovastatin disposition."
    }
  },
  {
    "question": "What is the dosing recommendation for lovastatin in pediatric patients with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for lovastatin adjusted for ABCG2 decreased function."
    }
  },
  {
    "question": "What is the recommended lovastatin dose for a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for lovastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using lovastatin."
    }
  },
  {
    "question": "What are the expected plasma lovastatin concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in CYP2C9 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP2C9's role in lovastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for lovastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for lovastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended lovastatin dose for a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for lovastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using lovastatin."
    }
  },
  {
    "question": "What are the expected plasma lovastatin concentrations in a CYP3A4 intermediate metabolizer?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in CYP3A4 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A4's role in lovastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for lovastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for lovastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended lovastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for lovastatin in CYP3A5 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using lovastatin."
    }
  },
  {
    "question": "What are the expected plasma lovastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A5 enzyme in the metabolism of lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A5's role in lovastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for lovastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for lovastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What is the recommended lovastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for lovastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking lovastatin."
    }
  },
  {
    "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pharmacodynamic data (LDL-C reduction) for lovastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What HMGCR variants are associated with altered statin response?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
    }
  },
  {
    "question": "What is the function of HMGCR in the mechanism of action of lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of HMGCR as the pharmacological target of lovastatin."
    }
  },
  {
    "question": "What is the dosing recommendation for lovastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for lovastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the recommended lovastatin dose for an individual with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for lovastatin in individuals with SLCO1B1 low function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking lovastatin."
    }
  },
  {
    "question": "What are the expected plasma lovastatin concentrations in an individual with SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for lovastatin in individuals with SLCO1B1 intermediate function."
    }
  },
  {
    "question": "What diplotypes define SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 intermediate function phenotype."
    }
  },
  {
    "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of lovastatin?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting lovastatin clearance."
    }
  },
  {
    "question": "What is the dosing recommendation for lovastatin in pediatric patients with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "lovastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for lovastatin adjusted for SLCO1B1 low function."
    }
  },
  {
    "question": "What is the recommended pitavastatin dose for an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pitavastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking pitavastatin."
    }
  },
  {
    "question": "What are the expected plasma pitavastatin concentrations in an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What genotypes define ABCG2 normal function?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Genotype or diplotype definitions for the ABCG2 normal function phenotype."
    }
  },
  {
    "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of ABCG2's role as an efflux transporter affecting pitavastatin disposition."
    }
  },
  {
    "question": "What is the dosing recommendation for pitavastatin in pediatric patients with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for pitavastatin adjusted for ABCG2 decreased function."
    }
  },
  {
    "question": "What is the recommended pitavastatin dose for a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pitavastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using pitavastatin."
    }
  },
  {
    "question": "What are the expected plasma pitavastatin concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in CYP2C9 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 normal metabolizer?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP2C9's role in pitavastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for pitavastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for pitavastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended pitavastatin dose for a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pitavastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using pitavastatin."
    }
  },
  {
    "question": "What are the expected plasma pitavastatin concentrations in a CYP3A4 intermediate metabolizer?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in CYP3A4 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A4 normal metabolizer?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A4's role in pitavastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for pitavastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for pitavastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended pitavastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pitavastatin in CYP3A5 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using pitavastatin."
    }
  },
  {
    "question": "What are the expected plasma pitavastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A5 enzyme in the metabolism of pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A5's role in pitavastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for pitavastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for pitavastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What is the recommended pitavastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pitavastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking pitavastatin."
    }
  },
  {
    "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pharmacodynamic data (LDL-C reduction) for pitavastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What HMGCR variants are associated with altered statin response?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
    }
  },
  {
    "question": "What is the function of HMGCR in the mechanism of action of pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of HMGCR as the pharmacological target of pitavastatin."
    }
  },
  {
    "question": "What is the dosing recommendation for pitavastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for pitavastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the recommended pitavastatin dose for an individual with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pitavastatin in individuals with SLCO1B1 low function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking pitavastatin."
    }
  },
  {
    "question": "What are the expected plasma pitavastatin concentrations in an individual with SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pitavastatin in individuals with SLCO1B1 intermediate function."
    }
  },
  {
    "question": "What diplotypes define SLCO1B1 low function?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype."
    }
  },
  {
    "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of pitavastatin?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting pitavastatin clearance."
    }
  },
  {
    "question": "What is the dosing recommendation for pitavastatin in pediatric patients with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "pitavastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for pitavastatin adjusted for SLCO1B1 low function."
    }
  },
  {
    "question": "What is the recommended pravastatin dose for an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pravastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking pravastatin."
    }
  },
  {
    "question": "What are the expected plasma pravastatin concentrations in an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What genotypes define ABCG2 decreased function?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Genotype or diplotype definitions for the ABCG2 decreased function phenotype."
    }
  },
  {
    "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of ABCG2's role as an efflux transporter affecting pravastatin disposition."
    }
  },
  {
    "question": "What is the dosing recommendation for pravastatin in pediatric patients with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for pravastatin adjusted for ABCG2 decreased function."
    }
  },
  {
    "question": "What is the recommended pravastatin dose for a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pravastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using pravastatin."
    }
  },
  {
    "question": "What are the expected plasma pravastatin concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in CYP2C9 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP2C9's role in pravastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for pravastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for pravastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended pravastatin dose for a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pravastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using pravastatin."
    }
  },
  {
    "question": "What are the expected plasma pravastatin concentrations in a CYP3A4 intermediate metabolizer?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in CYP3A4 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A4's role in pravastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for pravastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for pravastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended pravastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pravastatin in CYP3A5 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using pravastatin."
    }
  },
  {
    "question": "What are the expected plasma pravastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A5 enzyme in the metabolism of pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A5's role in pravastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for pravastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for pravastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What is the recommended pravastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pravastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking pravastatin."
    }
  },
  {
    "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pharmacodynamic data (LDL-C reduction) for pravastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What HMGCR variants are associated with altered statin response?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
    }
  },
  {
    "question": "What is the function of HMGCR in the mechanism of action of pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of HMGCR as the pharmacological target of pravastatin."
    }
  },
  {
    "question": "What is the dosing recommendation for pravastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for pravastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the recommended pravastatin dose for an individual with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for pravastatin in individuals with SLCO1B1 low function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking pravastatin."
    }
  },
  {
    "question": "What are the expected plasma pravastatin concentrations in an individual with SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pravastatin in individuals with SLCO1B1 intermediate function."
    }
  },
  {
    "question": "What diplotypes define SLCO1B1 normal function?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 normal function phenotype."
    }
  },
  {
    "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of pravastatin?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting pravastatin clearance."
    }
  },
  {
    "question": "What is the dosing recommendation for pravastatin in pediatric patients with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "pravastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for pravastatin adjusted for SLCO1B1 low function."
    }
  },
  {
    "question": "What is the recommended rosuvastatin dose for an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for rosuvastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking rosuvastatin."
    }
  },
  {
    "question": "What are the expected plasma rosuvastatin concentrations in an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What genotypes define ABCG2 normal function?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Genotype or diplotype definitions for the ABCG2 normal function phenotype."
    }
  },
  {
    "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of ABCG2's role as an efflux transporter affecting rosuvastatin disposition."
    }
  },
  {
    "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for rosuvastatin adjusted for ABCG2 decreased function."
    }
  },
  {
    "question": "What is the recommended rosuvastatin dose for a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for rosuvastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using rosuvastatin."
    }
  },
  {
    "question": "What are the expected plasma rosuvastatin concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in CYP2C9 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP2C9's role in rosuvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for rosuvastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended rosuvastatin dose for a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for rosuvastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using rosuvastatin."
    }
  },
  {
    "question": "What are the expected plasma rosuvastatin concentrations in a CYP3A4 intermediate metabolizer?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in CYP3A4 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A4 normal metabolizer?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A4's role in rosuvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for rosuvastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended rosuvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for rosuvastatin in CYP3A5 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using rosuvastatin."
    }
  },
  {
    "question": "What are the expected plasma rosuvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions for the CYP3A5 poor metabolizer (non-expresser) phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A5 enzyme in the metabolism of rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A5's role in rosuvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for rosuvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for rosuvastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What is the recommended rosuvastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for rosuvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking rosuvastatin."
    }
  },
  {
    "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pharmacodynamic data (LDL-C reduction) for rosuvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What HMGCR variants are associated with altered statin response?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
    }
  },
  {
    "question": "What is the function of HMGCR in the mechanism of action of rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of HMGCR as the pharmacological target of rosuvastatin."
    }
  },
  {
    "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for rosuvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the recommended rosuvastatin dose for an individual with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for rosuvastatin in individuals with SLCO1B1 low function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking rosuvastatin."
    }
  },
  {
    "question": "What are the expected plasma rosuvastatin concentrations in an individual with SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for rosuvastatin in individuals with SLCO1B1 intermediate function."
    }
  },
  {
    "question": "What diplotypes define SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 intermediate function phenotype."
    }
  },
  {
    "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of rosuvastatin?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting rosuvastatin clearance."
    }
  },
  {
    "question": "What is the dosing recommendation for rosuvastatin in pediatric patients with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "rosuvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for rosuvastatin adjusted for SLCO1B1 low function."
    }
  },
  {
    "question": "What is the recommended simvastatin dose for an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for simvastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with ABCG2 decreased function taking simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with ABCG2 decreased function taking simvastatin."
    }
  },
  {
    "question": "What are the expected plasma simvastatin concentrations in an individual with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in individuals with ABCG2 decreased function."
    }
  },
  {
    "question": "What genotypes define ABCG2 decreased function?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Genotype or diplotype definitions for the ABCG2 decreased function phenotype."
    }
  },
  {
    "question": "What is the function of the ABCG2 transporter in the pharmacokinetics of simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of ABCG2's role as an efflux transporter affecting simvastatin disposition."
    }
  },
  {
    "question": "What is the dosing recommendation for simvastatin in pediatric patients with ABCG2 decreased function?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "ABCG2",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for simvastatin adjusted for ABCG2 decreased function."
    }
  },
  {
    "question": "What is the recommended simvastatin dose for a CYP2C9 poor metabolizer?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for simvastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP2C9 poor metabolizer taking simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP2C9 poor metabolizers using simvastatin."
    }
  },
  {
    "question": "What are the expected plasma simvastatin concentrations in a CYP2C9 intermediate metabolizer?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in CYP2C9 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C9 normal metabolizer?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C9 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C9 enzyme in the metabolism of simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP2C9's role in simvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for simvastatin in pediatric patients with a CYP2C9 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP2C9",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for simvastatin in CYP2C9 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended simvastatin dose for a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for simvastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A4 poor metabolizer taking simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A4 poor metabolizers using simvastatin."
    }
  },
  {
    "question": "What are the expected plasma simvastatin concentrations in a CYP3A4 intermediate metabolizer?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in CYP3A4 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A4 poor metabolizer?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP3A4 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A4 enzyme in the metabolism of simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A4's role in simvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for simvastatin in pediatric patients with a CYP3A4 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A4",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for simvastatin in CYP3A4 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended simvastatin dose for a CYP3A5 poor metabolizer (non-expresser)?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for simvastatin in CYP3A5 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of SAMS for a CYP3A5 normal metabolizer (expresser) taking simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in CYP3A5 normal metabolizers using simvastatin."
    }
  },
  {
    "question": "What are the expected plasma simvastatin concentrations in a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP3A5 normal metabolizer (expresser)?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions for the CYP3A5 normal metabolizer (expresser) phenotype."
    }
  },
  {
    "question": "What is the function of the CYP3A5 enzyme in the metabolism of simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of CYP3A5's role in simvastatin metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for simvastatin in pediatric patients who are CYP3A5 normal metabolizers (expressers)?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "CYP3A5",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for simvastatin in CYP3A5 normal metabolizers."
    }
  },
  {
    "question": "What is the recommended simvastatin dose for an individual with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for simvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the risk of SAMS for an individual with an HMGCR variant associated with reduced statin response when taking simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk data for SAMS in individuals with HMGCR variants taking simvastatin."
    }
  },
  {
    "question": "What are the expected LDL-C reduction levels in an individual with an HMGCR variant associated with reduced statin response taking simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pharmacodynamic data (LDL-C reduction) for simvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What HMGCR variants are associated with altered statin response?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Definitions of HMGCR variants or genotypes associated with altered statin efficacy."
    }
  },
  {
    "question": "What is the function of HMGCR in the mechanism of action of simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of HMGCR as the pharmacological target of simvastatin."
    }
  },
  {
    "question": "What is the dosing recommendation for simvastatin in pediatric patients with an HMGCR variant associated with reduced statin response?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "HMGCR",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing adjustments for simvastatin based on HMGCR genotype."
    }
  },
  {
    "question": "What is the recommended simvastatin dose for an individual with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Dose adjustment protocol for simvastatin in individuals with SLCO1B1 low function."
    }
  },
  {
    "question": "What is the increased risk of SAMS for an individual with SLCO1B1 low function taking simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Quantified risk or odds ratio for SAMS in individuals with SLCO1B1 low function taking simvastatin."
    }
  },
  {
    "question": "What are the expected plasma simvastatin concentrations in an individual with SLCO1B1 intermediate function?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for simvastatin in individuals with SLCO1B1 intermediate function."
    }
  },
  {
    "question": "What diplotypes define SLCO1B1 low function?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Diplotype definitions and corresponding function scores for the SLCO1B1 low function phenotype."
    }
  },
  {
    "question": "What is the function of the SLCO1B1 transporter in the pharmacokinetics of simvastatin?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Description of SLCO1B1's role as a hepatic uptake transporter affecting simvastatin clearance."
    }
  },
  {
    "question": "What is the dosing recommendation for simvastatin in pediatric patients with SLCO1B1 low function?",
    "answer": {
      "Drug Name": "simvastatin",
      "Gene Name": "SLCO1B1",
      "CPIC Guideline Name": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (January 2022).pdf",
      "Content to Search": "Pediatric dosing guidelines for simvastatin adjusted for SLCO1B1 low function."
    }
  },
  {
    "question": "What is the dosing recommendation for aminosalicylic acid in a G6PD deficient individual?",
    "answer": {
      "Drug Name": "aminosalicylic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for aminosalicylic acid in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking aminosalicylic acid?",
    "answer": {
      "Drug Name": "aminosalicylic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with aminosalicylic acid use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes, such as hemoglobin drop, in a G6PD deficient individual exposed to aminosalicylic acid?",
    "answer": {
      "Drug Name": "aminosalicylic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters (hemoglobin, reticulocyte count) in G6PD deficient individuals after aminosalicylic acid administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "aminosalicylic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which aminosalicylic acid causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "aminosalicylic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of aminosalicylic acid-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for aminosalicylic acid in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "aminosalicylic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines or contraindications for aminosalicylic acid in G6PD deficient children."
    }
  },
  {
    "question": "What is the recommended aspirin dose for a G6PD deficient individual, particularly regarding high vs. low doses?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dose-specific recommendations for aspirin use (e.g., analgesic vs. antiplatelet doses) in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking high-dose aspirin?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with high-dose aspirin use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes, such as hemoglobin drop, in a G6PD deficient individual exposed to high-dose aspirin?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after high-dose aspirin administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which aspirin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of aspirin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for aspirin in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "aspirin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for aspirin in G6PD deficient children, considering risks of both hemolysis and Reye's syndrome."
    }
  },
  {
    "question": "Is chloramphenicol contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "chloramphenicol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for chloramphenicol in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chloramphenicol?",
    "answer": {
      "Drug Name": "chloramphenicol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with chloramphenicol use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to chloramphenicol?",
    "answer": {
      "Drug Name": "chloramphenicol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters (hemoglobin, reticulocyte count) in G6PD deficient individuals after chloramphenicol administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "chloramphenicol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which chloramphenicol causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "chloramphenicol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of chloramphenicol-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for chloramphenicol in a neonate with G6PD deficiency?",
    "answer": {
      "Drug Name": "chloramphenicol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Neonate-specific dosing guidelines for chloramphenicol in G6PD deficient infants, considering risks of both hemolysis and gray baby syndrome."
    }
  },
  {
    "question": "What is the recommended chloroquine dose for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "chloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for chloroquine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chloroquine?",
    "answer": {
      "Drug Name": "chloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with chloroquine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to chloroquine?",
    "answer": {
      "Drug Name": "chloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after chloroquine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "chloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which chloroquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "chloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of chloroquine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for chloroquine in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "chloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for chloroquine in G6PD deficient children."
    }
  },
  {
    "question": "Is chlorpropamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "chlorpropamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for chlorpropamide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking chlorpropamide?",
    "answer": {
      "Drug Name": "chlorpropamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with chlorpropamide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to chlorpropamide?",
    "answer": {
      "Drug Name": "chlorpropamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after chlorpropamide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "chlorpropamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which chlorpropamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "chlorpropamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of chlorpropamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for chlorpropamide in an elderly patient with G6PD deficiency and renal impairment?",
    "answer": {
      "Drug Name": "chlorpropamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for chlorpropamide in elderly G6PD deficient patients with comorbidities like renal impairment."
    }
  },
  {
    "question": "What is the dosing recommendation for ciprofloxacin in a G6PD deficient individual?",
    "answer": {
      "Drug Name": "ciprofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for ciprofloxacin in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking ciprofloxacin?",
    "answer": {
      "Drug Name": "ciprofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with ciprofloxacin use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to ciprofloxacin?",
    "answer": {
      "Drug Name": "ciprofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after ciprofloxacin administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "ciprofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which ciprofloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "ciprofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of ciprofloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for ciprofloxacin in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "ciprofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for ciprofloxacin in G6PD deficient children."
    }
  },
  {
    "question": "Is dabrafenib contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "dabrafenib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for dabrafenib in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dabrafenib?",
    "answer": {
      "Drug Name": "dabrafenib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with dabrafenib use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to dabrafenib?",
    "answer": {
      "Drug Name": "dabrafenib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after dabrafenib administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "dabrafenib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which dabrafenib causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "dabrafenib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of dabrafenib-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for dabrafenib in a cancer patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "dabrafenib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for dabrafenib in G6PD deficient cancer patients, considering the specific indication (e.g., melanoma)."
    }
  },
  {
    "question": "Is dapsone contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "dapsone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for dapsone in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dapsone?",
    "answer": {
      "Drug Name": "dapsone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with dapsone use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to dapsone?",
    "answer": {
      "Drug Name": "dapsone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after dapsone administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "dapsone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which dapsone causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "dapsone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of dapsone-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for dapsone in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "dapsone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for dapsone in G6PD deficient children."
    }
  },
  {
    "question": "Is dimercaprol contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "dimercaprol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for dimercaprol in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking dimercaprol?",
    "answer": {
      "Drug Name": "dimercaprol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with dimercaprol use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to dimercaprol?",
    "answer": {
      "Drug Name": "dimercaprol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after dimercaprol administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "dimercaprol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which dimercaprol causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "dimercaprol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of dimercaprol-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for dimercaprol in a G6PD deficient patient being treated for heavy metal poisoning?",
    "answer": {
      "Drug Name": "dimercaprol",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for dimercaprol in G6PD deficient patients with heavy metal poisoning."
    }
  },
  {
    "question": "Is doxorubicin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "doxorubicin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for doxorubicin in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking doxorubicin?",
    "answer": {
      "Drug Name": "doxorubicin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with doxorubicin use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to doxorubicin?",
    "answer": {
      "Drug Name": "doxorubicin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after doxorubicin administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "doxorubicin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which doxorubicin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "doxorubicin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of doxorubicin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for doxorubicin in a pediatric cancer patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "doxorubicin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for doxorubicin in G6PD deficient children undergoing chemotherapy."
    }
  },
  {
    "question": "Is furazolidone contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "furazolidone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for furazolidone in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking furazolidone?",
    "answer": {
      "Drug Name": "furazolidone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with furazolidone use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to furazolidone?",
    "answer": {
      "Drug Name": "furazolidone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after furazolidone administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "furazolidone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which furazolidone causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "furazolidone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of furazolidone-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for furazolidone in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "furazolidone",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for furazolidone in G6PD deficient children."
    }
  },
  {
    "question": "Is gliclazide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "gliclazide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for gliclazide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking gliclazide?",
    "answer": {
      "Drug Name": "gliclazide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with gliclazide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to gliclazide?",
    "answer": {
      "Drug Name": "gliclazide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after gliclazide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "gliclazide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which gliclazide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "gliclazide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of gliclazide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for gliclazide in a diabetic patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "gliclazide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for gliclazide in G6PD deficient patients with type 2 diabetes."
    }
  },
  {
    "question": "Is glimepiride contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "glimepiride",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for glimepiride in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glimepiride?",
    "answer": {
      "Drug Name": "glimepiride",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with glimepiride use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to glimepiride?",
    "answer": {
      "Drug Name": "glimepiride",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after glimepiride administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "glimepiride",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which glimepiride causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "glimepiride",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of glimepiride-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for glimepiride in a diabetic patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "glimepiride",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for glimepiride in G6PD deficient patients with type 2 diabetes."
    }
  },
  {
    "question": "Is glipizide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "glipizide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for glipizide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glipizide?",
    "answer": {
      "Drug Name": "glipizide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with glipizide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to glipizide?",
    "answer": {
      "Drug Name": "glipizide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after glipizide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "glipizide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which glipizide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "glipizide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of glipizide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for glipizide in a diabetic patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "glipizide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for glipizide in G6PD deficient patients with type 2 diabetes."
    }
  },
  {
    "question": "Is glyburide (glibenclamide) contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "glyburide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for glyburide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking glyburide?",
    "answer": {
      "Drug Name": "glyburide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with glyburide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to glyburide?",
    "answer": {
      "Drug Name": "glyburide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after glyburide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "glyburide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which glyburide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "glyburide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of glyburide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for glyburide in a diabetic patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "glyburide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for glyburide in G6PD deficient patients with type 2 diabetes."
    }
  },
  {
    "question": "What is the recommended hydroxychloroquine dose for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "hydroxychloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for hydroxychloroquine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking hydroxychloroquine?",
    "answer": {
      "Drug Name": "hydroxychloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with hydroxychloroquine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to hydroxychloroquine?",
    "answer": {
      "Drug Name": "hydroxychloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after hydroxychloroquine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "hydroxychloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which hydroxychloroquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "hydroxychloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of hydroxychloroquine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for hydroxychloroquine in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "hydroxychloroquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for hydroxychloroquine in G6PD deficient children."
    }
  },
  {
    "question": "Is mafenide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "mafenide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for mafenide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mafenide?",
    "answer": {
      "Drug Name": "mafenide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with mafenide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to mafenide?",
    "answer": {
      "Drug Name": "mafenide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after mafenide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "mafenide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which mafenide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "mafenide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of mafenide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the recommendation for using topical mafenide on a burn patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "mafenide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Guidelines for topical mafenide use in G6PD deficient burn patients, considering systemic absorption."
    }
  },
  {
    "question": "Is mepacrine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "mepacrine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for mepacrine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mepacrine?",
    "answer": {
      "Drug Name": "mepacrine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with mepacrine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to mepacrine?",
    "answer": {
      "Drug Name": "mepacrine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after mepacrine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "mepacrine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which mepacrine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "mepacrine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of mepacrine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for mepacrine in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "mepacrine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for mepacrine in G6PD deficient children."
    }
  },
  {
    "question": "Is mesalazine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "mesalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for mesalazine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking mesalazine?",
    "answer": {
      "Drug Name": "mesalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with mesalazine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to mesalazine?",
    "answer": {
      "Drug Name": "mesalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after mesalazine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "mesalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which mesalazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "mesalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of mesalazine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for mesalazine in a patient with inflammatory bowel disease and G6PD deficiency?",
    "answer": {
      "Drug Name": "mesalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for mesalazine in G6PD deficient patients with IBD."
    }
  },
  {
    "question": "Is methylene blue contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "methylene blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for methylene blue in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking methylene blue?",
    "answer": {
      "Drug Name": "methylene blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with methylene blue use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to methylene blue?",
    "answer": {
      "Drug Name": "methylene blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after methylene blue administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "methylene blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which methylene blue causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "methylene blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of methylene blue-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the recommendation for using methylene blue to treat methemoglobinemia in a G6PD deficient patient?",
    "answer": {
      "Drug Name": "methylene blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Guidelines for methylene blue use for methemoglobinemia in G6PD deficient patients, including potential for paradoxical worsening."
    }
  },
  {
    "question": "Is moxifloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "moxifloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for moxifloxacin in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking moxifloxacin?",
    "answer": {
      "Drug Name": "moxifloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with moxifloxacin use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to moxifloxacin?",
    "answer": {
      "Drug Name": "moxifloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after moxifloxacin administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "moxifloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which moxifloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "moxifloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of moxifloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for moxifloxacin in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "moxifloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for moxifloxacin in G6PD deficient children."
    }
  },
  {
    "question": "Is nalidixic acid contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "nalidixic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for nalidixic acid in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nalidixic acid?",
    "answer": {
      "Drug Name": "nalidixic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with nalidixic acid use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to nalidixic acid?",
    "answer": {
      "Drug Name": "nalidixic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after nalidixic acid administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "nalidixic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which nalidixic acid causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "nalidixic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of nalidixic acid-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for nalidixic acid in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "nalidixic acid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for nalidixic acid in G6PD deficient children."
    }
  },
  {
    "question": "Is nicorandil contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "nicorandil",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for nicorandil in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nicorandil?",
    "answer": {
      "Drug Name": "nicorandil",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with nicorandil use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to nicorandil?",
    "answer": {
      "Drug Name": "nicorandil",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after nicorandil administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "nicorandil",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which nicorandil causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "nicorandil",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of nicorandil-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for nicorandil in a cardiac patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "nicorandil",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for nicorandil in G6PD deficient patients with angina."
    }
  },
  {
    "question": "Is nitrofural (nitrofurazone) contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "nitrofural",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for nitrofural in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nitrofural?",
    "answer": {
      "Drug Name": "nitrofural",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with nitrofural use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to nitrofural?",
    "answer": {
      "Drug Name": "nitrofural",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after nitrofural administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "nitrofural",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which nitrofural causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "nitrofural",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of nitrofural-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the recommendation for using topical nitrofural in a G6PD deficient patient?",
    "answer": {
      "Drug Name": "nitrofural",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Guidelines for topical nitrofural use in G6PD deficient patients."
    }
  },
  {
    "question": "Is nitrofurantoin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "nitrofurantoin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for nitrofurantoin in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking nitrofurantoin?",
    "answer": {
      "Drug Name": "nitrofurantoin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with nitrofurantoin use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to nitrofurantoin?",
    "answer": {
      "Drug Name": "nitrofurantoin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after nitrofurantoin administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "nitrofurantoin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which nitrofurantoin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "nitrofurantoin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of nitrofurantoin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for nitrofurantoin in a pregnant patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "nitrofurantoin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for nitrofurantoin in pregnant G6PD deficient patients, especially near term."
    }
  },
  {
    "question": "Is norfloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "norfloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for norfloxacin in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking norfloxacin?",
    "answer": {
      "Drug Name": "norfloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with norfloxacin use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to norfloxacin?",
    "answer": {
      "Drug Name": "norfloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after norfloxacin administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "norfloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which norfloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "norfloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of norfloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for norfloxacin in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "norfloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for norfloxacin in G6PD deficient children."
    }
  },
  {
    "question": "Is ofloxacin contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "ofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for ofloxacin in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking ofloxacin?",
    "answer": {
      "Drug Name": "ofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with ofloxacin use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to ofloxacin?",
    "answer": {
      "Drug Name": "ofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after ofloxacin administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "ofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which ofloxacin causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "ofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of ofloxacin-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for ofloxacin in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "ofloxacin",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for ofloxacin in G6PD deficient children."
    }
  },
  {
    "question": "Is pegloticase contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "pegloticase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for pegloticase in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking pegloticase?",
    "answer": {
      "Drug Name": "pegloticase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with pegloticase use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to pegloticase?",
    "answer": {
      "Drug Name": "pegloticase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after pegloticase administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "pegloticase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which pegloticase causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "pegloticase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of pegloticase-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for pegloticase in a patient with chronic gout and G6PD deficiency?",
    "answer": {
      "Drug Name": "pegloticase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for pegloticase in G6PD deficient patients with chronic gout."
    }
  },
  {
    "question": "Is phenazopyridine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "phenazopyridine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for phenazopyridine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking phenazopyridine?",
    "answer": {
      "Drug Name": "phenazopyridine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with phenazopyridine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to phenazopyridine?",
    "answer": {
      "Drug Name": "phenazopyridine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after phenazopyridine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "phenazopyridine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which phenazopyridine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "phenazopyridine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of phenazopyridine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for phenazopyridine in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "phenazopyridine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for phenazopyridine in G6PD deficient children."
    }
  },
  {
    "question": "Is primaquine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "primaquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for primaquine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking primaquine?",
    "answer": {
      "Drug Name": "primaquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with primaquine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to primaquine?",
    "answer": {
      "Drug Name": "primaquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after primaquine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "primaquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which primaquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "primaquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of primaquine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for primaquine for malaria prophylaxis in a G6PD deficient child?",
    "answer": {
      "Drug Name": "primaquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for primaquine in G6PD deficient children for malaria treatment or prophylaxis."
    }
  },
  {
    "question": "Is probenecid contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "probenecid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for probenecid in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking probenecid?",
    "answer": {
      "Drug Name": "probenecid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with probenecid use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to probenecid?",
    "answer": {
      "Drug Name": "probenecid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after probenecid administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "probenecid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which probenecid causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "probenecid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of probenecid-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for probenecid in a patient with gout and G6PD deficiency?",
    "answer": {
      "Drug Name": "probenecid",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for probenecid in G6PD deficient patients with gout."
    }
  },
  {
    "question": "Is quinine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "quinine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for quinine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking quinine?",
    "answer": {
      "Drug Name": "quinine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with quinine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to quinine?",
    "answer": {
      "Drug Name": "quinine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after quinine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "quinine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which quinine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "quinine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of quinine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for quinine for malaria treatment in a G6PD deficient child?",
    "answer": {
      "Drug Name": "quinine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for quinine in G6PD deficient children for malaria treatment."
    }
  },
  {
    "question": "Is rasburicase contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "rasburicase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for rasburicase in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking rasburicase?",
    "answer": {
      "Drug Name": "rasburicase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with rasburicase use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to rasburicase?",
    "answer": {
      "Drug Name": "rasburicase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after rasburicase administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "rasburicase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which rasburicase causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "rasburicase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of rasburicase-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for rasburicase for tumor lysis syndrome in a G6PD deficient cancer patient?",
    "answer": {
      "Drug Name": "rasburicase",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for rasburicase in G6PD deficient patients with tumor lysis syndrome."
    }
  },
  {
    "question": "Is sodium nitrite contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "sodium nitrite",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for sodium nitrite in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sodium nitrite?",
    "answer": {
      "Drug Name": "sodium nitrite",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sodium nitrite use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sodium nitrite?",
    "answer": {
      "Drug Name": "sodium nitrite",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sodium nitrite administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "sodium nitrite",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which sodium nitrite causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "sodium nitrite",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of sodium nitrite-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the recommendation for using sodium nitrite for cyanide poisoning in a G6PD deficient patient?",
    "answer": {
      "Drug Name": "sodium nitrite",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Guidelines for using sodium nitrite as a cyanide antidote in G6PD deficient patients."
    }
  },
  {
    "question": "Is sulfacetamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "sulfacetamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for sulfacetamide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfacetamide?",
    "answer": {
      "Drug Name": "sulfacetamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfacetamide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfacetamide?",
    "answer": {
      "Drug Name": "sulfacetamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfacetamide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "sulfacetamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which sulfacetamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "sulfacetamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of sulfacetamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the recommendation for using topical sulfacetamide in a G6PD deficient patient?",
    "answer": {
      "Drug Name": "sulfacetamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Guidelines for topical sulfacetamide use in G6PD deficient patients."
    }
  },
  {
    "question": "Is sulfadiazine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "sulfadiazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for sulfadiazine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfadiazine?",
    "answer": {
      "Drug Name": "sulfadiazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfadiazine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfadiazine?",
    "answer": {
      "Drug Name": "sulfadiazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfadiazine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "sulfadiazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which sulfadiazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "sulfadiazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of sulfadiazine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for sulfadiazine in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "sulfadiazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for sulfadiazine in G6PD deficient children."
    }
  },
  {
    "question": "Is sulfadimidine (sulfamethazine) contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "sulfadimidine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for sulfadimidine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfadimidine?",
    "answer": {
      "Drug Name": "sulfadimidine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfadimidine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfadimidine?",
    "answer": {
      "Drug Name": "sulfadimidine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfadimidine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "sulfadimidine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which sulfadimidine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "sulfadimidine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of sulfadimidine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for sulfadimidine in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "sulfadimidine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for sulfadimidine in G6PD deficient children."
    }
  },
  {
    "question": "Is sulfamethoxazole / trimethoprim contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "sulfamethoxazole / trimethoprim",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for sulfamethoxazole / trimethoprim in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfamethoxazole / trimethoprim?",
    "answer": {
      "Drug Name": "sulfamethoxazole / trimethoprim",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfamethoxazole / trimethoprim use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfamethoxazole / trimethoprim?",
    "answer": {
      "Drug Name": "sulfamethoxazole / trimethoprim",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfamethoxazole / trimethoprim administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "sulfamethoxazole / trimethoprim",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which sulfamethoxazole causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "sulfamethoxazole / trimethoprim",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of sulfamethoxazole-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for sulfamethoxazole / trimethoprim in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "sulfamethoxazole / trimethoprim",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for sulfamethoxazole / trimethoprim in G6PD deficient children."
    }
  },
  {
    "question": "Is sulfanilamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "sulfanilamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for sulfanilamide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfanilamide?",
    "answer": {
      "Drug Name": "sulfanilamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfanilamide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfanilamide?",
    "answer": {
      "Drug Name": "sulfanilamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfanilamide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "sulfanilamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which sulfanilamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "sulfanilamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of sulfanilamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the recommendation for using topical sulfanilamide in a G6PD deficient patient?",
    "answer": {
      "Drug Name": "sulfanilamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Guidelines for topical sulfanilamide use in G6PD deficient patients."
    }
  },
  {
    "question": "Is sulfasalazine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "sulfasalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for sulfasalazine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfasalazine?",
    "answer": {
      "Drug Name": "sulfasalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfasalazine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfasalazine?",
    "answer": {
      "Drug Name": "sulfasalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfasalazine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "sulfasalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which sulfasalazine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "sulfasalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of sulfasalazine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for sulfasalazine in a patient with rheumatoid arthritis and G6PD deficiency?",
    "answer": {
      "Drug Name": "sulfasalazine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for sulfasalazine in G6PD deficient patients with rheumatoid arthritis."
    }
  },
  {
    "question": "Is sulfisoxazole contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "sulfisoxazole",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for sulfisoxazole in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking sulfisoxazole?",
    "answer": {
      "Drug Name": "sulfisoxazole",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with sulfisoxazole use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to sulfisoxazole?",
    "answer": {
      "Drug Name": "sulfisoxazole",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after sulfisoxazole administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "sulfisoxazole",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which sulfisoxazole causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "sulfisoxazole",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of sulfisoxazole-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for sulfisoxazole in a pediatric patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "sulfisoxazole",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for sulfisoxazole in G6PD deficient children."
    }
  },
  {
    "question": "Is tafenoquine contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "tafenoquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for tafenoquine in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tafenoquine?",
    "answer": {
      "Drug Name": "tafenoquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with tafenoquine use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to tafenoquine?",
    "answer": {
      "Drug Name": "tafenoquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after tafenoquine administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "tafenoquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which tafenoquine causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "tafenoquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of tafenoquine-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for tafenoquine for malaria prophylaxis in a G6PD deficient child?",
    "answer": {
      "Drug Name": "tafenoquine",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Pediatric-specific dosing guidelines for tafenoquine in G6PD deficient children for malaria prophylaxis."
    }
  },
  {
    "question": "Is tolazamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "tolazamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for tolazamide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tolazamide?",
    "answer": {
      "Drug Name": "tolazamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with tolazamide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to tolazamide?",
    "answer": {
      "Drug Name": "tolazamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after tolazamide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "tolazamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which tolazamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "tolazamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of tolazamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for tolazamide in a diabetic patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "tolazamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for tolazamide in G6PD deficient patients with type 2 diabetes."
    }
  },
  {
    "question": "Is tolbutamide contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "tolbutamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for tolbutamide in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking tolbutamide?",
    "answer": {
      "Drug Name": "tolbutamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with tolbutamide use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to tolbutamide?",
    "answer": {
      "Drug Name": "tolbutamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after tolbutamide administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "tolbutamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which tolbutamide causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "tolbutamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of tolbutamide-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for tolbutamide in a diabetic patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "tolbutamide",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for tolbutamide in G6PD deficient patients with type 2 diabetes."
    }
  },
  {
    "question": "Is toluidine blue contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "toluidine blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for toluidine blue in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking toluidine blue?",
    "answer": {
      "Drug Name": "toluidine blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with toluidine blue use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to toluidine blue?",
    "answer": {
      "Drug Name": "toluidine blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after toluidine blue administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "toluidine blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which toluidine blue causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "toluidine blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of toluidine blue-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the recommendation for using toluidine blue as a diagnostic dye in a G6PD deficient patient?",
    "answer": {
      "Drug Name": "toluidine blue",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Guidelines for using toluidine blue as a dye in G6PD deficient patients."
    }
  },
  {
    "question": "Is trametinib contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "trametinib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for trametinib in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking trametinib?",
    "answer": {
      "Drug Name": "trametinib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with trametinib use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to trametinib?",
    "answer": {
      "Drug Name": "trametinib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after trametinib administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "trametinib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which trametinib causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "trametinib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of trametinib-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for trametinib in a cancer patient with G6PD deficiency?",
    "answer": {
      "Drug Name": "trametinib",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for trametinib in G6PD deficient cancer patients."
    }
  },
  {
    "question": "Is high-dose vitamin C contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "vitamin c",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for high-dose vitamin C in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking high-dose vitamin C?",
    "answer": {
      "Drug Name": "vitamin c",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with high-dose vitamin C use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to high-dose vitamin C?",
    "answer": {
      "Drug Name": "vitamin c",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after high-dose vitamin C administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "vitamin c",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which high-dose vitamin C causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "vitamin c",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of high-dose vitamin C-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the recommendation for intravenous vitamin C administration in a G6PD deficient patient?",
    "answer": {
      "Drug Name": "vitamin c",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Guidelines for IV vitamin C use in G6PD deficient patients, particularly in the context of sepsis or cancer therapy."
    }
  },
  {
    "question": "Is vitamin K contraindicated or should dosing be adjusted for a G6PD deficient individual?",
    "answer": {
      "Drug Name": "vitamin k",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing protocol or contraindication for vitamin K in G6PD deficient individuals."
    }
  },
  {
    "question": "What is the quantified risk of acute hemolytic anemia for a G6PD deficient individual taking vitamin K?",
    "answer": {
      "Drug Name": "vitamin k",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Incidence rates or risk multipliers for acute hemolytic anemia with vitamin K use in G6PD deficient patients."
    }
  },
  {
    "question": "What are the expected hematological changes in a G6PD deficient individual exposed to vitamin K?",
    "answer": {
      "Drug Name": "vitamin k",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Data on hematological parameters in G6PD deficient individuals after vitamin K administration."
    }
  },
  {
    "question": "What G6PD genotypes are classified as deficient (e.g., Class I, II, or III variants)?",
    "answer": {
      "Drug Name": "vitamin k",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Definitions of G6PD genotypes and their classification into different functional/phenotypic classes of deficiency."
    }
  },
  {
    "question": "What is the mechanism by which vitamin K causes oxidative stress leading to hemolysis in G6PD deficient individuals?",
    "answer": {
      "Drug Name": "vitamin k",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Biochemical mechanism of vitamin K-induced oxidative damage to red blood cells in the context of G6PD deficiency."
    }
  },
  {
    "question": "What is the dosing recommendation for vitamin K in a G6PD deficient neonate?",
    "answer": {
      "Drug Name": "vitamin k",
      "Gene Name": "G6PD",
      "CPIC Guideline Name": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022).pdf",
      "Content to Search": "Dosing guidelines for vitamin K administration to G6PD deficient newborns."
    }
  },
  {
    "question": "How should acebutolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for acebutolol based on ADRA2C genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking acebutolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for acebutolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of acebutolol therapy?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with acebutolol."
    }
  },
  {
    "question": "What is the dosing recommendation for acebutolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for acebutolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "How should acebutolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for acebutolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking acebutolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for acebutolol stratified by ADRB1 genotype."
    }
  },
  {
    "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB1 receptor in the mechanism of action of acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for acebutolol."
    }
  },
  {
    "question": "What is the dosing recommendation for acebutolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for acebutolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "How should acebutolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for acebutolol based on ADRB2 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking acebutolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for acebutolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of acebutolol therapy?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with acebutolol."
    }
  },
  {
    "question": "What is the dosing recommendation for acebutolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for acebutolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "How should acebutolol dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for acebutolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using acebutolol."
    }
  },
  {
    "question": "What are the expected plasma acebutolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for acebutolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in acebutolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for acebutolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for acebutolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should acebutolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for acebutolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking acebutolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for acebutolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK4 gene product in the context of acebutolol therapy?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for acebutolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for acebutolol in hypertensive patients, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "How should acebutolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for acebutolol based on GRK5 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking acebutolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking acebutolol?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for acebutolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK5 gene product in the context of acebutolol therapy?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for acebutolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "acebutolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for acebutolol in heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "How should atenolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for atenolol based on ADRA2C genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking atenolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for atenolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of atenolol therapy?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with atenolol."
    }
  },
  {
    "question": "What is the dosing recommendation for atenolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for atenolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "How should atenolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for atenolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking atenolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for atenolol stratified by ADRB1 genotype."
    }
  },
  {
    "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB1 receptor in the mechanism of action of atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for atenolol."
    }
  },
  {
    "question": "What is the dosing recommendation for atenolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for atenolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "How should atenolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for atenolol based on ADRB2 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking atenolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for atenolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of atenolol therapy?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with atenolol."
    }
  },
  {
    "question": "What is the dosing recommendation for atenolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for atenolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "How should atenolol dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for atenolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using atenolol."
    }
  },
  {
    "question": "What are the expected plasma atenolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for atenolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in atenolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for atenolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for atenolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should atenolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for atenolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking atenolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for atenolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK4 gene product in the context of atenolol therapy?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for atenolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for atenolol in hypertensive patients, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "How should atenolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for atenolol based on GRK5 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking atenolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking atenolol?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for atenolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK5 gene product in the context of atenolol therapy?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for atenolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "atenolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for atenolol in heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "How should betaxolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for betaxolol based on ADRA2C genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking betaxolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for betaxolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of betaxolol therapy?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with betaxolol."
    }
  },
  {
    "question": "What is the dosing recommendation for betaxolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for betaxolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "How should betaxolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for betaxolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking betaxolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for betaxolol stratified by ADRB1 genotype."
    }
  },
  {
    "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB1 receptor in the mechanism of action of betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for betaxolol."
    }
  },
  {
    "question": "What is the dosing recommendation for betaxolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for betaxolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "How should betaxolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for betaxolol based on ADRB2 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking betaxolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for betaxolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of betaxolol therapy?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with betaxolol."
    }
  },
  {
    "question": "What is the dosing recommendation for betaxolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for betaxolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "How should betaxolol dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for betaxolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using betaxolol."
    }
  },
  {
    "question": "What are the expected plasma betaxolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for betaxolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in betaxolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for betaxolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for betaxolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should betaxolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for betaxolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking betaxolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for betaxolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK4 gene product in the context of betaxolol therapy?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for betaxolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for betaxolol in hypertensive patients, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "How should betaxolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for betaxolol based on GRK5 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking betaxolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking betaxolol?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for betaxolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK5 gene product in the context of betaxolol therapy?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for betaxolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "betaxolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for betaxolol in heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "How should bisoprolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for bisoprolol based on ADRA2C genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking bisoprolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for bisoprolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of bisoprolol therapy?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with bisoprolol."
    }
  },
  {
    "question": "What is the dosing recommendation for bisoprolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for bisoprolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "How should bisoprolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for bisoprolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking bisoprolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for bisoprolol stratified by ADRB1 genotype."
    }
  },
  {
    "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB1 receptor in the mechanism of action of bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for bisoprolol."
    }
  },
  {
    "question": "What is the dosing recommendation for bisoprolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for bisoprolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "How should bisoprolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for bisoprolol based on ADRB2 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking bisoprolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for bisoprolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of bisoprolol therapy?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with bisoprolol."
    }
  },
  {
    "question": "What is the dosing recommendation for bisoprolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for bisoprolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "How should bisoprolol dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for bisoprolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using bisoprolol."
    }
  },
  {
    "question": "What are the expected plasma bisoprolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for bisoprolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in bisoprolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for bisoprolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for bisoprolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should bisoprolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for bisoprolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking bisoprolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for bisoprolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK4 gene product in the context of bisoprolol therapy?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for bisoprolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for bisoprolol in hypertensive patients, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "How should bisoprolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for bisoprolol based on GRK5 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking bisoprolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking bisoprolol?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for bisoprolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK5 gene product in the context of bisoprolol therapy?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for bisoprolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "bisoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for bisoprolol in heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "How should carvedilol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for carvedilol based on ADRA2C genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking carvedilol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for carvedilol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of carvedilol therapy?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with carvedilol."
    }
  },
  {
    "question": "What is the dosing recommendation for carvedilol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for carvedilol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "How should carvedilol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for carvedilol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking carvedilol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for carvedilol stratified by ADRB1 genotype."
    }
  },
  {
    "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB1 receptor in the mechanism of action of carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for carvedilol."
    }
  },
  {
    "question": "What is the dosing recommendation for carvedilol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for carvedilol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "How should carvedilol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for carvedilol based on ADRB2 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking carvedilol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for carvedilol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of carvedilol therapy?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with carvedilol."
    }
  },
  {
    "question": "What is the dosing recommendation for carvedilol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for carvedilol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "How should carvedilol dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for carvedilol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using carvedilol."
    }
  },
  {
    "question": "What are the expected plasma carvedilol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for carvedilol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in carvedilol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for carvedilol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for carvedilol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should carvedilol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for carvedilol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking carvedilol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for carvedilol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK4 gene product in the context of carvedilol therapy?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for carvedilol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for carvedilol in hypertensive patients, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "How should carvedilol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for carvedilol based on GRK5 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking carvedilol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking carvedilol?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for carvedilol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK5 gene product in the context of carvedilol therapy?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for carvedilol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "carvedilol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for carvedilol in heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "How should esmolol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for esmolol based on ADRA2C genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking esmolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for esmolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of esmolol therapy?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with esmolol."
    }
  },
  {
    "question": "What is the dosing recommendation for esmolol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for esmolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "How should esmolol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for esmolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking esmolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for esmolol stratified by ADRB1 genotype."
    }
  },
  {
    "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB1 receptor in the mechanism of action of esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for esmolol."
    }
  },
  {
    "question": "What is the dosing recommendation for esmolol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for esmolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "How should esmolol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for esmolol based on ADRB2 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking esmolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for esmolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of esmolol therapy?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with esmolol."
    }
  },
  {
    "question": "What is the dosing recommendation for esmolol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for esmolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "How should esmolol dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for esmolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using esmolol."
    }
  },
  {
    "question": "What are the expected plasma esmolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for esmolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in esmolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for esmolol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for esmolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should esmolol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for esmolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking esmolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for esmolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK4 gene product in the context of esmolol therapy?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for esmolol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for esmolol in hypertensive patients, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "How should esmolol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for esmolol based on GRK5 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking esmolol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking esmolol?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for esmolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK5 gene product in the context of esmolol therapy?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for esmolol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "esmolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for esmolol in heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "How should labetalol dosing be adjusted for an individual with an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for labetalol based on ADRA2C genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced therapeutic response for an individual with the ADRA2C Ins/Del polymorphism taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy (e.g., blood pressure control) in individuals with the ADRA2C Ins/Del polymorphism taking labetalol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate or blood pressure) in a patient with the ADRA2C Ins/Del polymorphism taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for labetalol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C variants (e.g., Ins/Del) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of labetalol therapy?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the alpha-2C adrenergic receptor in cardiovascular regulation and its interaction with labetalol."
    }
  },
  {
    "question": "What is the dosing recommendation for labetalol in patients with heart failure and an ADRA2C polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for labetalol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "How should labetalol dosing be adjusted for an individual with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for labetalol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the risk of reduced therapeutic response for an individual homozygous for the ADRB1 Gly389 allele (Gly/Gly) when taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for reduced efficacy in ADRB1 Gly389/Gly389 individuals taking labetalol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRB1 Arg389Arg genotype taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data (heart rate, blood pressure response) for labetalol stratified by ADRB1 genotype."
    }
  },
  {
    "question": "What ADRB1 genotypes are associated with enhanced beta-blocker response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 genotypes (e.g., Arg389Arg) and their association with increased beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB1 receptor in the mechanism of action of labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for labetalol."
    }
  },
  {
    "question": "What is the dosing recommendation for labetalol in pediatric patients with the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for labetalol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "How should labetalol dosing be adjusted for an individual with ADRB2 polymorphisms like Gly16Arg or Gln27Glu?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for labetalol based on ADRB2 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gly16Arg polymorphism taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the ADRB2 Gly16Arg polymorphism taking labetalol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with the ADRB2 Gln27Glu polymorphism taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for labetalol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 variants (e.g., Gly16Arg, Gln27Glu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of labetalol therapy?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of the beta-2 adrenergic receptor and its interaction with labetalol."
    }
  },
  {
    "question": "What is the dosing recommendation for labetalol in patients with asthma and an ADRB2 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for labetalol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "How should labetalol dosing be adjusted for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for labetalol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects (e.g., bradycardia) in CYP2D6 poor metabolizers using labetalol."
    }
  },
  {
    "question": "What are the expected plasma labetalol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for labetalol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in labetalol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for labetalol in elderly patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for labetalol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should labetalol dosing be adjusted for an individual with a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for labetalol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK4 A142V polymorphism taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with GRK4 variants taking labetalol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in blood pressure) in a patient with a GRK4 polymorphism taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for labetalol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 variants and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK4 gene product in the context of labetalol therapy?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 4 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for labetalol in patients with hypertension and a GRK4 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for labetalol in hypertensive patients, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "How should labetalol dosing be adjusted for an individual with a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for labetalol based on GRK5 genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the GRK5 Gln41Leu polymorphism taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for altered efficacy in individuals with the GRK5 Gln41Leu polymorphism taking labetalol."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., change in heart rate) in a patient with a GRK5 polymorphism taking labetalol?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for labetalol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 variants (e.g., Gln41Leu) and their association with beta-blocker efficacy."
    }
  },
  {
    "question": "What is the function of the GRK5 gene product in the context of labetalol therapy?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of the role of G protein-coupled receptor kinase 5 in adrenergic receptor desensitization."
    }
  },
  {
    "question": "What is the dosing recommendation for labetalol in patients with heart failure and a GRK5 polymorphism associated with altered response?",
    "answer": {
      "Drug Name": "labetalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for labetalol in heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "What is the recommended metoprolol dose for an individual with the ADRA2C Ins/Del polymorphism associated with decreased response?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for metoprolol based on ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of metoprolol in patients with the ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data, such as heart rate or blood pressure changes, for metoprolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of metoprolol therapy?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on the sympathetic nervous system and beta-blocker effects."
    }
  },
  {
    "question": "What is the dosing recommendation for metoprolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for metoprolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "What is the recommended metoprolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for metoprolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of metoprolol in patients with the ADRB1 Arg389Arg genotype."
    }
  },
  {
    "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data, such as heart rate changes, for metoprolol stratified by ADRB1 Ser49Gly genotype."
    }
  },
  {
    "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB1 gene product in the context of metoprolol therapy?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, the primary target for metoprolol."
    }
  },
  {
    "question": "What is the dosing recommendation for metoprolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for metoprolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "What is the recommended metoprolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for metoprolol based on ADRB2 Gly16Arg genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of metoprolol in patients with the ADRB2 Gln27Glu polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data, such as blood pressure changes, for metoprolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of metoprolol therapy?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to beta-blocker side effects and efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for metoprolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for metoprolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "What is the recommended metoprolol dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for metoprolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of bradycardia for a CYP2D6 poor metabolizer taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for bradycardia or other adverse effects in CYP2D6 poor metabolizers using metoprolol."
    }
  },
  {
    "question": "What are the expected plasma metoprolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for metoprolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role as the primary metabolizing enzyme for metoprolol."
    }
  },
  {
    "question": "What is the dosing recommendation for metoprolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for metoprolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended metoprolol dose for an individual with a GRK4 variant associated with altered response?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for metoprolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of metoprolol in patients with high-activity GRK4 variants."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data, such as blood pressure changes, for metoprolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK4 enzyme in the context of metoprolol therapy?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on beta-blocker efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for metoprolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for metoprolol in patients of African ancestry, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "What is the recommended metoprolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for metoprolol based on GRK5 Gln41Leu genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with metoprolol in patients with the GRK5 Leu41 variant."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking metoprolol?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data, such as changes in ejection fraction, for metoprolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK5 enzyme in the context of metoprolol therapy?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on beta-blocker efficacy, particularly in heart failure."
    }
  },
  {
    "question": "What is the dosing recommendation for metoprolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
    "answer": {
      "Drug Name": "metoprolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for metoprolol in elderly heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "What is the recommended nadolol dose for an individual with the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nadolol based on ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of nadolol in patients with the ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nadolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of nadolol therapy?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on nadolol effects."
    }
  },
  {
    "question": "What is the dosing recommendation for nadolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for nadolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "What is the recommended nadolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nadolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of nadolol in patients with the ADRB1 Arg389Arg genotype."
    }
  },
  {
    "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nadolol stratified by ADRB1 Ser49Gly genotype."
    }
  },
  {
    "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB1 gene product in the context of nadolol therapy?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for nadolol."
    }
  },
  {
    "question": "What is the dosing recommendation for nadolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for nadolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "What is the recommended nadolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nadolol based on ADRB2 Gly16Arg genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of nadolol in patients with the ADRB2 Gln27Glu polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nadolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of nadolol therapy?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to nadolol therapy."
    }
  },
  {
    "question": "What is the dosing recommendation for nadolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for nadolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "What is the recommended nadolol dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nadolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using nadolol."
    }
  },
  {
    "question": "What are the expected plasma nadolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for nadolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in nadolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for nadolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for nadolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended nadolol dose for an individual with a GRK4 variant associated with altered response?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nadolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of nadolol in patients with high-activity GRK4 variants."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nadolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK4 enzyme in the context of nadolol therapy?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on nadolol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for nadolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for nadolol in patients of African ancestry, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "What is the recommended nadolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nadolol based on GRK5 Gln41Leu genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with nadolol in patients with the GRK5 Leu41 variant."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking nadolol?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nadolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK5 enzyme in the context of nadolol therapy?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on nadolol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for nadolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
    "answer": {
      "Drug Name": "nadolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for nadolol in elderly heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "What is the recommended nebivolol dose for an individual with the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nebivolol based on ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of nebivolol in patients with the ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nebivolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of nebivolol therapy?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on nebivolol effects."
    }
  },
  {
    "question": "What is the dosing recommendation for nebivolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for nebivolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "What is the recommended nebivolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nebivolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of nebivolol in patients with the ADRB1 Arg389Arg genotype."
    }
  },
  {
    "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nebivolol stratified by ADRB1 Ser49Gly genotype."
    }
  },
  {
    "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB1 gene product in the context of nebivolol therapy?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for nebivolol."
    }
  },
  {
    "question": "What is the dosing recommendation for nebivolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for nebivolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "What is the recommended nebivolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nebivolol based on ADRB2 Gly16Arg genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of nebivolol in patients with the ADRB2 Gln27Glu polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nebivolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of nebivolol therapy?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to nebivolol therapy."
    }
  },
  {
    "question": "What is the dosing recommendation for nebivolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for nebivolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "What is the recommended nebivolol dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nebivolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using nebivolol."
    }
  },
  {
    "question": "What are the expected plasma nebivolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for nebivolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in nebivolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for nebivolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for nebivolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended nebivolol dose for an individual with a GRK4 variant associated with altered response?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nebivolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of nebivolol in patients with high-activity GRK4 variants."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nebivolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK4 enzyme in the context of nebivolol therapy?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on nebivolol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for nebivolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for nebivolol in patients of African ancestry, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "What is the recommended nebivolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for nebivolol based on GRK5 Gln41Leu genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with nebivolol in patients with the GRK5 Leu41 variant."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking nebivolol?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for nebivolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK5 enzyme in the context of nebivolol therapy?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on nebivolol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for nebivolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
    "answer": {
      "Drug Name": "nebivolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for nebivolol in elderly heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "What is the recommended pindolol dose for an individual with the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for pindolol based on ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of pindolol in patients with the ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for pindolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of pindolol therapy?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on pindolol effects."
    }
  },
  {
    "question": "What is the dosing recommendation for pindolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for pindolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "What is the recommended pindolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for pindolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of pindolol in patients with the ADRB1 Arg389Arg genotype."
    }
  },
  {
    "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for pindolol stratified by ADRB1 Ser49Gly genotype."
    }
  },
  {
    "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB1 gene product in the context of pindolol therapy?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for pindolol."
    }
  },
  {
    "question": "What is the dosing recommendation for pindolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for pindolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "What is the recommended pindolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for pindolol based on ADRB2 Gly16Arg genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of pindolol in patients with the ADRB2 Gln27Glu polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for pindolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of pindolol therapy?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to pindolol therapy."
    }
  },
  {
    "question": "What is the dosing recommendation for pindolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for pindolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "What is the recommended pindolol dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for pindolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using pindolol."
    }
  },
  {
    "question": "What are the expected plasma pindolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for pindolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in pindolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for pindolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for pindolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended pindolol dose for an individual with a GRK4 variant associated with altered response?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for pindolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of pindolol in patients with high-activity GRK4 variants."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for pindolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK4 enzyme in the context of pindolol therapy?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on pindolol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for pindolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for pindolol in patients of African ancestry, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "What is the recommended pindolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for pindolol based on GRK5 Gln41Leu genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with pindolol in patients with the GRK5 Leu41 variant."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking pindolol?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for pindolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK5 enzyme in the context of pindolol therapy?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on pindolol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for pindolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
    "answer": {
      "Drug Name": "pindolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for pindolol in elderly heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "What is the recommended propranolol dose for an individual with the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for propranolol based on ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of propranolol in patients with the ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for propranolol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of propranolol therapy?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on propranolol effects."
    }
  },
  {
    "question": "What is the dosing recommendation for propranolol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for propranolol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "What is the recommended propranolol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for propranolol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of propranolol in patients with the ADRB1 Arg389Arg genotype."
    }
  },
  {
    "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for propranolol stratified by ADRB1 Ser49Gly genotype."
    }
  },
  {
    "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB1 gene product in the context of propranolol therapy?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for propranolol."
    }
  },
  {
    "question": "What is the dosing recommendation for propranolol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for propranolol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "What is the recommended propranolol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for propranolol based on ADRB2 Gly16Arg genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of propranolol in patients with the ADRB2 Gln27Glu polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for propranolol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of propranolol therapy?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to propranolol therapy."
    }
  },
  {
    "question": "What is the dosing recommendation for propranolol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for propranolol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "What is the recommended propranolol dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for propranolol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using propranolol."
    }
  },
  {
    "question": "What are the expected plasma propranolol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for propranolol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in propranolol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for propranolol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for propranolol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended propranolol dose for an individual with a GRK4 variant associated with altered response?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for propranolol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of propranolol in patients with high-activity GRK4 variants."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for propranolol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK4 enzyme in the context of propranolol therapy?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on propranolol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for propranolol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for propranolol in patients of African ancestry, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "What is the recommended propranolol dose for an individual with the GRK5 Gln41Leu polymorphism?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for propranolol based on GRK5 Gln41Leu genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with propranolol in patients with the GRK5 Leu41 variant."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking propranolol?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for propranolol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK5 enzyme in the context of propranolol therapy?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on propranolol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for propranolol in elderly patients with heart failure and the GRK5 Leu41 variant?",
    "answer": {
      "Drug Name": "propranolol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for propranolol in elderly heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "What is the recommended sotalol dose for an individual with the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for sotalol based on ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRA2C Ins/Del polymorphism when taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of sotalol in patients with the ADRA2C Ins/Del polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects (e.g., heart rate reduction) in a patient with the ADRA2C Ins/Del polymorphism taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for sotalol stratified by ADRA2C genotype."
    }
  },
  {
    "question": "What ADRA2C polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRA2C polymorphisms (e.g., Ins/Del) and their impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRA2C gene product in the context of sotalol therapy?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRA2C's role as an alpha-2C adrenergic receptor and its influence on sotalol effects."
    }
  },
  {
    "question": "What is the dosing recommendation for sotalol in patients with heart failure and the ADRA2C Ins/Del polymorphism?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRA2C",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for sotalol in heart failure patients, adjusted for ADRA2C genotype."
    }
  },
  {
    "question": "What is the recommended sotalol dose for an individual with the ADRB1 Arg389Gly polymorphism (Gly/Gly genotype)?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for sotalol based on ADRB1 Arg389Gly genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with the ADRB1 Arg389Arg genotype when taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of sotalol in patients with the ADRB1 Arg389Arg genotype."
    }
  },
  {
    "question": "What are the expected changes in heart rate response in a patient with the ADRB1 Ser49Gly polymorphism taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for sotalol stratified by ADRB1 Ser49Gly genotype."
    }
  },
  {
    "question": "What ADRB1 polymorphisms (e.g., Ser49Gly, Arg389Gly) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB1 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB1 gene product in the context of sotalol therapy?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB1's role as the beta-1 adrenergic receptor, a primary target for sotalol."
    }
  },
  {
    "question": "What is the dosing recommendation for sotalol in pediatric patients with hypertension and the ADRB1 Arg389Gly polymorphism?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB1",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pediatric dosing guidelines for sotalol adjusted for ADRB1 genotype."
    }
  },
  {
    "question": "What is the recommended sotalol dose for an individual with the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for sotalol based on ADRB2 Gly16Arg genotype."
    }
  },
  {
    "question": "What is the quantified risk of altered therapeutic response for an individual with the ADRB2 Gln27Glu polymorphism when taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on the efficacy of sotalol in patients with the ADRB2 Gln27Glu polymorphism."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with the ADRB2 Gly16Arg polymorphism taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for sotalol stratified by ADRB2 genotype."
    }
  },
  {
    "question": "What ADRB2 polymorphisms (e.g., Gly16Arg, Gln27Glu) are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of ADRB2 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the ADRB2 gene product in the context of sotalol therapy?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of ADRB2's role as the beta-2 adrenergic receptor and its relevance to sotalol therapy."
    }
  },
  {
    "question": "What is the dosing recommendation for sotalol in patients with asthma and the ADRB2 Gly16Arg polymorphism?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "ADRB2",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for sotalol in asthmatic patients, adjusted for ADRB2 genotype."
    }
  },
  {
    "question": "What is the recommended sotalol dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for sotalol in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using sotalol."
    }
  },
  {
    "question": "What are the expected plasma sotalol concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for sotalol in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Description of CYP2D6's role in sotalol metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for sotalol in elderly patients with hypertension who are CYP2D6 poor metabolizers?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing adjustments for sotalol in elderly CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended sotalol dose for an individual with a GRK4 variant associated with altered response?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for sotalol based on GRK4 genotype."
    }
  },
  {
    "question": "What is the quantified risk of reduced blood pressure response for an individual with a high-activity GRK4 variant when taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on reduced efficacy of sotalol in patients with high-activity GRK4 variants."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on blood pressure in a patient with a low-activity GRK4 variant taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for sotalol stratified by GRK4 genotype."
    }
  },
  {
    "question": "What GRK4 polymorphisms are associated with altered beta-blocker response?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK4 polymorphisms and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK4 enzyme in the context of sotalol therapy?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK4's role in desensitizing adrenergic receptors and its influence on sotalol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for sotalol in patients of African ancestry with hypertension and a high-activity GRK4 variant?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for sotalol in patients of African ancestry, adjusted for GRK4 genotype."
    }
  },
  {
    "question": "What is the recommended sotalol dose for an individual with the GRK5 Gln41Leu polymorphism?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dose adjustment protocol for sotalol based on GRK5 Gln41Leu genotype."
    }
  },
  {
    "question": "What is the quantified risk of adverse outcomes in heart failure for an individual with the GRK5 Leu41 variant when taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Risk multipliers or clinical data on heart failure outcomes with sotalol in patients with the GRK5 Leu41 variant."
    }
  },
  {
    "question": "What are the expected pharmacodynamic effects on cardiac function in a patient with the GRK5 Gln41Gln genotype taking sotalol?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Pharmacodynamic data for sotalol stratified by GRK5 genotype."
    }
  },
  {
    "question": "What GRK5 polymorphisms are associated with altered beta-blocker response in heart failure?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Definitions of GRK5 polymorphisms (e.g., Gln41Leu) and their functional impact on beta-blocker therapy."
    }
  },
  {
    "question": "What is the function of the GRK5 enzyme in the context of sotalol therapy?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Explanation of GRK5's role in desensitizing adrenergic receptors and its influence on sotalol efficacy."
    }
  },
  {
    "question": "What is the dosing recommendation for sotalol in elderly patients with heart failure and the GRK5 Leu41 variant?",
    "answer": {
      "Drug Name": "sotalol",
      "Gene Name": "GRK5",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy (July 2024).pdf",
      "Content to Search": "Dosing guidelines for sotalol in elderly heart failure patients, adjusted for GRK5 genotype."
    }
  },
  {
    "question": "What is the recommended citalopram dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for citalopram in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 ultrarapid metabolizer taking citalopram?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects or lack of efficacy in CYP2B6 ultrarapid metabolizers using citalopram."
    }
  },
  {
    "question": "What are the expected plasma concentrations of citalopram in a CYP2B6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for citalopram in CYP2B6 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of citalopram?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in the metabolic pathway of citalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for citalopram in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended citalopram dose for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol or alternative medication recommendation for citalopram in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the increased risk of failed therapy for a CYP2C19 ultrarapid metabolizer taking a standard dose of citalopram?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for lack of efficacy in CYP2C19 ultrarapid metabolizers using citalopram."
    }
  },
  {
    "question": "What are the expected plasma concentrations of citalopram in a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for citalopram in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the metabolism of citalopram?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's primary role in the metabolic pathway of citalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for citalopram in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended citalopram dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for citalopram in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking citalopram?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using citalopram."
    }
  },
  {
    "question": "What are the expected plasma concentrations of citalopram in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for citalopram in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of citalopram?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role in the metabolic pathway of citalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for citalopram in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for citalopram in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should citalopram dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for citalopram based on HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What is the risk of poor response to citalopram for individuals with the HTR2A rs7997012 A allele?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for altered citalopram efficacy in patients with the HTR2A rs7997012 A allele."
    }
  },
  {
    "question": "What is the expected clinical response to citalopram in a patient with the HTR2A rs7997012 G/G genotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for citalopram stratified by HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What HTR2A variants are associated with altered citalopram response?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of HTR2A variants and their corresponding impact on citalopram response."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the context of citalopram therapy?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of citalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for citalopram in adolescents with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for citalopram in adolescent patients, adjusted for HTR2A genotype."
    }
  },
  {
    "question": "How should citalopram dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for citalopram based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of adverse effects to citalopram for individuals with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of citalopram in patients with the SLC6A4 S/S genotype."
    }
  },
  {
    "question": "What is the expected clinical response to citalopram in a patient with the SLC6A4 L/S genotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for citalopram stratified by SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered citalopram response?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on citalopram response."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of citalopram?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, the primary target of citalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for citalopram in adolescents with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "citalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for citalopram in adolescent patients, adjusted for SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended desvenlafaxine dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for desvenlafaxine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking desvenlafaxine?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using desvenlafaxine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of desvenlafaxine in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for desvenlafaxine in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 normal metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of desvenlafaxine?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in the metabolic pathway of desvenlafaxine."
    }
  },
  {
    "question": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for desvenlafaxine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended desvenlafaxine dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for desvenlafaxine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking desvenlafaxine?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using desvenlafaxine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of desvenlafaxine in a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for desvenlafaxine in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the metabolism of desvenlafaxine?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in the metabolic pathway of desvenlafaxine."
    }
  },
  {
    "question": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2C19 ultrarapid metabolizer phenotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for desvenlafaxine in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the recommended desvenlafaxine dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for desvenlafaxine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking desvenlafaxine?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using desvenlafaxine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of desvenlafaxine in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for desvenlafaxine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of desvenlafaxine?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role in the metabolic pathway of desvenlafaxine."
    }
  },
  {
    "question": "What is the dosing recommendation for desvenlafaxine in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for desvenlafaxine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should desvenlafaxine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for desvenlafaxine based on HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What is the risk of poor response to desvenlafaxine for individuals with the HTR2A rs7997012 A allele?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for altered desvenlafaxine efficacy in patients with the HTR2A rs7997012 A allele."
    }
  },
  {
    "question": "What is the expected clinical response to desvenlafaxine in a patient with the HTR2A rs7997012 G/G genotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for desvenlafaxine stratified by HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What HTR2A variants are associated with altered desvenlafaxine response?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of HTR2A variants and their corresponding impact on desvenlafaxine response."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the context of desvenlafaxine therapy?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of desvenlafaxine."
    }
  },
  {
    "question": "What is the dosing recommendation for desvenlafaxine in adolescents with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for desvenlafaxine in adolescent patients, adjusted for HTR2A genotype."
    }
  },
  {
    "question": "How should desvenlafaxine dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for desvenlafaxine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of adverse effects to desvenlafaxine for individuals with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of desvenlafaxine in patients with the SLC6A4 S/S genotype."
    }
  },
  {
    "question": "What is the expected clinical response to desvenlafaxine in a patient with the SLC6A4 L/S genotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for desvenlafaxine stratified by SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered desvenlafaxine response?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on desvenlafaxine response."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of desvenlafaxine?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, a primary target of desvenlafaxine."
    }
  },
  {
    "question": "What is the dosing recommendation for desvenlafaxine in adolescents with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "desvenlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for desvenlafaxine in adolescent patients, adjusted for SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended duloxetine dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for duloxetine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking duloxetine?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using duloxetine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of duloxetine in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for duloxetine in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of duloxetine?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in the metabolic pathway of duloxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for duloxetine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended duloxetine dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for duloxetine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking duloxetine?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using duloxetine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of duloxetine in a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for duloxetine in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 normal metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the metabolism of duloxetine?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in the metabolic pathway of duloxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for duloxetine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended duloxetine dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol or alternative medication recommendation for duloxetine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of duloxetine?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using duloxetine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of duloxetine in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for duloxetine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of duloxetine?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's primary role in the metabolic pathway of duloxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for duloxetine in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for duloxetine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should duloxetine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for duloxetine based on HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What is the risk of poor response to duloxetine for individuals with the HTR2A rs7997012 A allele?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for altered duloxetine efficacy in patients with the HTR2A rs7997012 A allele."
    }
  },
  {
    "question": "What is the expected clinical response to duloxetine in a patient with the HTR2A rs7997012 G/G genotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for duloxetine stratified by HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What HTR2A variants are associated with altered duloxetine response?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of HTR2A variants and their corresponding impact on duloxetine response."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the context of duloxetine therapy?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of duloxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for duloxetine in adolescents with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for duloxetine in adolescent patients, adjusted for HTR2A genotype."
    }
  },
  {
    "question": "How should duloxetine dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for duloxetine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of adverse effects to duloxetine for individuals with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of duloxetine in patients with the SLC6A4 S/S genotype."
    }
  },
  {
    "question": "What is the expected clinical response to duloxetine in a patient with the SLC6A4 L/S genotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for duloxetine stratified by SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered duloxetine response?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on duloxetine response."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of duloxetine?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, a primary target of duloxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for duloxetine in adolescents with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "duloxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for duloxetine in adolescent patients, adjusted for SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended escitalopram dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for escitalopram in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking escitalopram?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using escitalopram."
    }
  },
  {
    "question": "What are the expected plasma concentrations of escitalopram in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for escitalopram in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of escitalopram?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in the metabolic pathway of escitalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for escitalopram in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended escitalopram dose for a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol or alternative medication recommendation for escitalopram in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What is the increased risk of failed therapy for a CYP2C19 ultrarapid metabolizer taking a standard dose of escitalopram?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for lack of efficacy in CYP2C19 ultrarapid metabolizers using escitalopram."
    }
  },
  {
    "question": "What are the expected plasma concentrations of escitalopram in a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for escitalopram in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the metabolism of escitalopram?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's primary role in the metabolic pathway of escitalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for escitalopram in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended escitalopram dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for escitalopram in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking escitalopram?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using escitalopram."
    }
  },
  {
    "question": "What are the expected plasma concentrations of escitalopram in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for escitalopram in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of escitalopram?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role in the metabolic pathway of escitalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for escitalopram in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for escitalopram in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should escitalopram dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for escitalopram based on HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What is the risk of poor response to escitalopram for individuals with the HTR2A rs7997012 A allele?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for altered escitalopram efficacy in patients with the HTR2A rs7997012 A allele."
    }
  },
  {
    "question": "What is the expected clinical response to escitalopram in a patient with the HTR2A rs7997012 G/G genotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for escitalopram stratified by HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What HTR2A variants are associated with altered escitalopram response?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of HTR2A variants and their corresponding impact on escitalopram response."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the context of escitalopram therapy?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of escitalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for escitalopram in adolescents with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for escitalopram in adolescent patients, adjusted for HTR2A genotype."
    }
  },
  {
    "question": "How should escitalopram dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for escitalopram based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of adverse effects to escitalopram for individuals with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of escitalopram in patients with the SLC6A4 S/S genotype."
    }
  },
  {
    "question": "What is the expected clinical response to escitalopram in a patient with the SLC6A4 L/S genotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for escitalopram stratified by SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered escitalopram response?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on escitalopram response."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of escitalopram?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, the primary target of escitalopram."
    }
  },
  {
    "question": "What is the dosing recommendation for escitalopram in adolescents with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "escitalopram",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for escitalopram in adolescent patients, adjusted for SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended fluoxetine dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for fluoxetine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking fluoxetine?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using fluoxetine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of fluoxetine in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluoxetine in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of fluoxetine?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in the metabolic pathway of fluoxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluoxetine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended fluoxetine dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for fluoxetine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking fluoxetine?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using fluoxetine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of fluoxetine in a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluoxetine in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the metabolism of fluoxetine?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in the metabolic pathway of fluoxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluoxetine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended fluoxetine dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol or alternative medication recommendation for fluoxetine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of fluoxetine?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using fluoxetine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of fluoxetine in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluoxetine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of fluoxetine?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's primary role in the metabolic pathway of fluoxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluoxetine in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluoxetine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should fluoxetine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for fluoxetine based on HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What is the risk of poor response to fluoxetine for individuals with the HTR2A rs7997012 A allele?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for altered fluoxetine efficacy in patients with the HTR2A rs7997012 A allele."
    }
  },
  {
    "question": "What is the expected clinical response to fluoxetine in a patient with the HTR2A rs7997012 G/G genotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for fluoxetine stratified by HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What HTR2A variants are associated with altered fluoxetine response?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of HTR2A variants and their corresponding impact on fluoxetine response."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the context of fluoxetine therapy?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of fluoxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluoxetine in adolescents with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for fluoxetine in adolescent patients, adjusted for HTR2A genotype."
    }
  },
  {
    "question": "How should fluoxetine dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for fluoxetine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of adverse effects to fluoxetine for individuals with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of fluoxetine in patients with the SLC6A4 S/S genotype."
    }
  },
  {
    "question": "What is the expected clinical response to fluoxetine in a patient with the SLC6A4 L/S genotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for fluoxetine stratified by SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered fluoxetine response?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on fluoxetine response."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of fluoxetine?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, the primary target of fluoxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluoxetine in adolescents with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "fluoxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for fluoxetine in adolescent patients, adjusted for SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended fluvoxamine dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for fluvoxamine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking fluvoxamine?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using fluvoxamine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of fluvoxamine in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluvoxamine in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 normal metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of fluvoxamine?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in the metabolic pathway of fluvoxamine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluvoxamine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended fluvoxamine dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for fluvoxamine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking fluvoxamine?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using fluvoxamine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of fluvoxamine in a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluvoxamine in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the metabolism of fluvoxamine?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in the metabolic pathway of fluvoxamine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluvoxamine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended fluvoxamine dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol or alternative medication recommendation for fluvoxamine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking a standard dose of fluvoxamine?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using fluvoxamine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of fluvoxamine in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for fluvoxamine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of fluvoxamine?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's primary role in the metabolic pathway of fluvoxamine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvoxamine in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for fluvoxamine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should fluvoxamine dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for fluvoxamine based on HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What is the risk of poor response to fluvoxamine for individuals with the HTR2A rs7997012 A allele?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for altered fluvoxamine efficacy in patients with the HTR2A rs7997012 A allele."
    }
  },
  {
    "question": "What is the expected clinical response to fluvoxamine in a patient with the HTR2A rs7997012 G/G genotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for fluvoxamine stratified by HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What HTR2A variants are associated with altered fluvoxamine response?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of HTR2A variants and their corresponding impact on fluvoxamine response."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the context of fluvoxamine therapy?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of fluvoxamine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvoxamine in adolescents with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for fluvoxamine in adolescent patients, adjusted for HTR2A genotype."
    }
  },
  {
    "question": "How should fluvoxamine dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for fluvoxamine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of adverse effects to fluvoxamine for individuals with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of fluvoxamine in patients with the SLC6A4 S/S genotype."
    }
  },
  {
    "question": "What is the expected clinical response to fluvoxamine in a patient with the SLC6A4 L/S genotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for fluvoxamine stratified by SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered fluvoxamine response?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on fluvoxamine response."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of fluvoxamine?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, the primary target of fluvoxamine."
    }
  },
  {
    "question": "What is the dosing recommendation for fluvoxamine in adolescents with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "fluvoxamine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for fluvoxamine in adolescent patients, adjusted for SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended levomilnacipran dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for levomilnacipran in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking levomilnacipran?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using levomilnacipran."
    }
  },
  {
    "question": "What are the expected plasma concentrations of levomilnacipran in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for levomilnacipran in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of levomilnacipran?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in the metabolic pathway of levomilnacipran."
    }
  },
  {
    "question": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for levomilnacipran in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended levomilnacipran dose for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for levomilnacipran in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2C19 poor metabolizer taking levomilnacipran?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 poor metabolizers using levomilnacipran."
    }
  },
  {
    "question": "What are the expected plasma concentrations of levomilnacipran in a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for levomilnacipran in CYP2C19 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 normal metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2C19 enzyme in the metabolism of levomilnacipran?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in the metabolic pathway of levomilnacipran."
    }
  },
  {
    "question": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for levomilnacipran in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended levomilnacipran dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for levomilnacipran in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking levomilnacipran?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using levomilnacipran."
    }
  },
  {
    "question": "What are the expected plasma concentrations of levomilnacipran in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for levomilnacipran in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of levomilnacipran?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role in the metabolic pathway of levomilnacipran."
    }
  },
  {
    "question": "What is the dosing recommendation for levomilnacipran in pediatric patients with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for levomilnacipran in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should levomilnacipran dosing be adjusted for an individual with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for levomilnacipran based on HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What is the risk of poor response to levomilnacipran for individuals with the HTR2A rs7997012 A allele?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for altered levomilnacipran efficacy in patients with the HTR2A rs7997012 A allele."
    }
  },
  {
    "question": "What is the expected clinical response to levomilnacipran in a patient with the HTR2A rs7997012 G/G genotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for levomilnacipran stratified by HTR2A rs7997012 genotype."
    }
  },
  {
    "question": "What HTR2A variants are associated with altered levomilnacipran response?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of HTR2A variants and their corresponding impact on levomilnacipran response."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the context of levomilnacipran therapy?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of HTR2A's role as a serotonin receptor influencing the pharmacodynamic effects of levomilnacipran."
    }
  },
  {
    "question": "What is the dosing recommendation for levomilnacipran in adolescents with the HTR2A rs7997012 A/A genotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for levomilnacipran in adolescent patients, adjusted for HTR2A genotype."
    }
  },
  {
    "question": "How should levomilnacipran dosing be adjusted for an individual with the SLC6A4 L/L genotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing or therapeutic recommendations for levomilnacipran based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of adverse effects to levomilnacipran for individuals with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or clinical evidence for increased adverse effects of levomilnacipran in patients with the SLC6A4 S/S genotype."
    }
  },
  {
    "question": "What is the expected clinical response to levomilnacipran in a patient with the SLC6A4 L/S genotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data, such as remission rates, for levomilnacipran stratified by SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What SLC6A4 variants (e.g., 5-HTTLPR) are associated with altered levomilnacipran response?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "List and description of SLC6A4 variants and their corresponding impact on levomilnacipran response."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of levomilnacipran?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Explanation of SLC6A4's role as the serotonin transporter, a primary target of levomilnacipran."
    }
  },
  {
    "question": "What is the dosing recommendation for levomilnacipran in adolescents with the SLC6A4 S/S genotype?",
    "answer": {
      "Drug Name": "levomilnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing guidelines for levomilnacipran in adolescent patients, adjusted for SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended milnacipran dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for milnacipran in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using milnacipran."
    }
  },
  {
    "question": "What are the expected plasma concentrations of milnacipran in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for milnacipran in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in milnacipran metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for milnacipran in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for milnacipran in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "How should milnacipran dosing be adjusted for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for milnacipran in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using milnacipran."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma milnacipran concentrations in a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges for milnacipran in CYP2C19 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in milnacipran metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for milnacipran in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for milnacipran in elderly CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended milnacipran dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for milnacipran in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using milnacipran."
    }
  },
  {
    "question": "What are the expected plasma milnacipran concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for milnacipran in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role in milnacipran metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for milnacipran in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for milnacipran in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should milnacipran dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for milnacipran based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in milnacipran users with the HTR2A rs6313 G/G genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for milnacipran based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered milnacipran response?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definitions of HTR2A genotypes and their association with milnacipran efficacy."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the mechanism of action of milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for milnacipran."
    }
  },
  {
    "question": "What is the dosing recommendation for milnacipran in an adolescent with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for milnacipran in adolescents based on HTR2A genotype."
    }
  },
  {
    "question": "How should milnacipran dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for milnacipran based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in milnacipran users with the SLC6A4 s/s genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for milnacipran based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of milnacipran?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the serotonin transporter's (SERT) role as the primary target of milnacipran."
    }
  },
  {
    "question": "What is the dosing recommendation for milnacipran in an adolescent with the SLC6A4 s/s genotype?",
    "answer": {
      "Drug Name": "milnacipran",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for milnacipran in adolescents based on SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended paroxetine dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for paroxetine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using paroxetine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of paroxetine in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for paroxetine in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in paroxetine metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for paroxetine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for paroxetine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "How should paroxetine dosing be adjusted for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for paroxetine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using paroxetine."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma paroxetine concentrations in a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges for paroxetine in CYP2C19 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in paroxetine metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for paroxetine in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for paroxetine in elderly CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended paroxetine dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for paroxetine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using paroxetine."
    }
  },
  {
    "question": "What are the expected plasma paroxetine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for paroxetine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role as the primary metabolic pathway for paroxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for paroxetine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for paroxetine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should paroxetine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for paroxetine based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in paroxetine users with the HTR2A rs6313 G/G genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for paroxetine based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered paroxetine response?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definitions of HTR2A genotypes and their association with paroxetine efficacy."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the mechanism of action of paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for paroxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for paroxetine in an adolescent with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for paroxetine in adolescents based on HTR2A genotype."
    }
  },
  {
    "question": "How should paroxetine dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for paroxetine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in paroxetine users with the SLC6A4 s/s genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for paroxetine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of paroxetine?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the serotonin transporter's (SERT) role as the primary target of paroxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for paroxetine in an adolescent with the SLC6A4 s/s genotype?",
    "answer": {
      "Drug Name": "paroxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for paroxetine in adolescents based on SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended sertraline dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for sertraline in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using sertraline."
    }
  },
  {
    "question": "What are the expected plasma concentrations of sertraline in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for sertraline in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in sertraline metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for sertraline in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for sertraline in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "How should sertraline dosing be adjusted for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for sertraline in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using sertraline."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma sertraline concentrations in a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges for sertraline in CYP2C19 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role as a primary metabolic pathway for sertraline."
    }
  },
  {
    "question": "What is the dosing recommendation for sertraline in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for sertraline in elderly CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended sertraline dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for sertraline in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using sertraline."
    }
  },
  {
    "question": "What are the expected plasma sertraline concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for sertraline in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role in sertraline metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for sertraline in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for sertraline in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should sertraline dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for sertraline based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in sertraline users with the HTR2A rs6313 G/G genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for sertraline based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered sertraline response?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definitions of HTR2A genotypes and their association with sertraline efficacy."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the mechanism of action of sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for sertraline."
    }
  },
  {
    "question": "What is the dosing recommendation for sertraline in an adolescent with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for sertraline in adolescents based on HTR2A genotype."
    }
  },
  {
    "question": "How should sertraline dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for sertraline based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in sertraline users with the SLC6A4 s/s genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for sertraline based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of sertraline?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the serotonin transporter's (SERT) role as the primary target of sertraline."
    }
  },
  {
    "question": "What is the dosing recommendation for sertraline in an adolescent with the SLC6A4 s/s genotype?",
    "answer": {
      "Drug Name": "sertraline",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for sertraline in adolescents based on SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended venlafaxine dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for venlafaxine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using venlafaxine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of venlafaxine in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for venlafaxine in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 normal metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in venlafaxine metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for venlafaxine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for venlafaxine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "How should venlafaxine dosing be adjusted for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for venlafaxine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using venlafaxine."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma O-desmethylvenlafaxine concentrations in a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges for O-desmethylvenlafaxine in CYP2C19 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 normal metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in venlafaxine metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for venlafaxine in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for venlafaxine in elderly CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended venlafaxine dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for venlafaxine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using venlafaxine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of O-desmethylvenlafaxine in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for O-desmethylvenlafaxine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 normal metabolizer?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role in converting venlafaxine to its active metabolite, O-desmethylvenlafaxine."
    }
  },
  {
    "question": "What is the dosing recommendation for venlafaxine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for venlafaxine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should venlafaxine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for venlafaxine based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in venlafaxine users with the HTR2A rs6313 G/G genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for venlafaxine based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered venlafaxine response?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definitions of HTR2A genotypes and their association with venlafaxine efficacy."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the mechanism of action of venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for venlafaxine."
    }
  },
  {
    "question": "What is the dosing recommendation for venlafaxine in an adolescent with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for venlafaxine in adolescents based on HTR2A genotype."
    }
  },
  {
    "question": "How should venlafaxine dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for venlafaxine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in venlafaxine users with the SLC6A4 s/s genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for venlafaxine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of venlafaxine?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the serotonin transporter's (SERT) role as a primary target of venlafaxine."
    }
  },
  {
    "question": "What is the dosing recommendation for venlafaxine in an adolescent with the SLC6A4 s/s genotype?",
    "answer": {
      "Drug Name": "venlafaxine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for venlafaxine in adolescents based on SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended vilazodone dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vilazodone in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using vilazodone."
    }
  },
  {
    "question": "What are the expected plasma concentrations of vilazodone in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for vilazodone in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 intermediate metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in vilazodone metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for vilazodone in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for vilazodone in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "How should vilazodone dosing be adjusted for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vilazodone in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using vilazodone."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma vilazodone concentrations in a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges for vilazodone in CYP2C19 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 intermediate metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in vilazodone metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for vilazodone in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for vilazodone in elderly CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended vilazodone dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vilazodone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using vilazodone."
    }
  },
  {
    "question": "What are the expected plasma vilazodone concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for vilazodone in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role in vilazodone metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for vilazodone in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for vilazodone in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should vilazodone dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vilazodone based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in vilazodone users with the HTR2A rs6313 G/G genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for vilazodone based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered vilazodone response?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definitions of HTR2A genotypes and their association with vilazodone efficacy."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the mechanism of action of vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for vilazodone."
    }
  },
  {
    "question": "What is the dosing recommendation for vilazodone in an adolescent with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for vilazodone in adolescents based on HTR2A genotype."
    }
  },
  {
    "question": "How should vilazodone dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vilazodone based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in vilazodone users with the SLC6A4 s/s genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for vilazodone based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of vilazodone?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the serotonin transporter's (SERT) role as a primary target of vilazodone."
    }
  },
  {
    "question": "What is the dosing recommendation for vilazodone in an adolescent with the SLC6A4 s/s genotype?",
    "answer": {
      "Drug Name": "vilazodone",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for vilazodone in adolescents based on SLC6A4 genotype."
    }
  },
  {
    "question": "What is the recommended vortioxetine dose for a CYP2B6 poor metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vortioxetine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2B6 poor metabolizer taking vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2B6 poor metabolizers using vortioxetine."
    }
  },
  {
    "question": "What are the expected plasma concentrations of vortioxetine in a CYP2B6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for vortioxetine in CYP2B6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2B6 normal metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2B6 normal metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2B6 enzyme in the metabolism of vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2B6's role in vortioxetine metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for vortioxetine in a pediatric patient with a CYP2B6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2B6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for vortioxetine in CYP2B6 poor metabolizers."
    }
  },
  {
    "question": "How should vortioxetine dosing be adjusted for a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vortioxetine in CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the quantified risk of adverse effects for a CYP2C19 ultrarapid metabolizer taking vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2C19 ultrarapid metabolizers using vortioxetine."
    }
  },
  {
    "question": "What is the suggested therapeutic range for plasma vortioxetine concentrations in a CYP2C19 intermediate metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges for vortioxetine in CYP2C19 intermediate metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2C19 poor metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2C19 poor metabolizer phenotype."
    }
  },
  {
    "question": "What is the role of the CYP2C19 enzyme in the pharmacokinetics of vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2C19's role in vortioxetine metabolism."
    }
  },
  {
    "question": "What is the dosing recommendation for vortioxetine in an elderly patient with a CYP2C19 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2C19",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for vortioxetine in elderly CYP2C19 poor metabolizers."
    }
  },
  {
    "question": "What is the recommended vortioxetine dose for a CYP2D6 poor metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vortioxetine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "What is the increased risk of adverse effects for a CYP2D6 poor metabolizer taking vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk data for adverse effects in CYP2D6 poor metabolizers using vortioxetine."
    }
  },
  {
    "question": "What are the expected plasma vortioxetine concentrations in a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Plasma concentration ranges or AUC data for vortioxetine in CYP2D6 ultrarapid metabolizers."
    }
  },
  {
    "question": "What diplotypes define a CYP2D6 ultrarapid metabolizer?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Diplotype definitions and activity scores for the CYP2D6 ultrarapid metabolizer phenotype."
    }
  },
  {
    "question": "What is the function of the CYP2D6 enzyme in the metabolism of vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of CYP2D6's role as the primary metabolic pathway for vortioxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for vortioxetine in a pediatric patient with a CYP2D6 poor metabolizer phenotype?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "CYP2D6",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pediatric dosing adjustments for vortioxetine in CYP2D6 poor metabolizers."
    }
  },
  {
    "question": "How should vortioxetine dosing be adjusted for an individual with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vortioxetine based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the HTR2A rs6313 G/G genotype taking vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in vortioxetine users with the HTR2A rs6313 G/G genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the HTR2A rs6313 A-allele taking vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for vortioxetine based on HTR2A rs6313 genotype."
    }
  },
  {
    "question": "What genotypes of the HTR2A gene (e.g., rs6313) are associated with altered vortioxetine response?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definitions of HTR2A genotypes and their association with vortioxetine efficacy."
    }
  },
  {
    "question": "What is the function of the HTR2A gene product in the mechanism of action of vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the 5-HT2A receptor's role in antidepressant response and as a potential pharmacodynamic factor for vortioxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for vortioxetine in an adolescent with the HTR2A rs6313 G/G genotype?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "HTR2A",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for vortioxetine in adolescents based on HTR2A genotype."
    }
  },
  {
    "question": "How should vortioxetine dosing be adjusted for an individual with the SLC6A4 l/l genotype?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dose adjustment protocol for vortioxetine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What is the risk of non-response for an individual with the SLC6A4 s/s genotype taking vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Quantified risk or odds ratio for treatment non-response in vortioxetine users with the SLC6A4 s/s genotype."
    }
  },
  {
    "question": "What is the expected clinical response (pharmacodynamics) for a patient with the SLC6A4 l/s genotype taking vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Pharmacodynamic data (e.g., remission rates) for vortioxetine based on SLC6A4 5-HTTLPR genotype."
    }
  },
  {
    "question": "What do the SLC6A4 'l' and 's' alleles refer to in the context of the 5-HTTLPR polymorphism?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Definition of the long and short alleles of the SLC6A4 gene promoter polymorphism (5-HTTLPR)."
    }
  },
  {
    "question": "What is the function of the SLC6A4 gene product in the mechanism of action of vortioxetine?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Description of the serotonin transporter's (SERT) role as a primary target of vortioxetine."
    }
  },
  {
    "question": "What is the dosing recommendation for vortioxetine in an adolescent with the SLC6A4 s/s genotype?",
    "answer": {
      "Drug Name": "vortioxetine",
      "Gene Name": "SLC6A4",
      "CPIC Guideline Name": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants (April 2023).pdf",
      "Content to Search": "Dosing adjustments for vortioxetine in adolescents based on SLC6A4 genotype."
    }
  }
]